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Abstract
ADVANCED COMPUTATIONAL METHODOLOGIES TO STUDY
BINDING FREE ENERGIES OF BIOMOLECULAR COMPLEXES
by
Rajat Kumar Pal

Advisor: Dr. Emilio Gallicchio
Molecular recognition is the basis of biological mechanisms and is a key element to consider while
formulating effective and safe drugs. Pharmaceutical drugs are designed so as to bind a target protein even at very low concentrations to alter the diseased conditions without interfering with normal
biological processes. In a rational drug design process, this is achieved by acquiring information
about the chemical structure and the physical and chemical properties of the target protein receptor to gain insights on how changing the chemical composition of the substrate drug could affect
the protein-drug interaction and binding affinities. Computational models are used in conjunction with traditional experimental techniques to pre-screen lead drug-like molecules before they
are synthesized and assayed. Often, due to their computational speed, empirical molecular docking algorithms are used for these purposes as opposed to more accurate physics-based models.
Computational physics based models are also more difficult to properly set up and require long
simulation times to give reliable estimates of binding affinities to be effectively used for virtual
screening purposes. In this work, new methodologies have been developed to improve on critical
factors that affect the accuracy and usability of physics-based alchemical free energy models with
the overarching goal to eventually make these models applicable to free energy based virtual drug
screening. The critical factors that are addressed in this work are as follows: (i) the limitation of
implicit solvent model in proper treatment of hydration is addressed by developing a hybrid solvent
model, combining the thermodynamic properties of water molecules obtained from explicit solvent
iv

simulations with the implicit solvent energy function. The hybrid approach significantly improved
the binding affinity predictions in different systems tested, including host-guest and Dopamine
D3 complexes, (ii) to properly account for conformational reorganization effects in simulations,
improved force-field parameters are implemented for reliable prediction of Farnesoid X receptor
complexes, (iii) insufficient conformational sampling resulting from entropic bottlenecks in the alchemical transformations are avoided by implementing better soft-core potentials and introducing
a customized alchemical perturbation schedule. These together have been shown to be effective in
reducing the strength of a rare order/disorder phase transitions in alchemical simulations of binding, allowed interconversion between different binding modes of complexes, and achieve better
convergence of binding free energy estimates of protein-ligand complexes studied in this work.
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Chapter One: Introduction
1.1

Modeling macromolecular interactions: protein-ligand
binding

Molecular interactions play a critical role in biological processes. All major biological events
such as replication, transcription, translation, signal transduction etc. for growth, maintenance and
cell death occur and are regulated through molecular recognition, the process whereby molecules
bind specifically to their partners. Processes like the binding of substrates and inhibitors to target
proteins and enzymes are important examples where molecular recognition plays a crucial role.
Deviation of these interactions from the normal baseline leads to altered activities of these crucial
processes resulting in impairment and disease states. So, understanding the physical driving forces
involved in binding and the interplay between the various thermodynamic components has been an
important aspect of drug design applications [1].
Many protein-ligand complexes are characterized by the non-covalent association of the molecules
accompanied by entropy loss, conformational strain, desolvation of the protein and ligand, structural reorganization of the binding site and many other physical processes designed to accommodate the ligand which may favor or hinder binding. Though different computational methods have
been developed with the primary aim of accurately predicting the strength of these interactions,
1

describing the complexity of processes involved in biomolecular associations remains one of the
most difficult and unmet challenges in molecular modeling [1–3].
Computational approaches like molecular docking & scoring methods rely mostly on a rigid
description of structural aspects of receptor-ligand interactions. Docking is widely used in Virtual Screening applications [4] for ranking ligand libraries and hit identification based on the
interaction-energy scoring. But the usefulness of rigid structure-based scoring methods is limited
by the fact that they do not take into account contributions from conformational reorganization and
entropic effects which make them unsuitable for quantitative estimation of binding affinities.
Physics-based free energy methods are potentially capable of modeling reorganization effects
because they attempt to achieve a realistic representation of molecular interactions and atomic
motion [5]. These physics-based models are able to address the finer aspects of drug development
such as ligand optimization, drug specificity, resistance and toxicity. However, their reliability
remains low because of inaccuracy in modeling the potential function, limitations of the extent of
conformational sampling, and the influence of different solution conditions and ligand protonation
states [6,7]. Constant developments in this field have resulted in the formulation of many improved
free energy models addressing the issue of accuracy for applications in drug discovery process.
The primary goal of a quantitative model of molecular binding is to provide an estimate of the
strength of the association between a ligand and a receptor described by the standard free energy of
binding, ∆G◦b . The theory of molecular association equilibria [8] is formulated from the concepts
of Statistical Mechanics and are widely implemented in different free energy methods. One such
implementation is the free energy perturbation method (FEP) [9,10] which is useful for computing
the relative binding free energy between ligand pairs. End-point methods which estimate the free
energy of binding by computing the difference between the free energies of the unbound states and
bound states of the protein-ligand complex are useful for computing absolute binding free energies.
End-point approaches comprise the mining minima method [11], which analyze conformation of
the ligand and the complex in terms of enthalpic and entropic contributions. MM/PBSA [12],
MM/GBSA [13] methods also are formulated as end-point methods where enthalpic contribution
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to the free energy are computed from the molecular dynamics trajectories.
To define atomic properties and reproduce molecular geometries of molecules in terms of bond
lengths, bond angles, torsions etc. and the non-bonded interactions, a collection of equations and
associated constants have been formulated known as force field. Different force fields have been
developed for simulating different types of molecules. One of them is the Universal Force field
(UFF) [14] which has parameters for all atoms in the periodic table. Some of the most popular
modern force fields are CHARMM [15], AMBER [16], and OPLS [17] which are commonly used
in biomolecular simulations.
Free energy methods can be divided in two general classes: physical and alchemical.. In physical or conformational free energy methods, the bound and unbound states of the receptor-ligand
complex are connected by a physical path corresponding to a physical trajectory of the ligand in
and out of the receptor binding site. One example of this class of methods is the potential of mean
force [18] approach to calculate the binding affinity.
Alchemical binding free energy methods adopt, as the name suggests, a non-physical reaction
coordinate to connect, in a thermodynamic sense, the unbound and bound states of the complex.
Alchemical approaches are based on a potential energy function of the system which depends
parametrically on an alchemical progress parameter,λ , which is varied to interpolate between the
potential energy function of the initial state (the unbound state) to that of the final state (the bound
state). The intermediate states do not physically exist and have no direct meaning. The initial
and final states are connected by a series of non-physical intermediate alchemical states and the
system is propagated alchemically. As the binding free energy is a state function and depends only
on the initial and final states, the arbitrary choice of the reaction coordinate for the alchemical
process does not affect the binding free energy. Free energy perturbation (FEP) and thermodynamic integration (TI) are two common methodologies that are utilized in alchemical free energy
computations. Our alchemical perturbation method is described in detail later.
Due to slow structural transitions and conformational reorganization [19, 20], to achieve converged binding free energy estimates, enhanced sampling methods like replica-exchange molecular
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dynamics (REMD) [21] and accelerated molecular dynamics (AMD) [22] have been developed to
accelerate the conformational sampling and obtain converged free energy differences. One of the
key findings of this work is a family of alchemical perturbation function which accelerate conformational sampling and the convergence of binding free energies.
Water plays a very important role in almost all biomolecular interactions. So, defining an appropriate solvation environment is crucial for accurate modeling of protein-ligand conformational
equilibria and binding. To reproduce the presence of solvent medium with water molecules, two
main classes of water models have been developed: explicit solvation models which rely on using
discrete physical water molecules and implicit hydration models which represents the solvent as
a continuous medium. Explicit solvent models are widely used in studying molecular association
as they provide a detailed description of the hydration phenomena [23]. The downside of these
models is that they are computationally expensive, not only because of a large number of particles
included in the calculation but also due to the requirement of averaging over many solvent configurations to compute free energies [24]. Implicit solvent models, on the other hand, pre-averages the
solvent surrounding the solute molecules by representing it as a continuum which generally leads
to faster convergence.
In our implicit solvent model, the free energy of solvation includes electrostatic and non-polar
components. The non-polar component corresponds to the free energy of hydration of the electrically neutral solute while the electrostatic component calculates the free energy of turning on
the solute partial charges [25]. Methods based on the Poisson-Boltzmann(PB) [26] formulation of
electric potential in solution provide a virtually exact representation of the response of the solvent
within the dielectric continuum approximation. The implicit solvent approach to study molecular
association have led to the development of Generalized Born models (GB) [27]. These models
have been shown to efficiently reproduce the accuracy of the Poisson Boltzmann numerical solution with the representation of the solvent continuum.
The Double-Decoupling Method (DDM) [5, 24, 28] is considered the gold standard to compute
absolute receptor-ligand binding affinities with the explicit representation of the solvent. The dou-
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ble decoupling method is based on a thermodynamic cycle where the ligand is decoupled twice,
first from the receptor-ligand complex and then from the solvent. The binding free energy is calculated by subtracting the solvation energy of the ligand in water from the solvation energy of the
ligand when it is in the complex. Because it is based on the difference of two free energy changes,
DDM is known to have serious limitations for large ligands and for ligands with a non-zero net
charge. In this work, we utilize a Single-Decoupling Method (SDM) with implicit solvation which
overcomes some of the limitations of DDM. A direct transfer of the ligand from the solvent continuum to the receptor site can be achieved using implicit solvent because the solvation contribution
of each receptor-ligand complex conformation is a single-point evaluation rather than an average
over many conformations [29]. The key quantity considered in the Single-Decoupling Method is
the binding energy function, u(r), which is defined as the difference in the effective potential energies between bound and unbound states of a specific conformation r of the complex averaged over
the conformation of the solvent. An equivalent approach to calculate u(r) with explicit solvation
would require a computationally intensive potential of mean force calculation [24] involving likely
thousands of energy evaluations. A detailed representation of binding energies in both solvent
models is given in the next section. This work focuses on using implicit solvation and applies free
energy methods to compute binding free energies of protein-ligand complexes.
Water not only acts as a medium in which protein-ligand interactions occur, but it also plays
an important role in the binding process. It is widely accepted that the displacement of water
molecules from the active site by the ligand molecule contributes significantly to the overall thermodynamics of binding. Water molecules at the active site of the protein may be energetically
unfavorable because of lack of proper hydrogen bonding partners on the protein surface. Positional restraints imparted by the protein structure can also make these water molecules entropically
unstable. In these cases, displacement of these unhappy waters may help drive binding. On the
contrary, water molecules that establish stable interactions via multiple water-protein hydrogen
bonds may incur a large energetic penalty when displaced by the ligand at the active site. Thus,
water displacement from the active site may have different thermodynamic consequences, which
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are directly related to the binding affinity. Explicit solvent methods, which include, Hydration Site
Analysis [23, 30], GIST [31] and software tools like WaterMap [23, 32], WatSite2.0 [33] etc. that
have been developed to model these thermodynamic properties of water molecules and their effect
in protein-receptor binding [32]. There are currently no reported implicit solvent models that attempt to describe these effects. One of the aims of the work presented here is the description of
enclosed hydration effects in the context of an implicit representation of the solvent.

1.2

Statistical Mechanics theory of binding

The affinity between two molecules, a receptor, R and a ligand L can be expressed by the stan◦

dard binding free energy, ∆G◦b , or, equivalently, the equilibrium constant, Kb = e−∆Gb /kB T , for the
association equilibrium
R+L

(1.1)

RL

between a receptor molecule R and a ligand molecule L. The standard binding free energy is
written as

∆G◦b = −kB T ln Kb

(1.2)

where Kb is the binding constant
[RL]/C◦
Kb =
([R]/C◦ )([L]/C◦ )



(1.3)
eq

This is a dimensionless expression where C◦ is the concentration at the standard state, which is
set to 1 M or a 1 molecule/1668 Å3 , [RL] is the equilibrium concentration of the bound complex,
[R] and [L] are the equilibrium concentrations of free receptor and ligand. In this description
of binding, the complex RL is treated as a distinct chemical species distinct from free R and L
[1]. With these assumptions in place, the binding constant can be expressed as ratios of partition
functions in terms of statistical mechanics as proposed in [5]
6

Kb =

C◦ ZN,RL ZN
8π 2 ZN,R ZN,L

(1.4)

where the configurational partition function of the solvent bath containing N molecules is expressed as ZN .
ˆ
ZN =

drs e−βU(rs )

where rs specifies the degrees of freedom of the solvent. ZN,RL , ZN,R and ZN,L are the configurational partition functions of the complex, receptor and ligand, respectively in the solution. Each of
these partition functions in the above expression considers only the internal degrees of freedom of
each molecular species. For example, for a ligand placed in an arbitrary position and orientation
in solution, the configurational partition function, ZN,L is expressed as
ˆ
ZN,L =

dxL drs e−βU(xL, rs )

(1.5)

in which the integration runs over the 3nL − 6 internal degrees of freedom, xL , of the ligand with
nL being the number of atoms of the ligand. The potential energy of the solvent with the ligand
system is expressed as U(xL, rs ).
The three translational and three rotational degrees of freedom, comprising a total of six external degrees of freedom of the ligand, expressed as ζL , leads to as many additional internal degrees
of freedom of the complex describing the position and orientation of the ligand relative to the
receptor [34]. Thus, the configurational partition function for the complex is written as :
ˆ
dxR dxL dζL drs e−βU(xR, ,xL ,ζL ,rs )

ZN,RL =

(1.6)

bound

in which the integration runs over all bound conformation of the complex, i.e. conformations in
which the ligand is within a specified binding site. The range of positions and orientations of
the ligand relative to the receptor corresponding to the complex is defined by using an indicator
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function as proposed in [5, 34]. The indicator function is set to 1 for values of ζL corresponding
to the position and orientation of the ligand considered bound and 0 in all other values of ζL . The
integral of this indicator function measures the extent of the defined bound state as
ˆ
dζL I(ζL ) = Vsite Ωsite ,

(1.7)

where Vsite is the integral over translational coordinates and Ωsite the integral over the orientational
coordinates. Vsite represents the physical volume of the binding site, while Ωsite measures the allowed range of orientations of the ligand in the complex. If I(ζL ) is independent of the orientational
coordinates , then Ωsite = 8π 2 .

1.3
1.3.1

Alchemical approach for free energy estimation
Formulation in explicit solvent

In order to calculate the binding constant, eq. (1.4) by alchemical methods and also make it
amenable to computation, Kb can be expressed in terms of combinations of ensemble averages.
The ratio of partition function in the original expression is expressed in a way such that it looks
like an average. This is achieved by multiplying and dividing eq. (1.4) by eq. (1.7) times the
configurational partition function of the ligand in vacuum
ˆ
ZL =

dxL e−βU(xL ) ,

(1.8)

yielding the following equivalent expression for Kb

Kb =

Vsite Ωsite −β (∆G2 −∆G1 )
e
,
V ◦ 8π 2
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(1.9)

where C◦ = 1/V ◦ . In eq. (1.9) ∆G2 , defined by
´
−β ∆G2

e

=

dxR dxL dζL drs I(ζL )e−βU(xR ,rs ) e−βU(xL ) e−β u(xL ,ζL ,xR ,rs )
´
= he−β u(xL ,ζL ,xR ,rs ) iRslv +Lgas ,
−βU(x
,r
)
−βU(x
)
s
R
L
dxR dxL dζL drs I(ζL )e
e
(1.10)

is the free energy for establishing receptor-ligand and solvent-ligand interactions, while the ligand
is in the receptor binding site i.e. where I(ζL ) is a non-zero quantity. The quantity

u(xL , ζL , xR , rs ) = U(xR, , xL , ζL , rs ) −U(xR , rs ) −U(xL , rs )

(1.11)

is the binding energy between the ligand and the receptor plus solvent environment; U(xR , rs ) is
the potential energy of the receptor-solvent system in absence of the ligand and U(xL , rs ) is the
internal potential energy of the ligand. Similarly ∆G1 , defined by
´
−β ∆G1

e

=

dxL dζL drs I(ζL )e−βU(rs ) e−βU(xL ) e−β u(xL ,ζL ,rs )
´
= he−β u(xL ,ζL ,rs ) islv+Lgas ,
dxL dζL drs I(ζL )e−βU(rs ) e−βU(xL )

(1.12)

is the free energy for establishing ligand-solvent interactions (the same as the solvation free energy
of the ligand).
As specified in eqs. (1.10) and (1.12), the free energy changes ∆G2 and ∆G1 are expressed as
averages over the ensembles corresponding to the free solvated receptor with the ligand in the gas
phase (Rslv + Lgas ), and the pure solvent with the ligand in the gas phase (slv + Lgas ) respectively.
In either case the ligand is located in the binding site, as specified by the indicator function I(ζL ),
but not interacting with the receptor and the solvent. We will therefore refer to these states as
decoupled.
By inserting eq. (1.9) in eq. (1.2) we finally obtain an expression for the standard binding free
energy
∆G◦b = −kT ln

Ωsite
Vsite
− kT ln 2 + (−kT lne−β ∆G2 ) + (−kT lneβ ∆G1 )
◦
V
8π
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(1.13)

where
− kT ln

Vsite
= ∆G◦t
◦
V

(1.14)

is the free energy for transferring the ligand from a solution at concentration C◦ to a volume of size
Vsite and
− kT ln

Ωsite
= ∆Gr
8π 2

(1.15)

is a free energy penalty (Ωsite is smaller than 8π 2 ) for restricting the isotropic distribution of ligand
orientations in solution to the those allowed in the complex. Thus the expression for the standard
binding free energy can be written as

∆G◦b = ∆G◦t + ∆Gr + ∆G2 − ∆G1

(1.16)

the expression can further simplified by expressing the concentration-independent component of
the standard free energy of binding as ∆GI

∆GI = ∆G2 − ∆G1 ,

(1.17)

This is the excess free energy of binding. All the other terms in eq. (1.13) can be evaluated analytically. The primary purpose to undergo binding simulations is to compute this excess free energy
of binding.
The alchemical thermodynamic path underlying eq. (1.16) is illustrated in Fig. 1.1 and is called
as a double decoupling (DDM) method [24, 28]. The overall binding process (upper horizontal
equilibrium) is decomposed into a thermodynamic cycle with three distinct processes. The ligand
is first transferred from the bulk solution at concentration C◦ to a volume in the bulk solution
identical to the binding site volume (left downward process) including any imposed orientational
restraints. The free energy associated with this first step is ∆G◦t + ∆Gr given by eqs. (1.14 and
1.15). In the second step (bottom horizontal process), the ligand is transferred from this volume
in solution to an equivalent volume in the gas phase; as noted above the free energy change for
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Rsolv + Lsolv,C

ΔGbº
º

ΔGtº+ ΔGr

RLsolv
ΔG 2

-ΔG1

Rsolv + Lsolv,site

Rsolv + Lgas,site

Figure 1.1: Thermodynamic cycle illustrating the decomposition of the standard binding free energy [eq.

(1.13)]. Rsolv is the solvated receptor, Lsolv,C◦ (upper left) is the ligand in solution at concentration C◦ ,
Lsolv,site (lower left) is the ligand solvated sequestered in the binding site, Lgas,site (lower right) is the ligand
in the gas phase in a volume equal to the binding site volume, and RLsolv is the solvated complex [1].

this step is the negative of the solvation free energy of the ligand. Finally (right upward process),
the interactions of the ligand with the receptor and the solvent are turned on while the ligand is
confined within the receptor binding site [1].

1.3.2

Implicit solvent representation

In implicit solvent, rather than integrating over the solvent degrees of freedom in order to obtain
the binding constant, the degrees of freedom of the solvent is represented by a solvent potential of
mean force. This is achieved by taking eq. 1.4 and multiply both numerator and denominator by
1/ZN2 i.e. divide every partition function in the binding constant expression by ZN that looks like
C◦
Kb = 2
8π

ZN,RL ZN
ZN ZN
ZN,R ZN,L
ZN ZN

(1.18)

Calculating all the ratios of partition functions yields the solvation potential of mean force. For
example, the ratio of ZN,R /ZN can be expressed in ensemble average as
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ZN,R
=
ZN

´

dxR drs e−βU(xR ) e−u(xR ,rs ) e−βU(rs )
´
drs e−βU(rs )
´
ˆ
e−β u(xR ,rs ) e−βU(rs )
−βU(xR ) drs´
= dxR e
drs e−βU(rs )
ˆ
= dxR e−βU(xR ) e−βW (xR )

(1.19)

In this expression, the solvent potential of mean force for the conformation of receptor at xR is
expressed as
´
e

−βW (xR )

=

drs e−β u(xR ,rs ) e−βU(rs )
´
= he−β u(xR ,rs ) islv
−βU(r
)
s
drs e

(1.20)

u(xR , rs ) is the receptor-solvent interaction energy, U(xR ) is the intra-molecular potential energy
of the receptor, U(rs ) is the solvent-solvent potential energy and the solvent potential of mean
force is expressed as W (xR ) [35]. Similarly, the other ratios of partition functions can be deduced
to obtain solvent potential of mean force for the ligand, W (xL ) and the complex, W (xR , xL , ζL ).
The solvation potential of mean force can also be considered as the solvation free energy of the
receptor at fixed conformation of the receptor as computed from eq. 1.20. The potential energies
calculated for each species includes the solvent potential of mean force for that particular species
i.e. receptor, ligand and complexes. Thus, the expression U in eq. 1.10 is replaced in this case by
an effective potential energy expression Ue f f = U +W . With this change, a similar expression of
binding constant like that of eq. 1.9 can be obtained in presence of implicit solvent as follows:

Kb =

Vsite Ωsite ZRL
Vsite Ωsite −β ∆GI
= ◦
e
◦
2
V 8π ZR+L
V 8π 2

(1.21)

where the excess free energy is defined as the ratio of the partition function of the complex in
bound state, ZRL and the configurational partition functions of the complex in unbound state, ZR+L
as ∆GI :
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´
−β ∆GI

e

=

dxR dxL dζL I(ζL )e−βUe f f (xR ) e−βUe f f (xL ) e−β u(xL ,ζL ,xR )
= he−β u(xL ,ζL ,xR ) iR+L ,
´
−βU
(x
)
−βU
(x
)
R
L
e
f
f
e
f
f
dxR dxL dζL I(ζL )e
e

(1.22)

This is the expression for excess binding free energy in presence of implicit solvent. The effective
binding energy in implicit solvent is expressed as the difference of effective potential energies as:

u(xL , ζL , xR ) = Ueff (xR, , xL , ζL ) −Ueff (xR ) −Ueff (xL )

(1.23)

The standard binding free energy in implicit solvent representation can be written as:

∆G◦b = ∆G◦t + ∆Gr + ∆GI ,

(1.24)

In this expression, ∆Gt◦ and ∆Gr have similar definition as in explicit solvent. ∆GI is defined as in
eq. 1.22. Thus, in this representation of the solvent, computation involves only one free energy
calculation comparing to that of in the explicit solvent where the expression for excess free energy
involves two calculations (eq. 1.12 and 1.10). Using an implicit solvent representation also favors
in calculating absolute binding free energies of receptor-ligand complexes.

1.4

Thermodynamic decompositions

The establishment of receptor-ligand interaction is the main driving force towards binding. But
these interactions are often formed at the expenses of processes like desolvation effects, loss of
degrees of freedom of the ligand and receptor, which are opposed by entropic forces. Energetic
factors also play significant role in binding, as for example, both the ligand and the receptor have
to lose free energy to adapt their conformations to match those compatible for binding [1]. Thus
several factors contribute to maintain the delicate balance in binding. These factors can be assessed by thermodynamic decomposition of the binding free energy, some of which are briefly
mentioned here. As this work focuses on free energy methods in implicit solvent, the details of the
13

decomposition are only shown with implicit solvent.

1.4.1

Enthalpy/entropy decomposition

Binding free energies of protein-ligand complexes can be decomposed to understand the enthalpic
i.e. energetic factors and entropic contribution relating to the loss of conformational degrees of
freedom [8]. The standard binding entropy is by definition, given by the temperature derivative of
the standard binding free energy. This can obtained from eq. (1.24):
∆Sb◦



∂ ∆G◦b
Ωsite Vsite ∆GI ∆Ue f f
∂W
=−
= k ln 2 ◦ −
+
−∆
∂T
8π V
T
T
∂T

(1.25)

where
∆Ueff = hUeff iRL − hUeff iR+L

(1.26)

is the change in total effective potential energy upon turning on receptor-ligand interactions and
and Ue f f (x) is temperature dependent.
The first term in eq. 1.25 depends on the standard concentration C◦ = 1/V ◦ which computes the
energetic penalties ∆Gt◦ + ∆Gr for imposing translational and orientational constraints. This is
referred to as translational entropy of binding
∆St◦ = k ln

Ωsite Vsite
,
8π 2 V ◦

(1.27)

The corresponding change in the average temperature derivative of the solvent potential of mean
force is given by


∂W
∆
∂T


=h

∂W
∂W
iRL − h
iR+L
∂T
∂T

(1.28)

The binding enthalpy is calculated as
∆Hb = ∆G◦b + T ∆Sb◦



∂W
= ∆Ueff − T ∆
∂T
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(1.29)

The second term in eq. 1.29 is the solvent contribution to the binding enthalpy.
The concentration independent terms of the standard binding entropy is referred to as the interaction entropy and is defined as [36]


∂ ∆GI
∆GI ∆Ueff
∂W
∆SI = −
=−
+
−∆
∂T
T
T
∂T

(1.30)

The sum of the first and second terms in eq. (1.30) is referred to as the configurational entropy of
binding, [8]
∆Sconf = −

∆GI ∆Ueff
+
,
T
T

(1.31)

For a temperature independent potential, the last term that corresponds to the change in solvent
entropy is zero. It can be shown that [8] eq. (1.31) is equivalent to taking the difference of the
entropies of the bound and uncoupled states each evaluated using the fundamental equation
ˆ
S = −k

dxρ(x) ln ρ(x)

(1.32)

where ρ(x) = e−βU(x) /Z is the configurational distribution function [1].
The term ∂W /∂ T cancel out when evaluating the interaction free energy as ∆GI = ∆Hb − T ∆SI
from eqs. (1.30) and (1.29) yielding

∆GI = ∆Ueff − T ∆Sconf .

1.4.2

(1.33)

The reorganization free energy

The binding process in implicit solvent can be thought as a result of two separate steps. In the first
step, both receptor and ligand undergoes conformational reorganization in the unbound state to
match the conformation of the bound complex. and then followed by next step where interactions
between receptor and ligand are established. The entropy change only takes place in the first step
and zero for the second step. The change of enthalpy takes place in the second step and is dependent
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on the establishment of receptor-ligand interaction energy huiRL , where u is the binding energy
averaged over all bound conformation of the complex. This is also called average interaction
energy. The ∆Greorg is the free energy for the conformational reorganization and is defined by the
identity
∆GI = ∆Greorg + huiRL

(1.34)

By adding and subtracting hUeff (xR ) +Ueff (xL )iR+L from eq. (1.34) and using eqs. (1.23, 1.26), and
1.31), the reorganization free energy can also be written as

∆Greorg = ∆Ureorg − T ∆Sconf

(1.35)

where ∆Sconf is the configurational entropy defined above, and

∆Ureorg = hUeff (xR ) +Ueff (xL )iRL − hUeff (xR ) +Ueff (xL )iR+L

(1.36)

is the reorganization energy defined as the change in the average internal potential energies of the
receptor and the ligand in going from to the unbound state to the bound state while they are not
interacting. The expression in eq. (1.35) confirms that the configurational entropy corresponds to
the entropic cost of reorganizing the conformational ensembles of the binding partners to form the
complex [1]. The reorganization free energy is necessarily positive because without mutual interactions, the ligand and the receptor would spontaneously relax to their conformational ensembles
at a lower free energy. Therefore, based on eq. (1.34), it can be concluded that the average binding
energy huiRL is the only term that can be favorable to binding, while reorganization always opposes
it [1].

1.5

Computational approaches to study protein-ligand binding

This dissertation research aims to develop methodologies and strategies to improve the free energy
models to make them applicable to free energy based virtual drug screening. Towards this goal,
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the critical factors are free energy estimation methodology, proper treatment of hydration, quality
of the potential energy functions and force fields used in the calculations and efficient sampling
of conformations. We attempted to address all these critical factors in this work. As mentioned
above, to address the limitations of the implicit solvent model to simulate solvent heterogeneity, especially at the binding site, we attempted to combine thermodynamic properties of water
molecules obtained from explicit solvent simulations with the implicit solvent energy function to
develop a hybrid approach to capture specific effects of water molecules in binding free energy
calculations. As a preliminary step to this goal, in the first part of Chapter 3, the effect of water
molecules on located at the binding site, on binding were investigated using a host-guest system
provided by the SAMPL5 blinded challenge, where we predicted the absolute binding free energies of a set of host-guest complexes without any prior knowledge of their experimental affinities
and then further refined our model to closely agree with the experiments. This kind of challenge
provides an opportunity for an unbiased validation of methodology and also improvement in the
computational approach to study binding. We then used this hybrid approach to study binding of
ligands to Dopamine D3 receptor, a more complex system than host-guest complexes and is also
of pharmacological interest discussed in detail in Chapter 3.
One of the most challenging task in formulating free energy models is to improve the efficiency
of conformational sampling. In order to achieve better sampling of all possible conformations of
the complexes during the simulations, many different enhanced sampling strategies have been
developed. Replica exchange methods are one such enhanced sampling strategy to accelerate the
convergence of free energy calculations. In this method, a series of molecular dynamics replicas
are simulated as parallel computing threads at different alchemical λ states and temperatures. Once
any pair of replicas completes a cycle of specified steps of binding energy calculation, a MC (Monte
Carlo) move is attempted as in eq. 2.25 to exchange between alchemical states (λ ) and temperature
values between the two. This is further explained in Chapter 2.
Despite the implementation of enhanced sampling methods, simulations of molecular binding
often suffer from insufficient conformational sampling. We have observed that similar to the states
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of the chemical system as a function of temperature, alchemical systems also undergo order/disorder phase transitions along the alchemical path which cause significant entropic bottlenecks and
hinders equilibration and efficient conformational sampling. In this work, we also focus on the
strategies to improve the estimation of absolute binding free energies by reducing order/disorder
phase transitions in alchemical methods discussed in Chapter 4 [37].
The effect of force-field parameters in conformational reorganization during binding free energy calculations are discussed in Chapter 5 where significant effect in the reorganization of ligands were noticed while simulating Farnesoid X receptor complexes in different force fields. We
implemented better force field parameters to improve reorganization effects during binding free
energy estimation of these complexes. The main part of this work is the software development
towards implementation of a better force-field in FXR complex simulations and validation of the
new parameterization. A manuscript with all the findings from this work is in preparation.
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2
Chapter Two : General Simulation Methods
In this section, all established and previously published methods used in this work are mentioned.
These methods include explicit solvent simulations to calculate the thermodynamic properties of
binding site water molecules, the binding free energy model and the enhanced sampling methods
that are used to perform the calculations in this work.

2.1

Hydration Site Analysis of the binding site

The thermodynamics and structural properties of water molecules at the binding site of the receptor
are studied using Hydration Site Analysis (HSA) [23, 30]. This is all done in explicit solvent
system where molecular dynamics simulation are performed on the host or the protein receptor,
in general, alone in a restrained configuration. The trajectories are then processed to obtain the
hydration site location identified as spherical sites where the density of water molecules are at
least twice compared to the water in the bulk solvent. The concept is based on the Inhomogeneous
Solvation Theory (IST) [38] where the solution is viewed as an inhomogeneous system with the
solute fixed at the origin, creating an external field that is the source of inhomogeneity. A clustering
algorithm is used to obtain the hydration site locations based on the water occupancy at particular
sites throughout the simulation [30, 39]. The total energy of the water Etotal for each of these
sites are calculated as the sum of the one-half of the mean water-water Eww and solute-water
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Esw interaction energies to model a pairwise interaction between each molecule of the pair. The
solvation energies obtained for each of these spherical sites are then compared with the neat water
simulation with the same water model (TIP3P, OPC etc.) to determine the energetically favorable
and unfavorable water sites with respect to the bulk solvent. . The HSA scores are calculated using
the following expression:

[Etotal (i) − Ebulk ]p(i)

(2.1)

where i is the index of the HSA hydration sites, p(i) is the water occupancy of the site, Etotal (i)
is the total energy of the site and Ebulk is the corresponding reference energy value obtained from
neat water simulation. The energy of the bulk water depends on the type of the water model used
in the study. In this work, explicit solvent simulations were run using two different water models.
For host-guest simulations in Chapter 3, a TIP3P [40] water model is used with an Ebulk = −9.53
kcal/mol. To undergo hydration site analysis of the Dopamine D3 receptor binding site in Chapter
3, an OPC [41] water model was used with an Ebulk = −12.24 kcal/mol.

2.2

The AGBNP2 implicit solvent model

The molecular systems are modeled using the OPLS-AA/AGBNP2 effective potential, in which the
OPLS-AA [42] force field defines the covalent and non-bonded inter-atomic interactions. Solvation
effects are modeled implicitly using the Analytic Generalized Born plus non-polar (AGBNP2)
model [25]. According to this model, the hydration free energy ∆Gh of the receptor-ligand complex
is computed as the sum of electrostatic ∆Gelec , non-polar, ∆Gnp , and short-range solute-water
interactions, ∆Ghs :

∆Gh = ∆Gelec + ∆Gnp + ∆Ghs

(2.2)

The electrostatic component of the hydration free energy is computed using a modified contin-
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uum dielectric Generalized Born model [43,44]. The non-polar component includes a surface-area
dependent term that accounts for the free energy of creating the solute cavity within the solvent,
and a Born-radius dependent term that accounts for long range solute-solvent van der Waals interactions [25]. In AGBNP2, short-ranged solute-solvent interactions, such as hydrogen bonding
are modeled by means of hydration spheres placed on the solute surface. A geometrical procedure
measures the water occupancy of each hydration sphere, which is then used to weigh its contribution to the solute hydration free energy according to the expression:

∆Ghs = ∑ hs S(ws )

(2.3)

s

where ws is the water occupancy factor of the sphere defined as

ws =

Vsfree
Vs

(2.4)

where Vs is the volume of each sphere and Vsfree is the volume of the portion of the sphere occupied by water. S is a switching function that smoothly turns off an hydration sphere if its water
occupancy is below a given threshold. The hs parameter measures the hydration strength of the
corresponding hydration site. Negative hs values describe hydration sites contributing favorably to
the hydration free energy, whereas positive values are used for sites which contribute unfavorably
to the hydration free energy [45].
In this study, strategies have been developed to customize and inform the strength of the
AGBNP2 hydration spheres to simulate the energy of water molecules within the spherical volume. Hydration spheres which are assigned positive hs values are used to define unfavorable water
molecules in the binding site of the host or receptor, whereas a negative hs value favors hydration.
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2.3

Single-decoupling absolute binding free energy protocol

Binding affinities are computed using the Binding Energy Distribution Analysis Method (BEDAM) [29], based on the theory of molecular association in statistical mechanics. It uses an implicit solvation model AGBNP2 [25] and employs an alchemical progress parameter λ mentioned
before, ranging from 0, corresponding to the uncoupled state of the complex to 1, corresponding
to the coupled state of the complex. The λ -dependent effective potential energy function for an
alchemical perturbation potential Wλ (u) that depends on λ and binding energy u described below
can be written as:

Uλ (r) = U0 (r) +Wλ (u)

(2.5)

where r = (rA , rB ) are the atomic co-ordinates of the receptor-ligand complex. U0 is the potential
energy of the complex when ligand and protein are separated at infinite distance from each other
and is expressed as U0 (r) = U(rA ) +U(rB ) where rA and rB are the co-ordinates of the individual
receptor and ligand. The quantity u is the binding energy and is defined as the change in the effective potential energy of the complex for bringing the receptor and ligand from infinite separation
to the conformation r denoted by the atomic coordinates of the complex as

u(r) = U(rA , rB ) − (U(rA ) +U(rB ))
Binding energies u are calculated at alchemical state λ and are averaged over conformations r from
the reference state 0. The free energy difference ∆G between two states 1 and 0 also called the
excess free energy is calculated as

∆G = −kT ln

Z1
= − kTlnhe−β Wλ (u) i0
Z0

(2.6)

where Z1 and Z0 are the corresponding configurational partition functions for bound and unbound
state, k is the Boltzmann constant, T is the temperature and β =
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1
kb T .

With a linear perturbation

potential, ∆Wλ (u) = λ u, the potential energy function becomes

Uλ (r) = U0 (r) + λ u

(2.7)

and when λ = 1, the expression for the excess binding free energy is written as

∆G = −kT lnhe−β u(r) i0

(2.8)

This formula is difficult to implement directly as conformations sampled from both bound and
unbound states are difficult to converge due to practically no overlaps between the two states.
A different approach is taken to calculate the excess binding free energies by collecting binding
energies from all samples at all λ states. All binding values were then combined in an efficient way
to compute binding free energies using the UWHAM (Unbinned Weighted Histogram Analysis)
[46] method. Average interaction energies ∆Eb are also obtained by averaging the binding energy
values of the complexes from the ensemble of conformations at the bound state or λ = 1.
Conformational sampling are carried out using the replica exchange molecular dynamics simulation described later. The uncertainties are measured as the standard error of the mean. Reorganization energy, reorganization free energy and the entropy are decomposed from binding energies
and other thermodynamic parameters discussed in Chapter 1. The uncertainty on all these quantities are computed by error propagation.

2.4

Probability densities of binding energies

Calculation of binding free energy of a receptor-ligand complex is based on the distribution of
binding energies at all λ states. The probability distribution of effective binding energy of a complex at any particular λ state can be defined using a δ function expressed as:

pλ (u0 ) = hδ [u(r) − u0 ]iλ
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(2.9)

where

δ [u(r) − u0 ] =




+∞ u(r) = u0


0

(2.10)

otherwise

This average can be also expressed in terms of integrals representing as ratio of partition function
at any particular λ as
´
pλ (u0 ) =

dx δ [u(r) − u0 ] e−βUλ (r)
´
dx e−βUλ (r)

(2.11)

Using the expression for hybrid potential function in eq. (2.5), the above equation can be further
written as
´
0

pλ (u ) =

dx δ [u(r) − u0 ] e−βU0 (r) e−βWλ (u)
´
dx e−βU0 (r) e−βWλ (u)

(2.12)

The denominator in the r.h.s of the above expression is the configurational partition function of the
complex at any state λ and is termed as Zλ . So, eq. (2.12) is simplified as
´
0

pλ (u ) =

dr δ [u(r) − u0 ] e−βU0 (r) e−βWλ (u)
Zλ

(2.13)

To calculate the integral, δ function impose a criteria stated in eq. (2.10) that says that the integral
has non zero value only when u(r) is equal to a particular binding energy value u0 . Thus, all
0

instances of u(r) can be replaced with u0 . The expression e−βWλ (u) is replaced by e−βWλ (u ) which
does not depend on r becomes a constant and can be computed out of the integral. Thus, eq. (2.13)
becomes
´
0

−βWλ (u0 )

pλ (u ) = e

dr δ [u(r) − u0 ] e−βU0 (r)
Zλ

(2.14)

The configurational partition function of the complex at λ = 0 , defined as Z0 can written as
´
Z0 = dx e−βU0 (r) . Multiplying and dividing the r.h.s of eq. (2.14), we get
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The above equation can be re-arranged to give the following expression

0

pλ (u0 ) = e−βWλ (u ) p0 (u0 )
According to eq. (2.15), the ratio of

Zλ
Z0

pressed in term of ensemble average as

Z0
Zλ

(2.15)

relates to the binding constant at a particular λ can be exZλ
Z0

0

= he−βWλ (u ) i0 . This is also called the excess component

of the equilibrium constant for binding and is expressed as K(λ ).
0

K(λ ) = he−βWλ (u ) i0

(2.16)

Thus, the probability density of the binding energy u0 for any alchemical state λ with a perturbation
potential Wλ (u) is

pλ (u0 ) =

0
1
p0 (u0 ) e−βWλ (u )
K(λ )

(2.17)

With a linear perturbation potential Wλ (u0 ) = λ u0 , the equilibrium constant is related by a double
sided Laplace transform of p0 (u), written alternative from eq. (2.16)
ˆ

+∞

K(λ ) =
−∞

0

du p0 (u0 ) e−β u

(2.18)

and the corresponding binding energy profile looks like as in Fig. 2.1 and is expressed as
1
∆Gb (λ ) = − lnK(λ )
β
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(2.19)

∆Gλ [kcal/mol]

10
5
0
−5
−10
0.00

0.25

0.50
λ

0.75

1.00

Figure 2.1: Binding free energy profile shown as a function of λ . Binding free energies at lower λ states are positive
and gradually as λ is incremented, ∆Gλ goes to a favorable value. The difference between ∆Gλ at λ = 0 and λ = 1 is
the binding free energy of the complex.

UWHAM assigns a λ -dependent statistical weight to each binding energy observation as described
in [46]. It then calculates pλ (u0 ) by binning samples based on their binding energies and creates a
histogram where the heights for each bin is calculated as sum of the weights of all binding energy
observation assigned to that bin. It then maximizes the likelihood of K(λ ) that fits the pλ (u0 )
obtained from the distribution of binding energies.

2.5

Soft-core binding energy function

The standard alchemical hybrid potential U(λ ) = U0 +Wλ (u) shown in eq. 2.5 leads to an unstable
free energy estimation near the decoupled state when λ ∼ 0. In the steep region at the core of the
Lennard-Jones (LJ) potential, receptor-ligand systems sample very large values of binding energy
because of mostly inter-atomic clashes, leading to MD instability, among other issues [47]. To
address this issue, soft-core binding energy functions are implemented which caps the binding
energy to a maximum value umax :
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usc (u) =




u

u≤0

(2.20)



umax fsc (y) u > 0
where u is the binding energy function, and fsc (y) is a function that smoothly goes from zero
at y = 0 to one as y goes to infinity. The soft-core binding energy function usc = usc (u) can be
interpreted as a map from the uncapped binding energy domain [−∞, +∞] of u to the [−∞, umax ]
domain of usc , which is capped with an upper bound at umax . It is to be noted that the soft-core
function is applied to the total binding energy and not to the individual pairwise interaction between
the receptor and the ligand atoms as implemented in other cases [48]. The end states and their free
energy difference are virtually unaffected by the replacement of u with usc . At the coupled state,
the binding energy distribution lays almost exclusively at negative binding energy values where u
and usc are the same [see eq. (2.20)]. At the uncoupled state (λ = 0) on the other hand, the biasing
potential is zero regardless of the form of the binding energy function.
One of the choice for fsc (y) that we considered to use in calculations done in Chapter 3 and 5
is a hyperbolic tangent,
fsc (y) = tanh(y)

(2.21)

where y = u/umax . One of the advantage of this soft-core function is that it is easily invertible
to give the binding energy as a function of u(usc ). The soft-core function is activated for binding
energies larger than a cutoff us , which is usually 0 (us = 0). For u > us , it can be derived from
eq. 2.20 and 2.21
(usc −us )
1 1 + umax
)
u(usc ) = umax ln(
2 1 − (usc −us )

(2.22)

umax

The biased potential Wλ (usc ) is calculated using the soft-core binding energy value usc (u) as a
function of the uncapped binding energies. Nonbonded forces are calculated based on the softcore treated hybrid potential.
In Chapter 4, we introduce a newly developed soft-core function and compared both soft-core
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functions in regard to efficient conformational sampling and convergence of the simulations.

2.6

Replica exchange conformational sampling

Replica exchange (RE) is a method to accelerate the convergence of free energy calculations.
Calculation of a series of molecular dynamics replicas are conducted as parallel computing threads
at different alchemical λ states and temperatures. In Hamiltonian replica exchange, for example,
a reduced potential energy function is defined as [49]

v(x; s) = βU(x; θ )

(2.23)

where s = (β , θ ) represents a joint thermodynamical and mechanical state of the system. Replica
exchange algorithm simulates M replicas of the system at states si = (βi , θi ). Conformational sampling is performed using straight MD. Once any pair of replicas completes a cycle of specified
steps of binding energy calculation, a replica can change its thermodynamic and mechanical state
by exchanging its current state with another replica. The exchange is regulated to ensure microscopic reversibility between the states of two replicas. Replica exchange methods are designed to
sample both molecular conformations and permutations between different discrete states and thus
sample joint distribution pRE (x1 , x2 ...., xM |{s}) which can be expressed as [49]
M

e[− ∑i=1 u(xi ;si )]
pRE (x1 , x2 ...., xM |{s}) =
ZRE

(2.24)

In this expression, xi is the molecular configuration of replica i at state si of M possible states. The
partition function of the RE ensemble is given by ZRE . The different permutation of M possible
states (s1 , s2 , s3 , ..., sM ) is represented as {s}. A Metropolis MC (Monte Carlo) move is attempted
to exchange the lambda and/or temperature values between the permutations after they have completed a cycle of calculation. The parameter swapping attempts are performed among randomly
selected pairs of replicas and the acceptance of updated parameters depend on the Metropolis-
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Hastings acceptance probability [49]

pss0 = min{1,

M
M
0
pRE (x1 , x2 ...., xM |{s0 })
} = min{1, e[− ∑i=1 u(xi ;si )+∑i=1 u(xi ;si )] }
pRE (x1 , x2 ...., xM |{s})

(2.25)

where {s0 } is the proposed state and {s} is the current state permutation.
For example, in Hamiltonian replica-exchange with Single decoupling method, the individual
states are different λ values and for temperature replica-exchange, these are different temperatures. The exchange of λ facilitates the intermolecular degrees of freedom while exchange of
temperature between a pair of replicas activates the intra-molecular degrees of freedom and hence
efficiently allows to explore the conformational space [50]. The whole process is based on parallel replica exchange algorithms(RE) [21]. Parallel two dimensional (alchemical and temperature
degrees of freedom) replica exchange calculations are able to speed up the convergence of the conformational equilibrium for binding by many orders of magnitude, at the same time, modeling the
intra-molecular degrees of freedom when simulating at higher temperatures.
All methods developed in this work are explained in detail in individual chapters of the thesis.
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3
Chapter Three: Inclusion of Enclosed
Hydration Effects to Study Binding in
Host-guest and Protein-ligand Systems
3.1

Introduction

One critical aspect of molecular recognition is the change in the hydration structure and hydration
energetics induced by ligand binding. [51–55] Water molecules trapped, for example, in hydrophobic pockets within the binding site can be energetically disfavored as well as entropically frustrated
relative to bulk water. Hence, displacements of these water molecules by the ligand can significantly enhance binding. [30, 39, 45, 56] These effects are particularly important when comparing a
series of ligands of interest which differ in the way they displace enclosed water molecules. The
rational design of ligands using these principles can lead to improvements of binding potency and
receptor selectivity. [57]
There have been significant efforts towards the development of methodologies to model the
thermodynamic parameters and structural properties of water molecules at the protein surfaces.
[23, 58–62] Most of these methods employ an explicit representation of the solvent, which is con-
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sidered the “gold standard” for modeling macromolecular complexes in part because of the capability of accurate representation of specific hydration environments. It is challenging, however, to
access the time scales required to sample the changes in hydration states and capturing the effects
of water expulsion from protein binding sites induced by ligand binding [60, 63–65]. In this chapter, we have described that the influence of confined hydration can be also represented by a hybrid
implicit solvent model trained on Hydration Site Analysis (HSA) [30, 39] data obtained with explicit solvation [45]. The primary purpose of this work is to explore the applicability of our hybrid
implicit solvent approach to study binding affinities in simple host-guest systems and extend to
studying pharmacologically important protein-ligand systems. To study the binding affinities in
host-guest systems, we participated in the SAMPL5 blind challenge where attempts were made to
predict binding free energies to rank guest molecules against three different supramolecular hosts,
all of which exhibit a hydrophobic binding cavity. After successful validation of the hybrid solvent
approach in SAMPL5 blinded challenge, we aimed to predict binding affinities of protein-ligand
complexes, selecting Dopamine D3 receptor as a model system to develop further. The Dopamine
D3 receptor is an important medicinal target in which the ligand recognition mechanism is heavily
influenced by hydration effects. Due to conformational variability, the complexities of hydration
and molecular interaction networks, and the lack of extensive structural information, it has been
very challenging, using conventional drug design and modeling approaches, to design effective
antagonists against the dopamine D3 family of receptors. We believe that molecular dynamics free
energy approaches combined with accurate modeling of hydration can be helpful in the design of
more effective and more specific antagonists.
Both of these studies are described in details in later sections. The work on SAMPL5 host-guest
blinded challenge has been published in Journal of Computer-Aided Molecular Design in 2017 and
is listed as one of the references in this thesis [45]. The application of hybrid solvent approach to
study binding in Dopamine D3 receptor complexes is recently published in PLOS One [66].
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3.2

SAMPL5 blinded challenge: Ranking of binding affinities
of host-guest complexes

This work was part of the SAMPL5 blinded experiment [45, 67] where we presented the absolute
binding free energies of 22 host-guest complexes by using a novel approach to treat the effect of
water displacement using the AGBNP2 implicit solvent model trained on thermodynamic properties of water from Hydration Site Analysis method in explicit solvent. The challenge included
three supramolecular hosts, the octa-acid, the methyl-octa-acid and the Cucurbituryl Clip(CB-Clip)
(Fig. 3.1). Six guests were provided for the octa-acid and methyl octa-acid and ten were provided
for the CB-Clip host. Some of the guests carried a net positive charge and some, a negative charge.
The octa-acid hosts contained eight carboxylate groups which were all modeled deprotonated imparting a total charge of -8 on the overall host. The 4 sulfonate containing CB-Clip host was also
modeled as deprotonated with a final charge of -4. The novelty of this work is the use of Hydration
Site Analysis information in alchemical binding free energy calculations.

Octa-acid

Methyl octa-acid

CBClip

Figure 3.1: Structure of the supramolecular hosts. The red spheres indicate the location of hydration sites within the
binding cavity of the hosts as identified from hydration site analysis [45]

3.2.1

Hydration Site Analysis of the host binding site

Hydration Site Analysis (HSA) was performed on the three SAMPL5 hosts in the explicit solvent
simulation and solvation energies with occupancies were obtained. The location of hydration sites
in these three hosts are shown in Fig. 3.1). The binding cavity in octa-acids are divided in three
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portions, the top, middle and bottom cavity. Using Hydration Site Analysis (HSA) described in
the Chapter 2, for the octa-acid host, a total of six hydration sites are identified within the binding
pocket, one in the bottom cavity, one in the middle cavity and four in the upper cavity (Fig. 3.1,
left). For the methyl octa-acid host, a total of seven hydration sites are identified, one in the
bottom cavity, four in the middle cavity and two in the upper cavity (Fig. 3.1, middle). For the
CB-Clip host, a total of nine hydration sites were identified by HSA, one of which is located at
the center of the host and the remaining eight were symmetrically distributed, spanning the region
from naphthalene rings to the outer edges of the cavity. In the binding free energy calculations, we
considered the central site plus the site sandwiched in between the two naphthalene rings (Fig. 3.1,
right). The HSA scores obtained from explicit solvent simulations were used to inform placement
of AGBNP2 hydration spheres as shown in the schematic in Fig. 3.2.

Figure 3.2: Schematic of the hybrid Explicit-Implicit Solvent model. (top) Hydration site analysis performed at the
receptor binding site and water clusters identified as hydration sites shown in green spheres. (bottom) AGBNP first
shell hydration model calculates the occupancy of a spherical volume w (blue sphere) placed within hydrogen bonding
distance with respect to solute atoms of the receptor shown as grey spheres.
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3.2.2

Placement of AGBNP2 hydration spheres

The location of the enclosed water sites in each region of the binding cavity and their energies
were then reproduced as best as possible using the AGBNP2 water spheres and anchoring methods
available in AGBNP2 and new methods developed in this work. Solute anchoring points correspond to hydrogen bonding sites such as along polar hydrogen bonds and lone pairs in various
geometries [25], in addition to anchoring points based on geometrical centers of groups of atoms.
Water sphere locations defined in this way naturally follow solute movements. The four top sites
of the octa-acid host, sites (1, 2, 3, and 4) in Table 3.1, were modeled with eight AGBNP2 hydration spheres placed perpendicularly to inner phenyl rings of the cavity (Fig. 3.3B, left). The
middle hydration site of the octa-acid host (site 5, Table 3.1A) was modeled by an AGBNP2 site
placed at the geometrical center of a set of aromatic carbons as shown in Fig. 3.3B, left. The bottom water site (site 0 in Table 3.1A) was placed similarly. The six hydration sites identified for
the methyl-octa-acid host (Table 3.1B), were modeled using three AGBNP2 hydration spheres as
indicated in Fig. 3.3A, middle. The one in the top cavity corresponds to sites 3 and 6, the second
in the middle of the cavity corresponds to sites 1, 2, 4 and 5, and finally the bottom site. All these
individual water sites were placed at the center of mass of specific set of carbons surrounding the
three regions in the pocket (Fig. 3.3B, middle). For the CB-Clip host, one water site was placed at
the center of mass of 4 aromatic carbons and 4 alkyl carbons in the center of the cavity as shown
in (Fig. 3.3B, right). The second water site was placed in between the two naphthalene rings at
the center of mass of 4 aromatic carbon atoms indicated (Fig. 3.3B, right). According to the water
occupancy and the hydrophobic nature of the cavity, energies were different at different portion
of the cavity. One limitation encountered was the placement of the water sites at exact locations
as identified by HSA. As all the water sites are identified within the cavity, the locations which
have no neighboring solute anchor points were modeled based on the geometrical center of a set of
atoms. For octa-acid, all the water sites could be modeled but for the methyl octa-acid, sites were
modeled by adding the energies of two or more water spheres at each region of the cavity.
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(A)

(B)

Octa-acid

Methyl octa-acid

CBClip

Figure 3.3: a) Position of the hydration spheres added to AGBNP2 parameters for each hosts, b) The carbon atoms
used to position the hydration sphere in all 3 hosts; the carbon atoms marked in magenta are used for positioning the
water sites on the top cavity of octa-acids; in CB-Clip, those carbons are used to position water site in between two
naphthalene rings; the center of masses of carbons marked in green were used to position water-sites in the middle
cavity of the octa-acids; carbons marked in orange were used to model a water site at the bottom cavity of the octaacids; in CB-Clip, a water site is positioned at the center of mass of those 4 carbons [45].

3.2.3

Benchmarking and binding free energy calculations

Prior to SAMPL5, our lab also participated in SAMPL4 challenge where only octa-acid host was
provided along with a set of ligands. Calculations performed in SAMPL4 used an empirical adjustment to score enclosed hydration sites [68]. These were done based on some known experimental
data. For SAMPL5 challenge, a few benchmarking binding energy calculations were performed
with a representative guest (G4) (Table 3.2 row 5) of octa-acid host with the mapped sites and
correction used in a previous SAMPL4 challenge [68]. The choice of guest 4 (adamantane type
ligand) for benchmarking was made based on its bulky structure and thus its ability to remove
all enclosed water molecules during ligand binding. Binding energies were also calculated in absence of any localized hydration correction to compare with the effect of water displacement and
improvement in the binding affinity. These simulations were also used to calculate the binding
energy correction required to reproduce experimental binding affinities. The correction was calcu-
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lated to be 7.3 kcal/mol and thus the raw energies obtained from the HSA calculations were scaled
to reproduce this correction and final enclosure energies and hs parameters assigned to AGBNP
sites were calculated.
Table 3.1: Summary of Hydration Site Analysis(HSA) results for three host systems investigated in this
study [45]
Site id
A.

B.

C.

Location

Occupancy

Esw

Eww

Etotal

[Etotal − Ebulk ]p

0.62
0.40
0.41
0.40
0.40
0.29

−4.57
−0.64
−0.61
−0.58
−0.58
−1.48

−2.42
−7.59
−7.41
−7.62
−7.55
−7.50

−6.99
−8.23
−8.02
−8.19
−8.13
−8.98

1.58
0.52
0.62
0.53
0.56
0.16

−4.52
−0.48
−0.73
−0.02
−0.85
−0.62
0.60

−2.14
−7.00
−6.84
−8.49
−6.83
−6.68
−9.67

−6.66
−7.48
−7.57
−8.51
−7.68
−7.30
−9.06

1.72
0.74
0.61
0.31
0.60
0.66
0.66

( p)

Octa-acid
0

bottom

1

top

2

top

3

top

4

top

5

middle

Methyl
octa-acid
0

bottom

1

top

2

top

3

rim

4

top

5

top

6

rim

0.60
0.36
0.31
0.31
0.32
0.30
0.27

center

0.92

−5.76 −2.27 −8.03

1.38

0.42

−1.55 −6.97 −8.52

0.42

CB-clip
0
3

naphthalene
rings

*All energetic quantities are expressed in kcal/mol. For CBclip, a total of nine hydration site were obtained in the cavity,
the two site used for AGBNP2 parametrization are reported
here.

Ebulk

= -9.53 kcal/mol

With this parameterization, benchmarking calculations were run using BEDAM and IMPACT
molecular dynamics engine without ionic screening on the SAMPL4 guests with octa-acid host
to train the model and reproduce the binding free energies that was previously reported in [68].
In this work, we used 18 intermediate λ states from 0 to 1 and 8 different different temperatures
between 300 and 534 K in order to achieve a significant sampling for binding affinity calculation.
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Simulations performed at multiple temperatures allow estimation of the conformational entropy of
◦
binding ∆Sconf
from the temperature derivative of the binding free energy (here we used a simple

finite difference estimator using adjacent binding free energy values). Reorganization free energies ∆G◦reorg were measured as the difference between the binding free energy and the average
interaction energy at the bound state as mentioned in Chapter. 1

∆G◦reorg = ∆G◦b − ∆Eb

(3.1)

Finally, the reorganization energy for each complex was measured by subtracting the entropic
component from the reorganization free energy as mentioned in Chapter 1.

◦
◦
∆Ereorg
= ∆G◦reorg + T ∆Sconf

(3.2)

Statistical uncertainties for the reorganization free energy, conformational entropy and reorganization energy were obtained from error propagation of the uncertainties of the binding free energy
and the average binding energy. Uncertainties are reported as twice the standard error. The main
molecular dynamics engine used is IMPACT [69].
After the initial calculation, it was observed that the HSA-derived water-site parameters could
not accurately describe the experimental affinities for the SAMPL4 octa-acid guests. It was established that HSA over-emphasized the benefit of displacing water from the bottom cavity but hardly
any of the prior SAMPL4 guests could occupy the bottom cavity because of their structural conformation (data not shown). An average deficit of 4 kcal/mol was observed in the binding affinity
calculation with the SAMPL4 guests. This was corrected by 1) including the 4 kcal/mol deficit and
2) by distributing the enclosure energies evenly among all the AGBNP hydration spheres for each
individual host. Enclosed water sites for methyl octa-acid host were also modeled in the same way.
The other host, CB-Clip, has no prior experimental values available. So, the two water sites identified by HSA were assigned the total enclosure energy without any scaling and AGBNP spheres
were scored accordingly.
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The binding free energy calculations with this parameterization significantly over-estimated
the affinities of the positively charged guests (guests 3 and 5 of the octa-acid host in Table 3.2,
and guest 6 and 10 of the Cb-Clip host in Table 3.4). This happened because of the high negative
charge density of the host which favored the binding of positively charged guests. The SAMPL4
predictions were successful because of the fact that none of the SAMPL4 guests were positively
charged and thus did not suffer from the same electrostatic effects.

3.2.4

Incorporation of Debye-Huckel Parameters in the Implicit Solvation
Model

As the experimental values were calculated by binding assays performed in buffered solution containing ions, the shortcoming on the current parameterization was addressed by implementing the
Debye-Huckel ionic screening parameter within the framework of the Generalized Born model
used for calculating the electrostatic effects in implicit solvent. In this work, the Generalized Born
components of the AGBNP model was modified based on the Debye-Huckel screening aimed at
modeling the effects of electrolytes present in the aqueous solution. Specifically, we adopted the
following functional form for the GB pair potential [70]
1
uGB = −
2



e−κri j
−
εout
εin
1



∑ rh
i, j

qi q j
−(ri2j /4Bi B j )

ri2j + Bi B j e

(3.3)
i

where ri j is the distance between atoms i and j, εout = 80 and εin = 1 are the dielectric constants
of the solvent and the interior of the solute respectively; qi and q j are the partial charges of atoms
i and j. The terms Bi and B j are the Born radii of atoms i and j. The Debye-Huckel screening
√
parameter is defined as κ = 8πλB I where I is the ionic strength of the solution and λB is the
Bjerrum length [27, 70]. For water at room temperature, λB =7.0 Å. The salt concentration (20
mM sodium phosphate) for the experimental studies of the octa-acid host was used to calculate the
ionic strength of the solution.
With the introduction of ionic screening effects, we found that the additional correction of 4
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kcal/mol derived from the SAMPL4 system, was no longer necessary. It can be assumed that
the additional correction that was required in favor of binding was to counter-balance the charge
repulsion effects between the highly negative charged host and the negatively charged guests in
SAMPL4. So, the positively charged guests in the current challenge, which did not require that
special correction, were over-estimated as a result.
Table 3.2: Calculated and experimental binding free energies with and without salt effects for octa-acid set and
thermodynamic decomposition of binding free energies with the inclusion of salt effects.
Without
salt effects

Guests Structure
a

b

O–

c

d

e

f

g

◦
−T ∆Sconf

∆G◦exp

∆G◦calc

∆G◦calcDH

∆Eb

∆G◦reorg

∆Ereorg

−5.4

−2.2±0.06

−3.8 ±
0.08

−15.5 ±
0.013

11.7 ±
0.085

1.0 ± 1.43

10.7 ±
1.43

−4.7

−6.3±0.06

−6.6 ±
0.09

−15.9 ±
0.010

9.2 ±
0.090

0.9 ± 1.55

8.4 ± 1.54

−4.5

−15.4 ±
0.06

−8.8 ±
0.09

−20.4 ±
0.012

11.6 ±
0.089

−0.9 ±
1.51

12.5 ±
1.51

−9.4

−6.3 ±
0.06

−6.8 ±
0.14

−20.0 ±
0.015

13.2 ±
0.144

1.3 ± 2.59

11.9 ±
2.59

−3.7

−11.3 ±
0.06

−6.3 ±
0.10

−16.6 ±
0.017

10.3 ±
0.101

1.7 ± 1.72

8.6 ± 1.71

−5.3

−7.4 ±
0.07

−7.0 ±
0.09

−18.8 ±
0.016

11.8 ±
0.097

0.2 ± 1.59

11.6 ±
1.59

5.8
−0.39

2.6
−0.04

O

G1

With salt effects

O

O–

G2
N

G3

N+

Br

G4

O

–

O

G5

N+

O

G6

O

N+
–

O

O–

RMSE
Correlation coefficient(r)

All values in kcal/mol. a Experimental binding free energy. b Predicted binding free energy without addition of ionic
effects. c Binding free energy prediction with the addition of salt effects. d Average interaction energy of the bound
complex at =1. The uncertainty is estimated as the standard error of the mean. e Reorganization free energy as
calculated using eq. 3.1, f Reorganization energy or intra-molecular strain as calculated using eq. 3.2, g Binding
entropy computed by finite difference method and evaluated at 300K; the uncertainty is computed by error
propagation for all the decompositions [45].
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With the introduction of ionic screening and removal of the empirical correction on the water
sites, the binding affinities calculated are in much better agreement with the experiments as shown
in column 5 of Tables. 3.2 and 3.3 for octa-acid and methyl-octa-acid hosts, respectively. The root
mean square error (RMSE) on the predictions (Tables. 3.2 and 3.3) are improved by more than a
factor of 2 for the octa-acids and by more than a factor of 3 in case of methyl octa-acid host. The
RMSE for the CB-Clip set (Table. 3.4 and Fig. 3.4C) improved from 4.7 to 3.6 kcal/mol. Introduction of ionic effects in these calculations have also improved the correlation with the experimental
values.
Table 3.3: Experimental and computed binding free energies with and without salt effects for methyl octa-acid hosts
and thermodynamic decompositions of binding free energies calculated with inclusion of salt effects.
Guests

∆G◦exp

Without
salt effects
◦b
∆Gcalc

∆G◦calcDH

∆Eb

∆G◦reorg

∆Ereorg

−5.3

−7.5 ±
0.06

−4.8 ±
0.08

−17.2 ±
0.013

12.4 ±
0.083

0.8 ± 1.40

11.5 ±
1.39

−5.1

−10.6 ±
0.06

−7.7 ±
0.09

−17.6 ±
0.013

9.9 ±
0.096

1.4 ± 1.65

8.5 ± 1.65

−6

−10.6 ±
0.06

−9.4 ±
0.09

−21.4 ±
0.013

12±0.104

0.7 ± 1.74

11.3 ±
1.74

−2.4

−2.4 ±
0.09

−0.7 ±
0.14

−21.1 ±
0.018

20.4 ±
0.161

6.7 ± 2.75

13.7 ±
2.75

−3.9

−14.5 ±
0.06

−5.7 ±
0.10

−16.5 ±
0.015

10.8 ±
0.105

1.2 ± 1.79

9.6 ± 1.78

−4.5

−8.9 ±
0.06

−5.8 ±
0.09

−18.0 ±
0.015

12.2 ±
0.097

1.4 ± 1.65

10.8 ±
1.65

Structure
a

O

G1
O–

With salt effects
c

d

e

f

g

◦
−T ∆Sconf

O

O–

G2
N

G3

N+

Br

G4

O

–

O

G5

N+

O

G6

O

N+
–

O

O–

6.7
2.1
RMSE
0.66
0.89
Correlation coefficient(r)
a
All values in kcal/mol. Experimental binding free energy. b Predicted binding free energy without addition of ionic
effects. c Binding free energy prediction with the addition of salt effects. d Average interaction energy of the bound
complex at =1. The uncertainty is estimated as the standard error of the mean. e Reorganization free energy as
calculated using eq. 3.1, f Reorganization energy or intra-molecular strain as calculated using eq. 3.2, g Binding
entropy computed by finite difference method and evaluated at 300K; the uncertainty is computed by error
propagation for all the decompositions [45].
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The correlation coefficient for all three hosts improved after the addition of salt effects, though
for the octa-acid set, it remained low (Fig.3.4). This is partly due to the small range of experimental
affinities of the octa-acid guests (less than 1.8 kcal/mol). Though the strongest binder in this set is
guest 4, calculations did not reproduce this feature well and predicted guest 3, a positively charged
ligand, to be the strongest binder with an affinity of −8.8 kcal/mol with ionic screening. Thus, it
seemed that despite improvement by treating salt effects, the trend of over-prediction of the affinity
of positively charged ligands, still remain in these calculations.
On the other hand, binding affinities of methyl octa-acid guests were in better agreement with
experiments. Binding affinities have a larger variation for this host. With ionic screening, guest
4 is predicted as the weakest binder for this set, which is in full agreement with the experimental
estimates. The calculations accurately predict the large loss of affinity of guest 4 upon methylation
of the host [45]. These calculations also predicted guest 3 as the strongest binder, in agreement
with the experiments.
Table 3.4: Experimental and computed binding free energies with and without salt effects for CBClip host-guest
complexes and thermodynamic decompositions of binding free energies calculated with inclusion of salt effects.

Without
Guests Structure

With salt effects

salt
effects
a

b

c

∆G◦exp

∆G◦calc

∆G◦calcDH

−5.8

−5.5 ± 0.07

−2.7 ± 0.1

−2.5

−1.3 ± 0.06

1.3 ± 0.1

−9.2 ± 0.07

−0.3 ± 0.1

+

H3N

G1

G2

G3

NH3+

NH3+
+

H3N

H2+
N
+

H3N

N+
H2

NH3+

−4.0

41

d

∆Eb
−30.1 ±
0.03

−20.2 ±
0.03

−47.2 ±
0.05

e

f

g

∆G◦reorg

∆Ereorg

◦
−T ∆Sconf

27.4 ± 0.1

9.6 ± 1.7

17.8 ± 0.1

21.5 ± 0.1

6.5 ± 1.3

15.0 ± 0.1

46.9 ± 0.1

14.4 ± 1.9

32.5 ± 0.1

H
N

H2N

NH2+

G4

H
N

N

G5

−7.3

−8.5 ± 0.08

−6.4 ± 0.1

−8.5

−5.8 ± 0.08

−6.2 ± 0.1

−8.7

−19.9 ± 0.1

−5.2

1.0 ± 0.07

−2.6 ± 0.2

−6.2

−7.2 ± 0.08

−6.1 ± 0.1

−7.4

−6.6 ± 0.08

−6.5 ± 0.1

−10.7

−15.1±0.09

N+

−35.2 ±
0.02

−26.2 ±
0.02

28.8 ± 0.1

11.1 ± 2.1

17.7 ± 0.1

20.0 ± 0.1

5.0 ± 2.0

15.0 ± 0.1

28.0 ± 0.12

10.3 ± 2.5

17.7 ± 0.1

23.5 ± 0.2

9.2 ± 2.9

14.2 ± 0.1

26.3 ± 0.2

6.8 ± 2.0

19.5 ± 0.1

22.1 ± 0.1

6.6 ± 2.1

15.5 ± 0.1

22.3 ± 0.1

5.6 ± 2.1

16.7 ± 0.1

O
HN+
N
O

G6

O
N
HN+

−16.8 ±

−44.8 ±

0.1

0.03

O

O

O

–

O

N
O

G7

O
O–

N

O

−26.1 ±
0.03

O

N+

G8
+

NH

N

H
N

NH2

G9
N+
H2

N

N+

G10
N

−32.3 ±
0.03

−28.6 ±
0.03

−14.3 ±

−36.6 ±

0.1

0.02

RMSE

4.7

3.6

Correlation coefficient(r)

0.67

0.90

All values in kcal/mol. a Experimental binding free energy. b Predicted binding free energy without addition of ionic
effects. c Binding free energy prediction with the addition of salt effects. d Average interaction energy of the bound
complex at =1. The uncertainty is estimated as the standard error of the mean. e Reorganization free energy as
calculated using eq. 3.1, f Reorganization energy or intra-molecular strain as calculated using eq. 3.2, g Binding
entropy computed by finite difference method and evaluated at 300K; the uncertainty is computed by error propagation
for all the decompositions [45].

The values of binding free energies and average binding energy were decomposed to study
entropic contribution and the conformational reorganization in the host-guest binding predictions.
The reorganization energy reflects the intra-molecular change in the energy of the host and the
guest to attain an appropriate conformation to bind each other. It is also referred to as the intra-
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molecular energy strain because it often opposes binding. The complex of guest 4 in methyl
octa-acid is found to have large unfavorable reorganization energy (20.4 kcal/mol) whereas have
the most favorable host-guest interaction energy (-21.1 kcal/mol).
(A)

(B)

(C)

Figure 3.4: Calculated standard binding free energies from the SAMPL5 octa-acid (A), methyl octa-acid (B) and CBClip (C) complexes against the corresponding experimental values. The points in green filled circles are the binding
free energies obtained with the incorporation of salt effects. Filled black triangles are the free energies obtained
without salt effects. RMSE = Root Mean-Squared Error, r = Pearson correlation coefficient [45]

The large reorganization may be attributed to sideways orientation of Bromine atom which
required a tilting of the head group carboxylate to accommodate the bromine atom within the
binding cavity. Similar reorganization events were also observed for the CB-Clip guests. The
average binding energies for the CB-Clip complexes have a particular wide range, from -20.4
kcal/mol to -47.2 kcal/mol. Interestingly, binding energies are imperfect predictors of affinity in
this set. For example, guest 3, which is the second weakest binder in the set, is predicted to have
the strongest interactions with the host (-47.2 kcal/mol). Conversely, guest 5, which is one of the
top binders, has relatively weak interactions with the host (-26.2 kcal/mol). Clearly, as observed
previously [68,71], reorganization (entropic loss and intra-molecular energy strain) is an important
determinant of binding.
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3.2.5

Discussion

One key outcome of this work has been the realization of the significance of water displacement
effects in these host-guest systems. Based on the comparison between AGBNP2 binding energies with and without the inclusion of the explicit solvent data derived from HSA analysis, it was
estimated that water displacement effects account for approximately 7 kcal/mol of the binding
strength for the octa-acid host, 8 kcal/mol for the methyl octa-acid host and 4 kcal/mol for the CBClip host. These values are very significant when compared to binding free energies values which
range from -2 to -9 kcal/mol. Clearly, binding affinities would be grossly underestimated without
accounting for water expulsion effects. Conversely, the accurate modeling of the thermodynamics
of water enclosure is necessary to make accurate binding affinity predictions. Continuum solvent
representations, which consider the solvent as a uniform medium with bulk properties everywhere
including the interior of the host cavity, are, by definition unsuitable to represent the unique properties of discrete water molecules in these confined spaces.
Initial computational predictions of binding affinity lacked a proper treatment of ionic effects
because highly negatively charged host structure overestimating the affinities of the positively
charged guests. However, with the implementation of Debye-Huckel charge screening and removal of the empirical boost previously applied to match with the experiments, the systematic bias
in favor of positively charged guests is significantly reduced, as seen for examples in the case of
guests 3 and 5 of the octa-acid hosts, whose revised binding affinities move substantially closer to
the experimental values (Tables 3.2 and 3.3). The effect of ionic screening on negatively charged
guests is smaller, particularly for the octa-acid host. This charge asymmetry is due to a conformational reorganization process that occurs for positively charged guests. Without ionic screening
we observed that in approximately 70% of the bound conformations one of the benzoate groups of
the host is flipped up so as to make a favorable short ranged ionic interaction with the alkylammonium group of the guest (Fig. 3.5B). With ionic screening, this interaction is disrupted (it is seen in
less than 5% of the bound conformations) and binding is weakened. In complexes with negatively
charge guests, instead, charge repulsion keeps like-charged groups away from each other and the
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effect of ionic screening is less important.
The predictions correctly reproduced the loss of affinity of guest 4 when going from unmethylated to methylated form of the octa-acid host. The methyl groups protrude into the opening,
partially occluding the mouth of the host cavity. Thermodynamic decomposition (see Tables 3.2
and 3.3) reveals that the loss of affinity is not due to weaker interaction between guest 4 and the
host (average binding energies are -20.0 kcal/mol and -21.1 kcal/mol for the unmethylated and
methylated hosts, respectively). Rather, the affinity loss is due to the more unfavorable reorganization free energy, and in particular to intra-molecular strain energy which is 5 times greater for the
methyl octa-acid than the octa-acid (Tables 3.2 and 3.3, Col. 8). Indeed, as shown in Fig. 3.5C, in
order to accommodate guest 4, which is a bulky molecule with a bulky bromine lateral substituent,
the methyl groups of the benzoate rings are forced upward, caused intra-molecular strain in the
host. This is not observed in the other guests of the set due to their slimmer profiles that can be
accommodated in the interior of the host and through the narrow opening.
(A)

(B)

(C)

Figure 3.5: Representative structures from the simulations of the complexes with the octa-acid with (A) the negatively
charged guest 1, and (B) with the positively charged guest 3 showing the flipping of the benzoate ring to form a shortranged ionic interaction with the alkylammonium head group of the ligand. (C) Representative structure of the complex
of the methyl octa-acid host with guest 4 showing the methyl benzoate rings forced upwards to accommodate the bulky
ligand [45].

CB-Clip guests were observed to have wider variety of binding trends. In these hosts, ionic
screening did not play a significant role in improving the binding affinities because almost all the
guests are positive charged with few exceptions. Consistent with its large charge density, ionic
screening, for example, disfavors the binding of guest by 9 kcal/mol. A similar effect, of smaller
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magnitude, is observed for guests 6 and 4. Conversely, the binding of the negatively charged
guest (guest 7) is strengthened by ionic screening. In all of these cases ionic screening shifts the
predictions closer to the experimental affinities.
Guests with an aromatic core tend to to bind better due to effective stacking interactions with
the naphthalene hydrophobic “claws” of the host. Guests 6 and 10, which optimally incorporate
both of these features, are correctly predicted to be the best binders. Guests with negatively charged
groups (guest 7) are correctly predicted to bind less well due to electrostatic repulsion with the
sulfonate groups. Trends of this kind generally track host-guest interaction energies as measured
by the average binding energy (Table 3.4, Col. 6). The most noticeable exception is guest 3, which
is one of the worst binders (both computationally and experimentally) even though it is predicted
to form the most favorable interactions with the host (-47 kcal/mol). These strong interactions
originate by the ability of this guest to engage all four sulfonate groups of the host. However
this is apparently achieved only at a great entropic loss (-32.5 kcal/mol, nearly double those of
other guests in the set), reflecting the loss of flexibility of the guest (and the host) upon binding.
The example of guest 3 underscores the complexity of molecular association equilibria and the
often seemingly contradictory structure-activity relationships emerging from drug screening and
optimization studies.
All major observations and findings discussed in this work is published [45].
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3.3

Binding affinities of Dopamine D3 receptor complexes

Overall, the previous work on host-guest systems underscores the need to accurately model the
molecular nature of water enclosure in binding. Continuum implicit solvent models, while useful in
other respects, do not capture these effects. The magnitude of water enclosure corrections, obtained
by HSA and strictly validated in a blinded fashion, cannot be ignored as they can be as large as the
magnitude of binding free energies. With a successful outcome from the hybrid solvation approach,
the idea is to develop customized implicit solvation models for protein receptors by incorporating
the free energies of water displacement of enclosed hydration sites as measured by HSA. A set
of study towards this approach is described in this section. Most of the findings discussed in this
study are published in [66].
Dopamine D3 receptors, which are part of the G-protein coupled receptor superfamily, are
increasingly important as drug targets for the treatment of a number of pathological conditions such
as Parkinson’s disease, schizophrenia and drug abuse [72–74]. Dopamine receptors are classified
under two families and five sub-types based on their location, pharmacological and physiological
properties: the D1 family, comprising the D1R and D5R receptors which stimulate the production
of cAMP, and the D2 family, comprising the D2R, D3R and D4R receptors which have inhibitory
functions and decrease cAMP production. Both these receptor families have been targeted for the
treatment of neurological disorders. While selectivity between D1 and D2-like receptors has been
achieved, it has been challenging to design specific antagonists within the D2 receptor subfamily.
Most of the drugs tested act as dual D2/D3 antagonists, with high D2 receptor occupancy. D2
receptor antagonism, however has been associated with serious neurological side effects [75, 76].
D3 receptors, on the other hand, have high affinity towards dopamine and any change in their
number and function were observed to cause significant effects in synaptic transmission [77–79].
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Figure 3.6: Crystal structure of the dopamine D3 receptor with Eticlopride bound at the binding site [80]. This
representation shows the approximate position of the orthosteric binding site (OBS) with a blue oval and the secondary
binding site (SBS) with a green oval [66].

The mechanism of antagonism of D3 receptors has been intensely studied to gain an understanding of how to develop potent and selective antagonists [80–84]. The crystal structure of the
D3 receptor in complex with eticlopride, [80] a dual D2/D3 antagonist, has been very helpful in
understanding the intermolecular interactions in the orthosteric binding site (OBS) of the D3 receptor. It also revealed a secondary binding site (SBS) which is believed to be a critical molecular
recognition site. A recent study has also suggested the existence of a cryptic pocket in the orthosteric binding site (OBS) of the dopamine D3 receptor [81]. These important discoveries have
provided valuable information for the development of D3 selective ligands [82, 85].
The orthosteric binding site (OBS) of D3 is surrounded by the helices III, V, VI and VII comprising Ser 1925.42 , Ser 1935.43 , Ser 1965.46 , Cys 1143.36 , His 3496.55 , Phe 3456.51 , Phe 3466.52 and
Val 1895.39 residues. The secondary binding site (SBS), also referred as the extracellular extension, is located at the interface of helices I, II, III, VII and the extracellular loops ECL1 and ECL2
(Fig. 3.6). The OBS is conserved in both D2 and D3 receptors but differ in the residue composition at the SBS. As exemplified by the structure of D3 bound to eticlopride (Fig. 3.6), [80] the
interaction of ligands to the OBS of D3 is characterized by a salt-bridge between the carboxylate
group of Asp 1103.32 in helix III of D3 and the protonated amine group of eticlopride. This saltbridge interaction is believed to be pharmacologically crucial in binding of ligands at the OBS of
dopamine D3 receptor and to other dopaminergic receptors [80]. Previous studies have highlighted
the challenges of designing specific antagonists against the dopamine D3 receptor [72, 78, 83, 84].
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Table 3.5: The chemical structures of the (-)-stepholidine derivatives considered in this work. The rings are labeled
alphabetically as referenced in the text. The chiral carbon is labeled by a star.
(-)-stepholidine C3 derivatives
x
1a
H
1b
H
1c
H
1d
H
1e
H
1f
H

R1
Et
n-Pr
n-Bu
n-Pen
n-Hex
2-fluoro ethyl

(-)-stepholidine C9 derivatives
x
2a
Br
2b
Br
2c
Br
2d
Br
2e
Br
2f
Br
2g
Br
3a
H
3b
H
3c
H
3d
H
3e
H
3f
H
3g
H

R2
Et
n-Pr
n-Bu
n-Pen
n-Hex
sec-Butyl
Methoxethyl
Et
n-Pr
n-Bu
n-Pen
n-Hex
sec-Butyl
Methoxethyl

In this study, we focus on the interaction of the D3 receptor with a series of derivatives of
(-)-stepholidine (Table 3.5), a natural product displaying dual D1 and D2 activity and observed
to have anti-psychotic activities [86–89]. The derivatives are classified into two groups based on
the position of modification at the tertrahydroprotoberberine (THPBs) scaffold. The first group of
compounds are named as (-)-stepholidine C9 derivatives where the substitution is at the C9 position. Another set of compounds were synthesized by Harding research group and assayed are
substituted at C3 position and are named as (-)-stepholidine C3 derivatives. The substitution were
made towards achieving a dual D1/D3 activity at the dopamine receptors (Table 3.5). The motivation of synthesis and substitution at the both C9 and C3 positions is to extend these molecules to
access the secondary binding site (SBS) which have the potential to improve receptor selectivity
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for these compounds [85]. Due to the lack of a crystal structure, the mode of interaction of (-)stepholidine derivatives with the D3 receptor remains uncertain [84,85,90]. Experimental affinities
and docking studies for C9 compounds were previously published [85]. Experimental affinities for
the C3 compounds are recently published[ref].

3.3.1

Objective

In this work, we report, for the first time, a novel computational strategy by using an implicit
solvent model to model the effects of water expulsion in protein-ligand binding by acquiring the
thermodynamic properties of binding site water molecules in dopamine D3 receptor from explicit
solvent simulations and estimating the binding free energies of (-)-stepholidine analogues. This
allowed us to capture localized enclosed hydration effects during free energy calculations which
could not be captured by using conventional descriptions of an implicit solvent. This work also
underscores the applicability of a hybrid solvation model to perform MD and binding free energy
calculations.

3.3.2

Computational Details

3.3.2.1

Hydration Site Analysis of Dopamine D3 receptor binding site (HSA) in explicit
solvent

Three representative receptor structure were used for the Hydration Site Analysis (HSA) in explicit
solvent. The receptor structures considered are the representative structures of the (-)-stepholidine,
C3 butyl (1c) and C9 butyl (3c) derivatives bound D3 complexes, without the ligand, respectively.
The docked poses were obtained from individual induced fit docking (IFD) simulations [91] using
the crystal structure receptor configuration of the dopamine D3 receptor (PDB ID - 3PBL). The
IFD protocol was performed in five steps: generation of ligand conformations, initial docking
with reduced receptor atom van der Waal radii, side chain minimization with Prime [92, 93], a
second docking step using the new receptor configuration and finally pose scoring. Receptor-
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ligand configuration with the highest IFD score ranking were selected, except in the case where
the highest scored pose did not maintain the well conserved Asp 1103.32 salt-bridge. The receptor
molecule from each highest scored pose, were then used for Hydration Site Analysis (HSA).
Explicit solvent simulation were performed using the ff14SB [94] force field and the OPC [41]
water model in a cubic box and all simulations were performed using the AMBER [95] software
package. In these simulations, position restraints were used on all heavy atoms with a force constant of 10.0 kcal/mol/Å2 . Each system was minimized and thermalized for 2.0 ns under NPT
conditions of 1 atm and 300K. NVT production MD simulations were run for 10.0 ns and snapshots of the trajectory were collected every 1.0 ps. High density spherical regions of 1Å radius
were identified using a clustering analysis on the water molecules which lies within 8 Å of the
superimposed ligand in D3 binding site. Individual hydration sites were then populated with all
water molecules that lies within 1 Å of the corresponding hydration site center. Average solvation
energies were calculated for each site by calculating the energies of the water molecules within 1
Å of each hydration site center in all 10,000 frames of the trajectory.

3.3.2.2

Parameterization of the AGBNP2 Enclosed Hydration Model

Even slight variations in atomic positions are known to cause significant changes in hydration
structure [31, 57, 96]. We attempted to capture specific ligand-induced conformational changes,
as well as thermal fluctuations of the hydration structure by considering multiple structures of
the D3 receptor derived from the induced fit docking (IFD) [91] with (-)-stepholidine, the 3c C9
analogue and the 1c C3 analogue (Table 3.9) starting from the PDB ID - 3PBL crystal structure of
the dopamine D3 receptor. Hydration site maps were obtained individually for each of the three
receptor structures using HSA analysis [30].
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(A)

(B)

Figure 3.7: (A) Location of hydration sites (red) within the binding cavity of the Dopamine D3 receptor as mapped
by Hydration Site Analysis. (B) Hydration spheres (green) of the AGBNP2 model for the same receptor structure in
(a). The positions of the AGBNP2 hydration spheres are functions of the internal coordinates of the receptor [66]. .

These hydration maps were then integrated into a single hydration map (see Fig. 3.7A) by
averaging the free energy weights of neighboring hydration sites from the individual receptor maps
(Table 3.6). The energies and water occupancies of the HSA hydration regions were used to obtain
the enclosed hydration corrections for the AGBNP2 hydration spheres using eq. (2.1).
The enclosed hydration sites with unfavorable hydration energy identified by HSA, and thus
good candidates for displacement by the ligand, were found to be distributed throughout the
binding cavity of the dopamine D3 receptor. These were reproduced as best as possible with
AGBNP2 hydration spheres within the limitations of the available anchoring methods [25, 45].
To ensure translational and rotational invariance of the AGBNP2 implicit solvation function, hydration spheres are located only in terms of molecular internal coordinates, that is by specifying
distance and angle geometries in relation to selected atoms of the receptor. The geometries that
were employed most often in this work have been for sites attached to polar hydrogen atoms and
for sites anchored to mimic the lone pair orbitals of carbonyl and carboxylate groups. When a
suitable anchoring geometry could not be found, AGBNP2 hydration spheres have been positioned
at the geometrical center of a group of atoms of the receptor, typically backbone Cα , Cβ and N
atoms [45]. The resulting AGBNP2 hydration sites are shown in Fig. 3.7B and their parameterization is listed in Table 3.7.
52

53

0.79

0.71

0.50

0.98

0.65

0.36

13

17

29

1

20

34

0.41

−11.41
42

34

4

−12.41
9

0.82

0.74

0.94

0.31

0.46

0.95

0.31
0.74

41
14

15

0.11

−12.07

0.47

2.92

−8.58

0.70

0.78

0.91

pbs

19

12

−11.52

0.67

6

Site Id

5

0.68

−10.82

−11.48

a

−12.59

3.02

−8.61

0.95

−11.17
0.69

0.82

−11.33

1.36

0.37

−11.81

−9.60

1.02

−10.59

−10.98

3.76

(E − Ebulk )×ps

−8.44

Etot

a

Steph

−11.56

12.08

−11.99

−11.74

10.97

0.56

0.12

0.23

0.15

0.58

2.34

0.87
2.49

−9.44
−8.86
−9.79

1.44

1.06

1.97

(Etot − Ebulk )×ps

−10.18

−10.88

−10.06

Etot

a

C9
a

37

25

3

24

10

1

35

29

21

12

22

16

14

2

0

Site Id

0.47

0.64

0.94

0.63

0.88

0.98

0.33

0.52

0.73

0.82

071

0.76

0.79

0.95

0.99

pbs

−12.06

−11.56

−11.44

−11.90

−11.30

−10.15

−8.00

−9.77

−10.87

−8.90

−9.79

−9.74

−11.02

−11.73

−8.95

Etot a

C3

0.09

0.43

0.75

0.21

0.83

2.04

1.40

1.28

0.99

2.73

1.74

1.90

0.98

0.47

3.29

(Etot − Ebulk )×ps a

(E − Ebulk ) × ps values calculated from all sites located at a particular region in all three receptor structures

0.56

0.09

1.02

0.98

2.30

7.31

9.16

1.74

5.76

3.80

8.50

7.08

Esum a,c

kcal/mol. The energy of the bulk water is Ebulk = 12.24 kcal/mol. b average occupancy of a particular water site calculated from HSA c Esum is the sum of all

0.89

5

a In

0.48

28

4

0.83

0.90

3

11

0.91

8

0.55

0.88

21

0.51

0.62

0

25

0.99

Site Id

26

pbs

0.19

0.03

0.34

0.33

0.77

2.44

3.05

0.58

1.92

1.27

2.83

2.36

structuresa

Average over 3

Table 3.6: Individual HSA scores from three receptor maps. The final HSA scores for each site and location within the binding site are obtained by averaging over
all three receptor structures.

Table 3.7: Summary of the placement and parameterization of the AGBNP2 enclosed hydration sites for the dopamine
D3 receptor binding site.
Locationa

HSA site
Idb
0 (Steph)

AGBNP2
site Idb
0,1

OBS

3,4,8,21
(Steph)

3,4,5

OBS

25,26
(Steph)
14,19,41
(C9)
1 (C3)
11 (Steph)
9 (c9)

18

OBS

OBS
OBS
OBS/SBS
boundary
OBS/SBS
boundary

pds

(E − Ebulk )e

(E − Ebulk )×ps f

1.00

2.36

2.36

0.86

3.28

2.83

0.66

1.92

1.27

Center of mass

0.57

5.32

3.05

Center of mass
Center of mass

0.87
0.83

2.80
2.32

2.44
1.92

9

AGBNP2
anchoring type c
Asp 110
backbone
(C=O)
Asp 110 side
chain
carboxylates
-C(=O)OCenter of mass

12
13
10

Ser 182
0.87
0.21
0.19
hydroxyl
hydrogen (O-H)
SBS
12 (C9)
11
Center of mass
0.63
0.92
0.58
SBS
34,42 (C9)
14
Center of mass
0.58
1.31
0.77
SBS
5 (C9)
15
Center of mass
0.95
0.34
0.33
SBS
15 (C9)
16
Center of mass
0.68
0.50
0.34
SBS
37 (C3)
17
Center of mass
0.34
0.08
0.03
a OBS: Orthosteric binding site; SBS: Secondary binding site. b Site Id as shown in Fig. 3.7 c See reference. d Average
water occupancy of the site measured by HSA e Average energy of the site relative to bulk measured by HSA, Ebulk =
−12.24 kcal/mol. f Overall energy score of the HSA sites indicated in column 2 and of the enclosed hydration score
of the AGBNP2 hydration spheres indicated in column 3 in kcal/mol [66].

Because of the complexities of enclosed hydration phenomena and their variations due to the
motion of receptor atoms, it has been challenging to formulate an unsupervised and automated
protocol to map HSA results to AGBNP2 spheres. Within the general framework outlined above,
some necessary ad-hoc adjustments were made. One adjustment was made to model strongly
unfavorable HSA hydration sites (HSA site Ids - 3,4,8 and 21) identified at hydrogen-bonding
distance to the carboxylate group of the critical Asp1103.32 residue. Because AGBNP2 attaches
eight equinergetic solvation spheres to carboxylate groups, we decided to distribute the HSA excess
energy of this site among the three out of eight carboxylate hydration spheres of Asp1103.32 with
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non-zero water occupancy. Adjustments were also made to treat HSA hydration sites in close
proximity to each other. Due to the limitations in mapping accurately the position of AGBNP2
spheres, in this case, we modeled nearby groups of HSA sites with a single AGBNP2 hydration
sphere by assigning to it the sum of the energy weights of each HSA site as shown in Table 3.7.

3.3.2.3

System preparation for the binding free energy calculations

The structure of the Dopamine D3 receptor was obtained from the published eticlopride bound
crystal structure (PDB ID - 3PBL) [80]. The bound ligand was removed from the co-crystallized
structure along with crystallographic waters. Protonation states were adjusted to reflect neutral
pH conditions. The receptor structure was prepared using the Protein Preparation Wizard of the
Maestro version 2016-3 (Schrodinger Inc.). The prepared protein structure was used to generate
the receptor grid for docking using default parameters. Docking was performed with Standard
Precision (SP) version of the Glide program (Schrodinger Release 2016-3) [97]. Positional constraints were applied to the alkyl nitrogen of the (-)-stepholidine and all the analogues to maintain
the salt-bridge interaction with Asp 1103.32 of the D3 receptor. The hydroxyl and thiol groups of
the receptor, such as of residues Ser 182ECL2 , Ser 1925.42 , Ser 1965.46 , Thr 1153.37 , Thr 3697.39 ,
Cys 1143.36 located near the binding site were allowed to rotate during docking.
The (-)-stepholidine analogues were built using the Maestro program (Schrodinger Release
2016-3). Alternative protonation states as well as chiral forms were generated for the 7 ± 2 pH
range using the LigPrep facility (Schrodinger Inc.) and ionization penalties were calculated with
Epik [98] at pH 7. The ionization free energies were recorded and added to the binding free energy
estimates to compute the predicted binding free energies. Only states where the alkyl nitrogen is
protonated were selected for docking calculations. We also included in the docking study the two
chiral forms of the protonated alkyl nitrogen for each compound as generated by LigPrep.
Binding poses generated by docking were selected based on their docking score for further
study by free energy methods. In all poses selected, the protonated alkyl nitrogen forms an ionic
interaction with the carboxylate group of Asp1103.32 (except for a pose of (-)-stepholidine de-
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scribed below). The derivatives considered here are all stereo-isomers and have an S configuration
at the chiral carbon connecting ring B and ring C of the (-)-stepholidine core (Table 3.5). The
adjacent protonated alkyl nitrogen atom is found in either the R or S configuration depending on
the nature and position of substitutions. For derivatives substituted at the C9 position, the aryl D
ring of the ()-stepholidine core (Fig. 3.8) is found near the secondary binding site (SBS), and the A
ring is placed within the orthosteric binding site (OBS). In these poses, the protonated alkyl nitrogen is always found to be in the R configuration. The opposite is observed for the C3-substituted
ligands, which instead are rotated by ∼ 180◦ and are found with the A ring placed near the SBS
and D ring within the OBS and with the protonated alkyl nitrogen in the S configuration (Fig. 3.8).
The (-)-stepholidine parent compound, as well as some derivatives with small substituents, were
observed to dock in the C9 or C3-like poses with similar docking scores. The issue of multiple
potential binding poses and chirality were investigated in detail for (-)-stepholidine. Unlike the
C9 and C3 derivatives with large substituents, which are restricted to a particular confirmation
within the binding site as revealed by docking, the (-)-stepholidine core is small enough to allow
for different binding poses. The tetra-cyclic structure has a pseudosymmetry around the N-C bond,
which corresponds to a ∼ 180◦ flip along the short molecular axis of the molecule, which results
in the switching of position of the A and D rings of the molecule as discussed above (Fig. 3.8).
The molecule also binds with binding poses related by a rotation along the long and perpendicular
molecular axis (Fig. 3.8), resulting in a total of four different bound poses related by rotation along
these axes. We computed the binding free energies of (-)-stepholidine corresponding to each of
these poses. To ensure that conformational sampling is restricted to a particular bound pose, a flatbottom torsional restraints were applied on dihedral angles between a set of receptor and ligand
atoms similarly as described elsewhere [34].
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Figure 3.8: Pseudosymmetry axis in (-)-stepholidine.

The starting conformations of complexes from docking underwent energy minimization and
thermalization. Hamiltonian Replica-exchange Molecular dynamics simulations were performed
starting from the thermalized structures using 28 intermediate lambda states distributed as follows:
0.0, 0.002, 0.005, 0.008, 0.009, 0.01, 0.0105, 0.012, 0.0135, 0.015, 0.02, 0.0225, 0.025, 0.03,
0.035, 0.04, 0.07, 0.1, 0.25, 0.35, 0.45, 0.55, 0.65, 0.71, 0.78, 0.85, 0.92, and 1.0. The volume
of the binding site, Vsite is defined as the spherical volume in which the center of mass of ligand
is within 3.5 Å of the center of mass of the binding site of the D3 receptor, defined as the center
of mass of the Cα atoms of the residues 110, 111, 114, 183, 188, 346, 349 and the Cβ atoms of
residues 342, 349 and the backbone nitrogen atom of residue 111. The binding site volume restraint
is implemented as a flat-bottom spherical harmonic potential with force constant of 3 kcal/mol/Å2
and tolerance of 3.5 Å which resulted in a free energy penalty ∆G◦t for transferring the ligand from
a solution of concentration C◦ to a volume of size Vsite , of about 1.32 kcal/mol, calculated from the
following expression:

∆G◦t = −kb T lnC◦Vsite

(3.4)

Additional torsional restraints were imposed for the four bound poses of (-)-stepholidine. A
dihedral angle φ was chosen between two atoms of the receptor, the Cα atoms the residues Val
862.60 of helix II, Ser 1654.57 of helix IV and two atoms of the ligand, namely carbon atom at C3
position and carbon atom at C10 position , respectively. A force constant of 0.2 kcal/mol/Å2 was
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applied on the dihedral φ and a tolerance in rotation was allowed up 90◦ for each of the four bound
poses. Apart from the definition of Vsite and energetic penalties associated with it, binding of these
ligands are also restricted over the orientational coordinates. The allowed range of orientation
within the complex was measured by integrating over the domain of angular coordinates, Ωsite [1].
The free energy penalty for restricting at a particular orientation within the complex is calculated
to be about 0.82 kcal/mol using the following expression [1]:

∆Gr = −kb T ln

Ωsite
8π 2

(3.5)

For calculating the binding free energies of (-)-stepholidine bound poses, both ∆G◦t and ∆Gr quantities were added to the calculated binding free energies. The receptor conformation was loosely
restrained to the crystallographic structure using flat-bottom positional restraints with a force constant of 25 kcal/mol/Å2 and a tolerance of 1.5 Å applied to the backbone Cα atoms, except for six
residues 180-185 of the ECL2 loop to account for its flexibility.
Temperature replica-exchange simulations were carried out to obtain conformational reservoirs
of the apo receptor. These utilized 23 replicas distributed between 300 and 400K [99]. The conformational ensemble collected at 300K was used as a source of apo-receptor conformations in the
replica-exchange simulations. Conformational reservoirs for each ligand were generated similarly
using eight replicas distributed between 300 and 600K. During the simulation, conformations of
receptor and ligands were randomly selected from the conformational reservoirs during exchanges
at the uncoupled state.
Single-decoupling binding free energy calculations were performed for approximately 1 ns per
replica for a total of 28 ns per complex. Binding energies samples from the last 500 ps were
used for the binding free energy estimates. Each cycle of replica lasted 10 ps with 1 fs MD timestep. Binding energies were collected every 10 ps for a total of ∼ 1150 binding energy samples
per complex. Most of the calculations were carried out at the XSEDE SuperMIC and Stampede2
clusters utilizing CPU’s and MIC devices.
To improve the convergence of the binding energies near the uncoupled state at λ = 0, we
58

employ a soft core binding energy function as described elsewhere. [46, 100] The binding energies
were analyzed using the UWHAM R-statistical package [46] to yield the binding free energy ΔG◦b .
As mentioned, the average interaction energy ΔEb of each complex was obtained from the value
of the average binding energy at the coupled state (λ = 1). Reorganization free energies ΔG◦reorg
were measured as the difference between the binding free energy and the average binding energy
as

∆G◦reorg = ∆G◦b − ∆Eb

3.3.3

(3.6)

Biochemical evaluation of (-)-stepholidine C3 analogues

The synthesis of all (-)-stepholidine derivatives were done by Harding research group and the procedure for synthesis are detailed in a recent publication [66]. All the (-)-stepholidine analogues
were biochemically evaluated by primary and secondary radioligand binding assays at dopamine
receptors to obtain the inhibition constants, Ki and reported in Table 3.8. The primary and secondary radioligand binding assays are characterized as Competition binding assays. In these assays, the binding of one or more fixed concentrations of a radioligand, L is measured in presence
of an increasing concentrations of a non-radiolabelled test compound, U. The data is analyzed to
determine the binding constant for the non-radiolabelled test compound at the receptor, and the
cooperativity between the test compound and the radioligand for binding to the receptor [101].
Cheng-Prusoff equation is then used to determine the equilibrium inhibition constant, Ki .

Ki =

IC50
1 + KLdL

(3.7)

where the concentration of the radioligand and the binding constant of the radioligand are expressed as L and KdL respectively. The IC50 is the concentration of the test compound at which
50 % of the receptor is bound to the test compound. In this type of assay, the inhibition constant
of the radioligand, Ki corresponds to the dissociation constant, KdU for the non-radiolabelled test
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Table 3.8: Measured inhibition constants (Ki ) for the (-)-stepholidine C3 analogues against the dopamine D3 receptor.
a,b

Compounds C3-substituent Ki
1a
Et
40.0
1b
n-Pr
46.0
1c
n-Bu
51.0
1d
n-Pen
33.0
1e
n-Hex
26.0
1f
2-fluroethyl
86.0
a Inhibition constants are calculated in nM. Experiments
were carried out in triplicate - SEM values are within 13%
of reported Ki ; b [3 H] N-methylspiperone used as
radioligand; chlorpromazine used as a reference
compound with Ki = 11.0 nM. The biochemical assay
details are provided in the main text [66].

compound [101]. In this way, the binding properties of non-radiolabelled test compounds with a
receptor are deduced from the extent of binding of a radiolabelled ligand to the same receptor.
Both the primary and secondary radioligand binding assays were done at the PDSP facility
(http://pdsp.med.unc.edu/). In the primary binding assays, compounds were tested at single concentrations (10 µM) in quadruplicate in 96-well plates. Compounds that showed a minimum of
50% inhibition at 10 µM were tagged for secondary radioligand binding assays to determine equilibrium binding affinity at specific targets. In the secondary binding assays, selected compounds
were tested in triplicate sets (3 sets of 96-well plates) at eleven different concentrations out of
which eight are in nanomolar range (0.1, 0.3, 1, 3, 10, 30, 100 and 300 nM) and rest of the three
concentration in micromolar range (1, 3, and 10 µM). Both primary and secondary radioligand
binding assays were carried out in a final of volume of 125 µl per well in appropriate binding
buffer. The radioligand concentration was usually at a concentration close to the Kd .

The Ki values obtained for C3 analogues showed relatively stronger inhibition of the dopamine
D3 receptor compared to that of C9 analogues [85] (Table 3.8). The analogues with the longest
C3 hexyl substituent (1e) exhibited the strongest inhibition, contrary to the C9 series of analogues
where the ethyl substituent (3a) showed strongest inhibition amongst the linear chain alkyl substituents (Table 3.9, 3a to 3e, column 4). The measured inhibition constants for the C3 analogues
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shows an increase in inhibitory activity with increasing chain length, which was not observed previously with the C9 analogue [85]. The length of the substitution in the C3 analogues, however, is
observed to have a relatively small influence on their Ki values (Table 3.8).
This work was conducted in the lab of Dr. Wayne Harding at Hunter College, CUNY.

3.3.4

Binding Free Energy Calculations

We validated the enclosed hydration model described above on fourteen (-)-stepholidine C9-substituted
analogues, including seven brominated and seven unbrominated derivatives (Table 3.9) studied previously by molecular docking [85]. We then employed the model to study the six novel derivatives
substituted at the C3 position (Table 3.10) with and without enclosed hydration effects to probe
their effect on the binding free energy predictions. Finally, the model was employed to explore
in detail the molecular recognition mechanism of the (-)-stepholidine parent compound by the D3
dopamine receptor, including the role of multiple binding poses and chirality (Table 3.11).
The (-)-stepholidine core is tetra-cyclic and composed of rings named ring A, B , C and D
(Table 3.5). The C9 position is located on ring D whereas the C3 position is located on ring A
at the opposite end of the molecule. As previously found, [85] the C9 analogues dock into the
binding site of the dopamine D3 receptor with ring A placed within the orthosteric binding site
(OBS) and ring D with the C9 alkyl substituents placed towards the secondary binding site (SBS)
(Fig. 3.9). Contrary to the C9 analogues, the C3 analogues dock in such a way that ring A with the
substituents at C3 position are faced toward the secondary binding site (SBS).
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Figure 3.9: Poses of the brominated (yellow) and non-brominated (green) analogues of (-)-stepholidine with the pentyl
chain substitution at the C9 position(2d and 3d), bound to the Dopamine D3 receptor. The bromine atom, shown in
brown color, is found in close proximity to Ile 183 of the ECL2 loop.

The computed binding free energies for the C9 analogues, reproduce to a reasonable degree the
experimental inhibition data obtained previously (Table 3.9) [85]. The overall overestimation of
the magnitude of the binding free energies is ascribed to the unknown free energy penalty incurred
to go from the apo to the holo configuration of the receptor [81], which is not modeled here.
The calculations reproduce the stronger affinity of unsubstituted compounds at the C12 position
relative to brominated ones (Table 3.9), which is due to their smaller reorganization free energy
penalties and consistent with the steric occlusion of the bromine atom placed near Ile 183ECL2
of the receptor (Fig. 3.13). Notable exceptions are the analogues with the secondary butyl and
methoxyethyl substitutions which showed relatively small reorganization free energies insensitive
to the presence of the bromine substitution.
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Table 3.9: Experimental and calculated binding free energies, average binding energies and reorganization free energies of the (-)-stepholidine C9 analogues.

a In

a,b,c

a,c

a,c

a,c

◦
∆Greorg

◦
∆Gexp

◦
∆Gcalc

∆Eb

Br

−8.8

−11.3

−46.2

34.9

Br
Br
Br
Br
Br
Br
H
H
H
H
H
H
H

−9.2
−6.8
−7.4
−7.5
−7.8
−8.4
−9.5
−9.2
−9.4
−7.5
−9.2
−8.7
−10.3

−11.6
−13.6
−15.0
−14.4
−14.1
−13.6
−13.4
−12.6
−14.3
−15.0
−14.9
−14.5
−12.5

−49.1
−52.1
−53.0
−54.8
−49.1
−46.6
−45.7
−47.9
−49.7
−50.8
−52.6
−49.3
−45.1

37.5
38.5
38.0
40.4
35.0
33.0
32.3
35.3
35.4
35.8
37.7
34.8
32.6

Ligands

C9 substituent

C12 substituent

2a

Et

2b
2c
2d
2e
2f
2g
3a
3b
3c
3d
3e
3f
3g

n-Pr
n-Bu
n-Pen
n-Hex
sec-Bu
Methoxyethyl
Et
n-Pr
n-Bu
n-Pen
n-Hex
sec-Bu
Methoxyethyl

kcal/mol. b Experimental values obtained from measured inhibition constants, Ki , using the relation ∆Gb = kb T lnKi [85].

Computed binding free energies for the C9 analogs without enclosed hydration effects is provided in Supplementary Table ST1.
c Approximate

uncertainties for all measurements are implied by the number of significant figures.

The calculations also reproduce the observed overall non-monotonic trend with the increase in
length of the alkyl chain at the C9 position. However, for the brominated compounds, 2a to 2g,
the calculations predict optimal affinity for the pentyl substituent (2d) whereas experimentally this
occurs for the propyl substituent (2b) (Table 3.9). For the unbrominated compounds, 3a to 3g,
our model predicts a small increase in affinity with alkyl chain length which plateaus at the pentyl
substituent (3d). the experimental affinities for the unbrominated compounds, however did not
show any specific trend with the increase of alkyl chain. Closer look into the experimental affinities revealed large discrepancies and unreliable uncertainties in the Ki measurements for the C9
analogues [85] at Dopamine D3 receptor. Thus, observations for these compounds is not reliable
to undergo a reasonable validation with the binding affinity predictions.
In this work, we also investigated a new group of (-)-stepholidine analogues with substitution
at C3 position as mentioned previously. To accommodate the long alkyl chain substituents, the C3
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analogues (Fig. 3.10) are found to dock to the dopamine D3 receptor in a binding pose which is
rotated around the short molecular axis (Fig. 3.8) relative to C9 analogues (Fig. 3.13) so that the
alkyl chain occupies the secondary binding site (SBS). This has the important consequence that
ring D, rather than ring A occupies the OBS. It also results in an inversion of chirality of the alkyl
nitrogen which now forms an S configuration to maintain the salt bridge with Asp 1103.32 .
(A)

(B)

Figure 3.10: A) The C3 pentyl analogue (3e, purple) of (-)-stepholidine is observed to interact with Ser 192 of the
receptor at the orthosteric binding site. In order for the C3 analogues to interact with Ser 192, the C10 hydroxyl group
is placed in proximity of Ser 192; B) The 3e C3 analogue in another observed binding pose in which it interacts with
Ser 196, rather than Ser 192. In this pose, ring D of the (-)-stepholidine core is bound deeper into the orthosteric
binding site and the ligand is twisted causing Tyr 365 in the SBS to rotate and move away from Ser 182 of ECL2. The
receptor is represented as a pink ribbon [66].

The calculated binding free energies for the novel C3 derivatives (Table 3.10, with enclosed
hydration model, column 7) are significantly less favorable than the ones predicted for the C9 analogues. Possible reasons for this observation is further discussed in the Discussion section. Nevertheless, the trends within the C3 series are well reproduced by our model. In agreement with the
observed inhibition data, calculated binding free energies are found to be rather insensitive to the
length of the substituent at the C3 position (Table 3.10, 3rd and 7th column). The slightly weaker
binding of the fluorinated analogue (1f) is also reproduced by the free energy model. The enclosed
hydration model is found to be an essential ingredient to reproduce the observed inhibition data.
Binding free energy estimates obtained without enclosed hydration grossly underestimate the magnitudes of the binding free energies derived by the measured inhibition constants (Table 3.10, 3rd
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Table 3.10: Experimental and calculated binding free energies, average binding energies and reorganization free
energies of the (-)-stepholidine C3 analogues with and without enclosed hydration corrections.
Compound

a

∆G◦exp

Without enclosed hydration model
a,b

1a
1b
1c
1d
1e
1f
a All

−10.1
−10.0
−9.95
−10.2
−10.4
−9.64

a,b

∆G◦calc

∆Eb

−2.2
−2.3
−1.8
−0.3
−3.9
−3.1

−36.9
−38.0
−40.3
−43.7
−39.6
−32.7

a,b

With enclosed hydration model
a,b

a,b

◦
∆Greorg

◦
∆Gcalc

∆Eb

34.7
35.7
38.5
43.4
35.7
29.6

−8.8
−10.4
−11.5
−10.6
−12.5
−8.9

−42.5
−44.7
−48.1
−55.6
−55.2
−43.2

a,b

◦
∆Greorg

33.7
34.3
36.6
45.0
42.7
34.3

values in kcal/mol. b Approximate uncertainties for all measurements are implied by the number of significant
figures [66].

and 4th columns). In contrast, binding free energy calculated with the enclosed hydration model
are significantly more favorable and in substantial better agreement with the experiments than
without enclosed hydration. The enhancement of binding affinities with the enclosed hydration
model is in accord with the idea that energetically frustrated enclosed water molecules contributed
favorably to binding when displaced by the ligand.

3.3.5

Binding affinities of different binding modes of (-)-stepholidine

The parent compound, (-)-stepholidine, of the ligand library investigated here is a well known potent antagonist of the dopamine receptor. [87] There have been modeling studies of (-)-stepholidine
binding to homology models of D1 and D2 receptors [84, 90]. Since structural data of the complex of (-)-stepholidine with D3 is not available, we also set out to investigate by modeling the
mode of interaction of this compound with the D3 receptor. Ligand docking of (-)-stepholidine to
the D3 receptor resulted in 5 bound poses, namely poses 1 through 5 (Fig. 3.11) for all of which
we obtained binding free energy estimates (Table 3.11). The multiple bound poses observed for
(-)-stepholidine are due to the ability of this molecule to rotate within the binding site by ∼ 180◦
around its short, long and perpendicular pseudosymmetry axes (Fig. 3.8).
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Pose 1

Pose 2

Pose 4

Pose 3

Pose 5

Figure 3.11: The five bound poses of (-)-stepholidine with dopamine D3 receptor that we investigated. (-)-stepholidine
is shown with green carbon atoms. The receptor structure is represented as pink ribbon and selected residues are
represented with cyan carbon atoms.

In pose 1, the aryl ring A is placed within the orthosteric binding site while ring D facing the
secondary binding site (SBS) (Fig. 3.11A) as for the C9 derivatives. Relative to this pose, pose 2 is
obtained by 180◦ rotation around the perpendicular molecular axis (Fig. 3.8) keeping the chirality
of alkyl nitrogen unchanged. Due to this rotation, in pose 2, the aryl ring D occupies the orthosteric
binding site. A 180◦ rotation around the short molecular axis starting from pose 1, results in pose
3 where the aryl ring D again occupies the orthosteric binding site. The main difference between
pose 2 and 3 is the orientation of ring D within the cavity, which results in alternative placement
within the orthosteric binding site of the methoxy substituent at C9 and hydroxy substituent at
C10 (Fig. 3.11). In pose 3, the chirality of the protonated alkyl nitrogen is also inverted relative
to pose 2. Pose 4 results from a 180◦ rotation around the long molecular axis relative to pose
1, along with an inversion of chirality of the alkyl nitrogen. This rotation keeps ring A within
the orthosteric binding site but flips it so as to switch the position of hydroxy and C3 methoxy
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substituents. Finally, pose 5, the last we considered, is obtained by inversion of the chirality of the
alkyl nitrogen relative to pose 1 without rotations so as to disrupt the salt-bridge interaction with
Asp 1103.32 (Fig. 3.11). This pose was considered in order to probe the influence of the salt-bridge
interaction on the binding affinity.
Table 3.11: Calculated binding free energies, average binding energies and reorganization free energies of five bound
conformations of (-)-stepholidine to dopamine D3 receptor
Chirality of Nitrogen ∆G◦calc a,b ∆Eb a,b ∆G◦reorg a,b
Pose 1
R
−13.4
−43.0
29.6
Pose 2
R
−6.0
−37.7
31.7
Pose 3
S
−7.2
−43.2
36.0
Pose 4
S
−4.9
−39.6
34.7
Pose 5
S
−0.2
−36.5
36.3
a All values are in kcal/mol. b Approximate uncertainties for all
measurements are implied by the number of significant figures.

Pose 1 of (-)-stepholidine, corresponding to the binding pose of C9 analogues was found to be
the most favorable with a binding free energy of −13.4 kcal/mol (Table 3.11, 3rd column) which
is within a reasonable agreement with the binding affinity of −10.3 kcal/mol of (-)-stepholidine
obtained from the inhibition constant. [85] In agreement with the observed trend, the calculated
binding free energy of pose 1 of (-)-stepholidine is more favorable than the one for the ethyl (3a)
C9 analogue (Table 3.9). Pose 1 is observed to have one of the most favorable average interaction
energies among the five binding poses, while being comparatively less penalized due by the reorganization free energy (Table 3.11, 4th and 5th column). Pose 3, which corresponds to the binding
pose of the C3 analogues, is found to be the second most favorable pose with a binding free energy approximately 6 kcal/mol less favorable than that of pose 1. Thermodynamic decomposition
reveals that pose 3 is disfavored mainly by reorganization free energy (36.0 kcal/mol vs. 29.6
kcal/mol for pose 1 from Table 3.11, 5th column) rather than by the interaction energy which is as
strong as for pose 1. Pose 2 of (-)-stepholidine, while displaying the same chirality on protonated
alkyl nitrogen as pose 1, is disfavored relative to pose 1 by more than 8 kcal/mol due to the loss of
critical hydrogen bonding interactions (see Discussion below). Pose 4 and especially, pose 5 are
found to have the weakest binding affinity. In the case of pose 5, this is clearly related to the loss
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of ionic interaction with Asp 1103.32 due to the opposite orientation of the hydrogen atom of the
protonated nitrogen.

3.3.6

Discussion

In this work, we have tested for the first time a hybrid computational model involving explicit and
implicit solvation to include the effect of the thermodynamics of confined water and applied it to
calculate binding free energies of protein-ligand complexes. We applied the model to calculate
the binding free energies for a series of antagonists of the dopamine D3 receptor, some of which
were reported previously, as well as novel compounds which have been synthesized and assayed
recently. In all cases tested, binding free energies were observed to be more favorable in the
presence of enclosed hydration effects compared to the basic implicit solvent.
In this work, we validated a novel class of dopamine D3 receptor antagonists computationally
using binding free energy predictions and analyzed predictions of the antagonists synthesized previously [85]. The inhibitory activity of the (-)-stepholidine C3 analogues justifies the motivation of
synthesis to increase interaction at the secondary binding site (SBS) by adding substituents at the
C3 position, with the strongest inhibition being observed for the longest substitution (1e). No such
specific trend between the length of alkyl chain and strength of inhibition was observed for (-)stepholidine C9 analogues that were studied previously [85] (Table 3.9, 2a to 2e, 3a to 3e, column
4).
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(A)

(B)

Figure 3.12: A) The C9 secondary butyl substituent (3f) is observed to make hydrophobic interaction with nearby Val
86, Leu 89 of helix II, and Phe 106 of helix III, B) The C9 methoxyethyl substituent (3g) can form intra-molecular
hydrogen bonds between the methoxy oxygen and C10 hydroxyl hydrogen. In both figures, the ligand is shown in
yellow CPK representation with only polar hydrogen visible. The receptor structure is represented as pink ribbon with
selected residues in cyan. The hydrogen bonding interaction is represented as dotted red lines.

While not all of the predictions quantitatively agree with the experimental findings, the modeling approach introduced here has provided key insights for this system. The calculations predicted
the stronger affinities of the unbrominated C9 analogues relative to the ones brominated at the
C12 position of the ring D, despite the fact that bromination strengthens ligand-receptor interactions by up to 2.4 kcal/mol (Table 3.9). According to our model, bromination induces a greater
reorganization free energy penalty than the additional interaction energy it provides. The greater
reorganization free energy is likely caused by steric hindrance due to the close proximity of the
bromine substituent to the Ile183ECL2 residue of the receptor (Fig. 3.9). This is an example of a
case in which free energy scoring is better suited at capturing binding affinity trends than energetic
determinants alone [100].
All of the compounds analyzed, consistently maintained an ionic interaction between the protonated alkyl nitrogen of the (-)-stepholidine core and the carboxylate group of Asp1103.32 of the
D3 receptor. All C9 compounds, brominated or not, maintained a bidentate hydrogen bonding
interaction with Ser1925.42 in the orthosteric binding pocket (OBS) (Fig. 3.9) of the D3 receptor,
but varied in terms of their interactions with the residues of the extracellular ECL2 loop near the
secondary binding site (SBS). For example, the C10 hydroxyl group is observed to make hydro69

gen bonding interactions either with backbone carbonyl of Cys181ECL2 (Fig. 3.9) or the side chain
hydroxyl group of Ser182ECL2 . This can be attributed to the flexibility of the linear alkyl chains at
the secondary binding site (SBS) of the dopamine D3 receptor.
3.5

∆∆Gοreorg (kcal/mol)

3
2.5

c
e
b

d

a

2
1.5
1
0.5
0
-2.5

g
-2

f

-1.5
-1
-0.5
∆∆Eb (kcal/mol)

0

0.5

Figure 3.13: Scatter plot of the differences in the reorganization free energies (∆∆G◦reorg ) vs. the differences in
the average interaction energies (∆∆Eb ) between the C9 brominated and the corresponding unbrominated analogues.
Negative values of the differences in average interaction energy (∆∆Eb ) favor brominated analogues, whereas positive
values of the difference in reorganization free energy (∆∆G◦reorg ) disfavor that of the brominated analogues. The alkyl
chain substitution are designated as a to f to indicate ethyl to hexyl chain substituent and f and g for the secondary-butyl
and methoxyethyl substituents, respectively. See Table 3.9 for the names and type of substitution of the C9 analogues.

The C9 branched secondary butyl (2f, 3f) and the C9 methoxyethyl (2g, 3g) analogues (both
brominated and unbrominated) experienced much less reorganization than the compounds containing linear chain substituents. Analysis of the molecular dynamics trajectories shows that the
secondary-butyl (2f, 3f) substituents are able to form stable hydrophobic interactions with nonpolar residues of the secondary binding site such as Val 862.60 , Leu 892.63 , Phe 1063.28 which is
not observed in most of the linear chain alkyl substituents (Fig. 3.12A). C9 methoxyethyl substituents (2g, 3g) are observed to form an intra-molecular hydrogen bonding interaction between
the hydroxyl group at C10 and the methoxy oxygen of the methoxyethyl chain at the C9 position
(Fig. 3.12B), thereby stabilizing the substituted chain at the secondary binding site (SBS). There
is a very small difference of about 0.3 kcal/mol in the reorganization free energy penalty for substituents f and g between C9 brominated and unbrominated analogues. The flexibility of the C9
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linear alkyl chain and the presence of the bromine atom at C12 position resulted in a significant
difference in reorganization between brominated and unbrominated analogues favoring the C9 unbrominated analogues (Fig. 3.13). Both of these modifications appear to have a synergistic effect
in modulating the stability of the C9-brominated ligands within the binding site.

3.3.7

Modeling of Dopamine D3 selective receptor ligands using molecular
docking

Apart from testing the tetrahydroprotoberine derivatives (THPB) in this work, we also investigated
receptor-ligand interactions of some highly D3 selective ligands and used molecular docking to
understand the underlying interactions for their specificity. This work is published in collaboration
with Harding research group at Hunter College, CUNY [82].
For the docking experiments, the crystal structure of the Dopamine D3 receptor(PDB ID 3PBL) [80] was used to generate the receptor grid. The receptor grid was generated using the
default parameters available in the Schrodinger Suite 2016-3. Positional constraints were applied
to the alkyl nitrogen to maintain the salt-bridge interaction between the protonated alkyl nitrogen
and the carboxylate group of the Asp 1103.32 of the receptor in the orthosteric binding site (OBS).
The hydroxyl and thiol groups of the receptor, such as of residues Serine/Threonine, Cysteine located near the binding site were allowed rotation during docking. Similar strategy was applied
to generate receptor grid for the Dopamine D2 receptor from the recently published crystal structure(PDB ID – 6CM4) [102].
Glide docking(Schrodinger Inc.) was performed for all the compounds listed in Table. 3.12 using the Standard Precision(SP). Several binding poses were obtained for molecules, out of which
the best poses are used to compare the binding modes of these compounds in both D2 and D3 receptor (Fig. 3.14). To study the interactions in compounds 7 and 8, the Glide docked conformation
for both posed are energy minimized using the IMPACT program [69]. The energy minimized
structures for compounds 7 and 8 are shown in Fig. 3.15.
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Table 3.12: List of compounds that are docked to both Dopamine D2 and D3 receptors. All experimental data are not
part of this thesis and are reported elsewhere [82].

Ligand scaffold
Ligands

R1

R2

D3
Docking scorea
R
S

D2
a

Kib

∆G◦Ki

Docking scorea
R
S

a

Kib

∆G◦Ki

4a

H

−6.159

−5.627

2.7 ± 0.4

−11.7

−

−7.033

800 ± 100

−8.3

4b

H

−7.330

−6.965

2.7 ± 0.4

−11.7

−7.470

−7.728

700 ± 100

−8.4

4c

H

−6.439

−7.893

22 ± 3.0

−10.5

−7.539

−7.130

na

na

4d

H

−6.334

−8.026

24 ± 3.1

−10.4

−6.581

−6.798

na

na

4e

H

−8.897

−6.922

8.7 ± 1.1

−11.0

−7.639

−6.962

na

na

4f

H

−6.647

−6.721

5.9 ± 0.8

−11.2

−6.867

−6.687

na

na

4g

H

−6.545

−7.287

12 ± 1.5

−10.8

−6.687

−6.815

na

na

4h

H

−7.536

−7.026

4.4 ± 0.6

−11.4

−6.102

−7.229

na

na

4i

H

−5.917

−7.202

2.1 ± 0.3

−11.8

−6.536

−6.661

1100 ± 100

−8.1

4j

H

−5.826

−6.826

3.4 ± 0.4

−11.6

−6.423

−6.445

> 10000

na

4k

H

−5.826

−6.452

10 ± 1.3

−10.9

−6.838

−6.265

na

na

6

H

−6.391

−7.191

28 ± 4.0

−10.3

−6.792

−6.889

860 ± 100

−8.3

7

H

−6.629

−7.422

6.3 ± 0.8

−11.2

−7.437

−7.000

na

na

Me −6.742 −7.151 410 ± 53 −8.7
−7.501 −6.450
b
in kcal/mol. Experimental Ki calculated in nM and is reported in [82].

na

na

8
a Calculated

The binding poses returned by Glide (Fig. 3.14) at the Dopamine D2 receptor (ochre) is observed to be different from the binding poses of the compounds with the Dopamine D3 receptor.
The 6-methoxy-3-methyl 1,2,3,4 tetrahydroisoquinolin-7-ol group is placed deep into the orthosteric pocket in D2, in comparison to D3, which may result in loss of specific hydrogen bonding
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interaction with Ser 193 of the D2 receptor(Ser 192 in D3).
The Trp 370 in the D3 is flipped to almost 90° in D2 structure (Trp 413) (not shown). Many
ligands with bulky groups in the secondary pocket have been observed to form a bent pose as being
probably due to steric hindrance at the secondary binding pocket due to the flipped conformation
of the Trp in Dopamine D2 receptor structure. The amino acid composition and orientation of
extracellular loop 2 , ECL2 is entirely different between D2 and D3 receptors. In D3, the extracellular loop 2 is well extended over the secondary binding pocket. The difference in position can be
seen in the Fig. 3.14.

Figure 3.14: Comparison of the binding modes of the ligands docked at both Dopamine D2 and D3 receptors. D3
receptor is colored “blue” with the ligand poses colored “green”. The D2 receptor structure is colored “red” while the
ligand poses for D2 is colored in “ochre”. The ECL2 in D2 and D3 are represented as tube in its respective receptor
color codes [82].

Compound 7 where the R2 is a hydrogen, can form one hydrogen bonding interaction with
the hydroxyl oxygen of the Ser192, the hydroxy oxygen from compound 7 acting as a donor
(Fig. 3.15). At the same time, the oxygen from the methoxy group can be seen to involve in
another hydrogen bonding interaction with the Ser 192 where the hydroxy oxygen from Ser 192
may be a H-bond donor. Thus, compound 7 is able to participate in 2 hydrogen bonding interactions
simultaneously.
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(A)

(B)

Figure 3.15: Bound pose of compound 7 and compound 8 after energy minimization at the Dopamine D3 receptor.
(A) Compound 7 is observed to form two hydrogen bonding interaction with Ser 192 shown in black dotted lines, (B)
Compound 8 is observed to form a single hydrogen bond interaction with Ser 192 [82].

In compound 8, which has methyl substitution in R2, can form alternate hydrogen bonding
interaction, using its two methoxy oxygen with the Ser 192 (Fig. 3.15). Thus, at any instant, it is
capable to form one hydrogen bonding interactions.
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4
Chapter Four: Overcoming Order/Disorder
Transition in Alchemical Binding Free
Calculations
4.1

Introduction

In the work discussed in Chapter 3, our focus was to improve absolute binding free energy estimation by modifying the solvent model to capture localized hydration effects. In this study, the
focus instead, is on strategies to develop new alchemical methodologies [2, 5, 24, 103, 104] for the
estimation of absolute binding free energies. While absolute binding free energies are more challenging to obtain than relative binding free energies, they provide a more stringent assessment of
protocols and force fields [105] and are better suited for ranking dissimilar compounds in virtual
screening applications [100, 106], as well as for investigating binding specificity [107].
While analyzing results of previous attempts of calculating binding free energies of proteinligand complexes in the lab, it has been observed that, analogously to conventional chemical systems as a function of temperature, alchemical systems undergo order/disorder phase transitions
along the alchemical path, and that these cause entropic bottlenecks which hinder the equilibra-
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tion and convergence of binding free energy estimates. An order/disorder transition occurs at a
critical value of the alchemical progress parameter where two conformational states exists and are
in equilibrium though one of the state has a much weaker receptor-ligand interaction energy with
respect to the other. The equilibrium exists because the high energy state is favored entropically
while the low energy state is energetically stabilized to an equal extent. This equilibrium between
ordered and disordered states, results in a bimodal binding energy distribution with two maxima
separated by wide binding energy gap corresponding to a range of binding energies that is poorly
sampled [6].
The binding free energy estimate, which depends precisely, in this case, on the relative weights
of competing modes, cannot be measured reliably because the relative populations of ordered
and disordered states cannot be easily converged due to rare crossing events between the two
states [108]. The effect of order/disorder transitions is analyzed here using the analytic theory of
alchemical binding recently proposed and developed in our lab [108] and the formalism developed
by Straub et al. [109, 110] for the modeling of conventional temperature-driven phase transitions.
The knowledge obtained from the analytical model is used to design novel alchemical perturbation
potentials [111] and soft-core functions [112] which attempt to eliminate or reduce the adverse
effects of rare order/disorder transitions. This advance leads to faster equilibration of the binding
free energy simulations by reducing the binding energy gap and, by so doing, increasing the number of transitions between bound and unbound states resulting in more robust binding free energy
estimates for challenging systems which are difficult to sample with conventional protocols.
In this work, we study four protein-ligand systems that exhibit order/disorder phase transition
bottlenecks as well as multiple binding poses separated by large free energy barriers. The first
system is the complex between the L99A mutant of the T4 lysozyme enzyme and 3-iodotoluene.
The T4 lysozyme system has been studied extensively both experimentally and by computational
modeling. The second is a medicinally important system that has been already discussed in Chapter 3 and is also a medicinally important system; the complex between (-)-stepholidine and the
Dopamine D3 receptor. The other two systems are also pharmacologically important protein-ligand
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systems; one of them is the Estrogen receptor-α (ER-α) complexed with a symmetric ligand,
5,11-cis-diethyl-5,6,11,12-tetra-hydrochrysene-2,8-diol (THC) [113], and the other is the VEGFR
(Vasculo Endothelial Growth Factor Receptor) inhibitor Axitinib bound to the T315I mutant of the
Abl1 kinase receptor [114]. In all these systems, we show that rare order/disorder transitions can
be addressed using the methodologies developed in this work leading to more efficient calculations
and reliable binding free energy estimates.
The results discussed here show that the newly developed methods are also capable of promoting transitions between different binding poses of the complex. For example, they can be
implemented to sample the correct bound conformation even when the simulation is started with
an incorrect bound pose. This feature could have a great practical impact in early drug discovery programs where an extensive set of co-crystal structures may not be available. While these
advances are very promising, we also discuss protein-ligand systems we encountered during this
study where, even rigorous conformational sampling was insufficient to identify the correct bound
pose because of severe kinetic traps..
The first part of this work with the complex with T4 lysozyme with 3-iodotoluene and another
system not discussed here has been recently published in The Journal of Chemical Physics [37].
The study presented here for the other three protein-ligand complexes of pharmaceutical interest
and on the issue of equilibration between different binding poses is currently being collected in a
manuscript to be submitted for publication. This chapter contains sections that are exact excerpts
taken from the manuscript accepted for publication by the Journal of Chemical Physics with very
few or minor changes.

4.1.1

Theory of Binding Free Energy estimation by alchemical transformations

As discussed in Chapter 1, a statistical mechanics formulation leads to the following expression
for the free energy pf binding: [1, 5, 34]
∆G◦b = ∆G◦site + ∆Gb
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(4.1)

where ∆Gb is the excess component of the binding free energy related to the work of desolvation
and the work for establishing ligand-receptor interactions, and
1
∆G◦site = − lnC◦Vsite
β

(4.2)

is the reversible work done for transferring the ligand molecule from a solution of standard ligand
concentration at C◦ = 1 M to a binding site region of specified volume Vsite . The excess binding
free energy is computed by means of an alchemical free energy perturbation schedule based on an
alchemical potential energy function Uλ (x), parametric on the alchemical progress parameter λ ,
which interpolates between the unbound state of the complex, described by the potential function
U0 (x), and that corresponding to the bound state, U1 (x). In this work, a solvent potential of mean
force formulation termed the Single-Decoupling Method (SDM) [1, 29, 104] is used to transfer the
ligand directly from the solution to the receptor binding site in a single alchemical process. In
this formulation, the degrees of freedom of the solvent are averaged out as discussed in Chapter 1.
Thus, the effective potential energy function includes a standard molecular mechanics component
describing covalent and non-bonded interactions plus an implicit solvation component to model
hydration effects [115]. In this implementation, the alchemical potential energy is expressed as
described in Chapter 2, eq. 2.5 and is re-written as

Uλ (x) = U0 (x) +Wλ (u(x))

(4.3)

where x represents the set of atomic coordinates of the molecular complex (receptor and ligand
both included),
u(x) = U1 (x) −U0 (x)

(4.4)

is the binding energy function, U0 (x) is the effective potential energy of the uncoupled state, U1 (x)
is the effective potential energy of the coupled state as discussed in Chapter 2, and Wλ (u(x)) is
the alchemical perturbation function, which varies parametrically with respect to the alchemical
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progress parameter λ .
In order to reproduce the physical coupled and uncoupled states of the complex at the beginning
and end states of the alchemical transformation, it is necessary that the alchemical perturbation
function is defined such that W0 (u) = 0 and W1 (u) = u at λ = 0 and λ = 1 respectively. The
linear function Wλ (u) = λ u satisfies this requirement and is the standard choice for the alchemical
perturbation function [116]. To obtain the binding free energy, set of samples of the binding
energies, ui , are collected during molecular dynamics simulations performed at a sequence of λ
values between 0 and 1. The excess free energy profile as a function of λ , ∆Gb (λ ), is obtained by
multi-state reweighting [117] using the UWHAM method [46]. The excess free energy of binding
in eq. 4.1 is by definition the value of free energy profile at λ = 1, ∆Gb = ∆Gb (1).
In this work, we took advantage of the analytic theory of binding to analyze the statistics of
the binding-energy function [108]. The analytic theory is extensively used here to analyze order/disorder transitions along the alchemical path and to derive soft-core functions and alchemical
perturbation functions with superior replica exchange efficiency than the conventional linear perturbation function Wλ (u) = λ u.

4.1.2

Overview of the Analytic theory of binding

The analytic theory of binding has been previously described [108]. Briefly, it provides analytic
expressions for the probability densities of the binding energy and also predicts the binding energy
profile as a function of the alchemical progress parameter λ for any kind of alchemical perturbation
potential that depends only on binding energy u(x). The predictions from this mathematical model
are fitted to the probability distribution of the binding energies obtained from actual molecular
simulations and refined in order to obtain model parameters. In this model, the central quantity is
the probability density of the binding energy u in the uncoupled state i.e. at λ = 0. The model
assumes that the statistics of the binding energy u is the superposition of two processes, one that
describes the sum of many “soft” background ligand-receptor interactions and that follows central
limit statistics, and another process that describes “hard” atomic collisions that follows max statis79

tics. The probability density p0 (u) is expressed as the superposition of probability densities of a
small number of binding modes
p0 (u) = ∑ ci p0i (u)

(4.5)

i

where ci are adjustable weights summing to 1 and p0i (u) is the probability density corresponding
to mode i described analytically as [108]:

p0i (u) = pbi g(u; ūbi , σbi ) +(1 − pbi )

´ +∞
0

pWCA (u0 ; nli , εi , ũi )g(u − u0 ; ūbi , σbi )du0

(4.6)

where g(u; ū, σ ) is the normalized Gaussian density function of mean ū and standard deviation σ
and
"

(1 + xC )1/2
pWCA (u; nl , ε, ũ) = nl 1 −
(1 + x)1/2
where x =

#nl −1

H(u) (1 + xC )1/2
,
4εLJ x(1 + x)3/2

(4.7)

p
p
u/ε + ũ/ε + 1 and xC = ũ/ε + 1. The model for each mode i depends on a number

of adjustable parameters corresponding to the following physical quantities [108]:
• ci : relative statistical weight of binding mode i
• pbi : probability that no atomic clashes occur while in binding mode i
• ūbi : the average background interaction energy of binding mode i
• σbi : the standard deviation of background interaction energy of binding mode i
• nli : the effective number of statistical uncorrelated atoms of the ligand in binding mode i
• εi : the effective ε parameter of an hypothetical Lennard-Jones interaction energy potential
describing the receptor-ligand interaction in binding mode i
• ũi : the binding energy value above which the collisional energy is not zero in binding mode
i
The parameters above, together with the weights ci , are varied to fit the binding energy distributions
obtained from numerical simulations [108] (see Fig. 4.7 and Table. 4.2 for examples).
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All other quantities of the alchemical transformation can be obtained from p0 (u). [1, 29] In
particular, given p0 (u), the probability density for the binding energy u for the state with perturbation potential Wλ (u) can be obtained by applying the Potential distribution theorem [118, 119] as
described in Chapter 2, eq. 2.15. The binding free energy profile is written as
1
∆Gb (λ ) = − ln K(λ )
β

(4.8)

where β = 1/kB T and K(λ ) is the excess component of the binding constant defined as
ˆ

+∞

K(λ ) =
−∞

4.1.3

p0 (u)e−βWλ (u) = he−βWλ (u) iλ =0

(4.9)

Order/disorder transitions during alchemical receptor-ligand binding

An order/disorder transition is a phenomenon that occurs whenever two conformational states with
significantly different average energies and entropies are in equilibrium. In these circumstances,
transfer of population from one state to another takes place in a narrow range of the controlling
thermodynamic parameter, typically temperature. For example, for the two-level system whereby
one state is energetically favored, and the other is entropically favored, the width of the temperature
transition δ T becomes increasingly narrow as the energy gap ∆E increases (δ T = 4kB Tm2 /∆E as
measured by the derivative of the population of the upper level with respect to temperature at
the midpoint temperature Tm ) [120]. In general, the hallmark of an order/disorder transition is
the presence of a bimodal energy distribution with a sudden transfer of population from the low
energy phase to the higher energy phase as the temperature is increased. The nature of temperatureactivated order/disorder transitions and the conformational sampling bottlenecks they cause has
been thoroughly investigated by John Straub and collaborators in a series of publications [109,
110, 121, 122].
In this work, we extend the analysis conducted by Straub et al. [109, 121] to investigate order/disorder transitions occurring along the alchemical path for binding. Because there are many
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more ways that ligand atoms clash with receptor atoms than configurations free of clashes, at small
λ weakly coupled configurations are entropically favored relative to coupled states. Conversely,
fully coupled configurations, which are free of severe clashes and are stabilized by favorable intermolecular interactions, predominate at large values of λ . Analogously to the temperature-driven
transitions, coupled and weakly coupled states separated by a sizeable energy gap, are in equilibrium at a critical value of the alchemical parameter λ . The occurrence of an order/disorder
equilibrium is evident from the presence of distinct modes of the binding energy distribution separated by a large binding energy gap.

4.2
4.2.1

Methods
Analyzing order/disorder transitions

Order/disorder transitions were first identified by looking for λ -states with binding energy probability densities pλ (u) with two or more modes i.e with two or more maxima, even though one of
them has a much weaker ligand-receptor interaction energy than the other. For a linear perturbation
potential, Wλ (u) = λ u and a natural log on both sides of eq. 2.17 yields

ln pλ (u) = − ln K(λ ) + ln p0 (u) − β λ u

(4.10)

As K(λ ) is a constant, taking a derivative with respect to u, we get
∂ ln pλ (u) ∂ ln p0 (u)
=
−βλ
∂u
∂u

(4.11)

The maxima and minima of this function occurs when ∂ ln pλ (u)/∂ u = 0 . Therefore, the stationary
points of pλ (u) under the alchemical potential function occur when
∂ ln p0 (u)
= βλ
∂u
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(4.12)

Therefore, if we define a new quantity named the λ -function of the system as

λ0 (u) ≡

1 ∂ ln p0 (u)
β
∂u

(4.13)

eq. 4.12 can be re-written for any perturbation potential as

λ0 (u) =

∂Wλ (u)
∂u

(4.14)

The λ -function is analogous to the energy-dependent statistical temperature in the canonical ensemble, TS (E), analyzed by Straub and co-workers [121]. The probability density of the binding
energy distribution, p0 (u) measured in the alchemical ensemble is analogous to the density of
states Ω(E) in the canonical ensemble. Thus, the λ function, λ0 (u) can be considered as a fundamental property of the system and is independent of alchemical progress parameter or method of
perturbation [37]. The λ -function for any receptor-ligand system can be obtained in the analytical
form using eqs. 4.5 and 4.13.
Graphical construction of eq. (4.14) is illustrated in Fig. 4.1 to locate the maxima and minima
of pλ (u) [121]. In the case of a linear perturbation (Wλ (u) = λ u), the stationary points of the
distribution of binding energies u at λ occur when λ0 (u) = λ , that is when the λ -function intersects
a horizontal line corresponding to the set value of λ (Fig. 4.1). For a general perturbation function
Wλ (u), the stationary points occur when λ0 (u) intersects the graph of the function ∂Wλ (u)/∂ u
as in eq. (4.14). As illustrated in Fig. 4.1, an order/disorder transition occurring with the linear
perturbation function can be avoided by using a suitable, non-linear, perturbation function [121].
The graphical construction in Fig. 4.1 also easily indicates the regions of binding energies
where pλ (u) is increasing or decreasing. When λ0 (u) > ∂Wλ (u)/∂ u > 0, that is when the curve
representing the derivative of the perturbation function is below the λ -function, pλ (u) has a positive derivative and increases with increasing u. Conversely, when ∂Wλ (u)/∂ u is above the λ function, pλ (u) is a decreasing. These behaviors are confirmed by our results as shown in Fig. 4.8.
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Figure 4.1: Illustration of the relationship between the λ -function λ0 (u) and the stationary points of the distributions
of binding energies as a function of the alchemical parameter λ . The stationary points occur where λ0 (u) (orange
lines) intersects the function ∂Wλ (u)/∂ u. In the case of a linear perturbation, Wλ (u) = λ u, the latter is represented by
an horizontal line at λ (blue dashed lines). When λ0 (u) varies monotonically (left panel), it intersects the horizontal
line at one point corresponding to the maximum of pλ (u) (blue, lower panels). Near an order/disorder transition (right
panels), λ0 (u) undergoes back-bending and intersects the u = λ line (blue dashed line) at three points corresponding
to two maxima and one in-between minimum of pλ (u) (blue). The bimodal behavior of pλ (u) can be converted a
single mode (green) by working with a non-linear perturbation function Wλ (u) whose derivative (green dashed line)
intersects λ0 (u) at only one point [37].

4.2.2

Soft-core binding energy functions

In this work, we developed a new soft-core function called rational soft-core function designed to
lessen the strength of order/disorder transitions

fsc (y) =

za − 1
,
za + 1

(4.15)

where z = 1 + 2y/a + 2(y/a)2 and a is an adjustable dimensionless exponent. This form of fsc (y) is
also invertible and lead to a C(2)-smooth soft-core binding energy function suitable for molecular
dynamics applications when included in eq. (2.20).
The hyperbolic tangent soft-core binding energy function discussed in Chapter 2 (eqs. 2.20
and 2.21) and the rational soft-core function in eq. (4.15) replaces the binding energy function u
in the binding energy-based alchemical potential of eq. (4.3). As an illustration, Fig. (4.2) shows
the effect of the soft-core function on the binding energy between two particles interacting by a
Lennard-Jones (LJ) interaction. While both soft-core functions cap the binding energy function to

84

u, usc [kcal/mol]

40
20
0
2

4

6

8

10

d [Å]
Figure 4.2: Illustration of the effect of the soft-core functions on the interaction energy between two atoms described
by Lennard-Jones potential (εLJ = 5 kcal/mol, σLJ = 3.5 Å, black curve) as function of distance r. Hyperbolic tangent
soft-core function, eqs. (2.20) and (2.21), with umax = 50 kcal/mol (blue curve). Rational soft-core function, eqs. (2.20)
and (4.15), with umax = 50 kcal/mol and a = 1/8 (orange curve). While the LJ potential grows rapidly to infinity as
d −12 at short distances, the soft-core versions plateau at umax . The rational soft-core function provides a smoother
transition and a smaller plateau region [37].

umax , the rational soft-core function leads to a smaller high-energy plateau region which, as shown
below, reduces the strength of order/disorder transitions near the decoupled states.

4.2.2.1

Probability density and λ -function of the soft-core binding energy

The soft-core binding energy function in eq. (2.20) is interpreted as a redefinition of the binding
energy of the system. Application of the alchemical theory for the soft-core definition of the
binding energy hinges on knowledge the probability density, psc
0 (usc ), of usc , the soft-core binding
energy, at λ = 0. This can be obtained from the probability density, p0 (u), of u using the variable
transformation formula:
0
psc
0 (usc ) = p0 [u(usc )]u (usc )

(4.16)

where u = u(usc ) is the inverse of the soft-core function in eq. (2.20). Since p0 (u) is available
in analytical form, and eq. (4.5) and both expressions in eqs. (2.21 and 4.15) are analytically
invertible and differentiable, eq. (4.16) provides an analytical expression of the probability density
of the soft-core binding energy at λ = 0.
To λ -function for the soft-core binding energy is obtained by differentiating the logarithm of

85

eq. (4.16) with respect to usc , yielding
λ0sc (usc ) =



1 ∂ ln psc
1
u00 (usc )
0
0 (usc )
=
λ0 (u)u (usc ) + 0
β
∂ usc
β
u (usc )

(4.17)

where λ0 (u) is the λ -function of the binding energy without soft-core in eq. (4.13) evaluated at
u = u(usc ).
It can be shown from eq. (4.17), and eqs. (2.20, 2.21, and 4.15), that the λ -functions with both
of the soft-core functions diverges to +∞ at usc = umax where the first derivative of the soft-core
function is zero. Interestingly, the characteristics of the singularity are system-independent (the
term λ0 (u)u0 (usc ) is zero at the singularity) and they depend only on the nature of the soft-core
function. As illustrated below, the divergence of λ0sc (usc ) implies that all distribution functions
of the soft-core binding energy, regardless of the form of the perturbation potential and of the alchemical schedule, will present a stationary point (a minimum, in fact) near usc = umax . Because,
∂ wλ (u)/∂ u is finite for any well-behaved perturbation function, near pλ (u) is necessarily an increasing function near usc = umax . However, in practice the upward trend of pλ (u) may not be
observed in alchemical states, such as bound states, for which the population near umax is negligibly small.

4.2.3

Alchemical Perturbation functions with replica-exchange that reduce
order/disorder transition

While suitable soft-core functions can reduce the binding energy gap across an order/disorder
transition, they can also create order/disorder sampling bottlenecks elsewhere along the alchemical
path (Fig. 4.9). It was observed that combining a soft-core function with new kinds of perturbation
potentials is particularly beneficial. One of the most effective perturbation potentials that was
identified is
Wλ (u) =

i
λ2 − λ1 h
ln 1 + e−α(u−u0 ) + λ2 u + w0
α

86

(4.18)

which is named as the integrated logistic biasing function. The parameters of this bias function,
such as, λ2 , λ1 , α, u0 , and w0 are all functions of λ . The name of this function comes from the fact
that its derivative is the logistic function or a “S”-shaped curve given by the expression
∂Wλ (u)
λ2 − λ1
=
+ λ1
∂u
1 + e−α(u−u0 )

(4.19)

which is sketched out in Figs. 4.1 and 4.8A.
The parameter λ1 is the height of the horizontal branch at the low binding energy end, and λ2
is the height at the high binding energy end. The parameter u0 controls the position of the switch
from λ1 to λ2 and also specifies the sigmoid’s midpoint, and α controls the logistic growth rate
which in this case operates the range of the switch. The parameter w0 is an overall energy offset.
As illustrated below, bimodal behavior can be avoided by properly tuning the parameters of the
integrated logistic function in regions of the alchemical path affected by order/disorder transitions.
Conversely, the integrated logistic biasing function behaves as a linear biasing function away from
the transition region.
The occurrence of an order/disorder phase transition has been shown to limit the rate at which
replicas diffuse in thermodynamic space [121], and hinder the ability of replica exchange to accelerate conformational sampling. This is because, at a phase transition, nearby thermodynamic
states can be separated by a large energy gap. In the alchemical case, the probability that two
replicas exchange their λ states is large when the two replicas have similar binding energies, and
it decreases rapidly when they are separated by a large binding energy gap. This effect is best
appreciated in the case of a linear perturbation potential Wλ (u) = λ u for two replicas on opposite
sides of the order/disorder transition. The replica in the ordered state with more favorable binding energy is preferentially at the larger value of λ whereas the replica in the disordered state is
more likely to have higher binding energy at a smaller value of λ . In this case, the probability of
exchange, which is proportional to the factor e(∆λ ∆u) , where ∆u > 0 is the difference in binding
energies and ∆λ < 0 is the difference in λ values between the two replicas, decreases exponen-
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tially with increasing binding energy separation. In this work, it is shown that Hamiltonian replica
exchange (RE) efficiency can be improved by using an alchemical perturbation potential, such as
the one proposed above, that removes or softens order/disorder transitions.

4.3

System preparation for binding free energy calculations

A total of four protein-ligand systems were studied in this work. The Dopamine D3 receptor
structure was prepared as described in Chapter 3. Specific details related to the Dopamine D3
receptor complex in this work, as well as details of system preparation for other systems are as
follows:

4.3.1

T4 lysozyme L99A receptor

The molecular structures of the L99A T4 lysozyme receptor (T4L) (PDB ID - 4W53) Fig. 4.3,
was prepared from the crystal structure [123] using the protein preparation wizard of Maestro
(Schrodinger Inc.) with default settings. Residues 1 through 71 of the T4 lysozyme receptor,
which do not participate in ligand binding, were removed. The positions of the Cα atoms of the
receptors were loosely restrained using a flat-bottom harmonic potential with a tolerance of 1.5 Å.
3-iodotoluene was placed in the binding site of T4L by superimposing it on the structure of bound
toluene. The binding site volume for the T4L system is defined as any conformation in which the
ligand center of mass is within 2.5 Å of the center of mass of the Cα atoms of residues 79, 84,
88, 91, 96, 104, 112, 113, 122, 133, and 150 of the T4L receptor. The ligand was sequestered
within the binding site by means of a flat-bottom harmonic potential with a force constant of 25
kcal/mol/Å2 applied to atoms with distances greater than 2.5 Å. With these settings, the value of
∆G◦site in eq. (4.2) is 1.97 kcal/mol. A flat bottom harmonic restraint of 25 kcal/mol/Å2 was applied
to all backbone Cα atoms of the receptor keeping side chains movement unrestricted.
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Figure 4.3: The complex between the L99A mutant of T4 lysozyme (T4L) and 3-iodotoluene. The carbon atoms of
the ligand are colored green and some of the residues lining the binding pockets are shown [37].

4.3.2

Dopamine D3 receptor

The co-crystallized structure of Dopamine D3 receptor bound to a dual D2/D3 antagonist Eticlopride was obtained from PDB ID - 3PBL [80]. The ligand was removed from the crystal structure
and the system was prepared as described in Chapter 3. The structure of the ligand, (-)-stepholidine,
was prepared using the LigPrep facility of Maestro (Schrodinger Inc.). Docking was performed
with Glide Standard Precision (SP) [97] with the R/S as well as S/S enantiomer configuration of ()-stepholidine i.e. in first case, the protonated nitrogen is in R configuration while the chiral carbon
is in S configuration and in second case, both are in S configuration. Docking yielded five main
poses of the ligand in the binding site (Pose 1 through 5) reported in Chapter 3 (Fig. 3.11). Out of
these five poses, one was obtained where the salt-bridge interaction between the protonated nitrogen of the ligand and Asp 110 was broken (Pose 5). In this pose, the protonated nitrogen was in S
configuration. As evolution of conformation in Molecular Dynamics (MD) is too slow to observe
a change in the chirality, Pose 5 was modified to change the chirality from S to R for the nitrogen.
Binding free energy calculations were performed with this starting pose, designated as Pose 5 and
with Pose 1 which have the salt-bridge interaction intact. In this study, Pose 1 was considered to
be the correct bound pose as it has the key salt-bridge interaction (Fig. 4.4A). Modified Pose 5
without the salt-bridge interaction, is considered as incorrect bound pose (Fig. 4.4B). Later on in

89

(A)

(B)

Figure 4.4: Different starting structures of D3R/(-)-stepholidine complex, (A) Pose 1 with intact salt bridge interaction
between the ligand and Asp 110, and (B) Pose 5 which lacks the salt-bridge interaction.

this chapter, while discussing the results for these calculations, the correct pose is called Pose 1
whereas incorrect pose is called Pose 5.

4.3.3

Estrogen receptor-α

The molecular structure of the co-crystallized Estrogen receptor-α (ER) with 5,11-cis-diethyl5,6,11,12-tetra-hydrochrysene-2,8-diol (THC) was obtained from PDB ID - 1L2I [113] (Fig. 4.5).
Schrodinger’s protein preparation wizard was used to prepare the system. The center of mass of
the receptor i.e. the position of binding site was defined within 3.5 Å of the center of mass of the
Cα atoms of residues 347, 349, 350, 353, 383, 384, 387, 388, 391, 394, 402, 404, 421, 424, 425,
428, 521, 524, 525, 528 and 540 of the ER-α receptor. In this system too, a force constant of 25
kcal/mol/Å2 was applied to atoms with distances greater than 3.5 Å to secure the ligand within the
binding site. A flat bottom harmonic restraint of 25 kcal/mol/Å2 was applied to all backbone Cα
atoms of the receptor keeping side chains movement unrestricted. The ligand THC has a structural
symmetry with two −OH groups at two ends of the molecule (Fig. 4.5, O23 marked as orange
sphere and O25 as pink sphere). These two hydroxyl groups interact with Glu 353 and His 524 of
the receptor, respectively, through hydrogen bonding (Fig. 4.5).
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Figure 4.5: Bound state crystal structure conformation of the Estrogen receptor-α bound to THC molecule. The
oxygen atoms O23 and O25 of THC are shown in purple and orange spheres (PDB ID - 1L2I) [113]. Hydrogen bond
interactions are shown in red dashed lines. The three axes of symmetry of the molecule are shown with dashed lines
of different color: the long molecular axis is shown as a blue line, the short molecular axis is shown in yellow line and
the perpendicular axis is shown as a black line.

4.3.4

Abl1 kinase receptor

The structure of T315I mutant of the Abl1 kinase receptor was obtained from the PDB ID - 4TWP
[114] (Fig. 4.6). Standard protein preparation was performed using the Protein Preparation wizard
of Schrodinger’s Maestro environment (Schrodinger Inc.). Standard docking procedures were used
to dock the ligand Axitinib using Schrodinger Glide SP [97]. Docking calculations yielded two
conformations which are separated by almost ∼ 8 kcal/mol in their docking scores. One of them
(Fig. 4.6A) corresponds to the crystal structure conformation of the ligand, where the carbonyl
(-C=O) oxygen of the benzamide group of the ligand and Lys 271 side chain protonated nitrogen
interacts by intermolecular hydrogen bonding at the binding pocket near the DFG motif of Abl1
kinase. In this conformation, the pyridine nitrogen, on the other end of the ligand interacts with
Tyr 253 through hydrogen bonding (Fig. 4.6A). This pose is termed as Axitinib1 in the rest of the
chapter. In the other docked pose, the ligand is rotated by ∼ 180◦ and docks with the pyridine
group near Lys 271 and the benzamide group near Tyr 253 (Fig. 4.6B). This pose is termed as
Axitinib2.
This second pose, with very unfavorable docking score, was particularly interesting, because
of its opposite orientation within the binding pocket and may act as good model system to study
the robustness of the proposed model in attaining equilibration between different binging poses
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(A)

(B)

Figure 4.6: Bound conformations obtained from docking of Axitinib to the Abl1 kinase receptor; A) “Axitinib1” pose
corresponding to the crystal structure and B) the “Axitinib2” pose considered as the incorrect pose.

and thereby, convergence of binding free energy estimates. Thus, both the poses Axitinib1 and
Axitinib2 were considered as starting conformations binding free calculations. The center of mass
of the binding site within the receptor was defined by the center of of mass of Cα atoms of residues
248, 249, 253, 269, 271, 315, 316, 317, 318, 319, 321, 368, 370 and 381. A force constant of
25 kcal/mol/Å2 was applied to atoms with distances greater than 3.5 Å to secure the ligand within
the binding site. To prevent collapse of the binding site during the simulation, two strategies were
applied: a flat bottom harmonic restraint of 25 kcal/mol/Å2 was applied to both Cα of the receptor
and Cβ atoms of the side chains and residues Lys 271 and Asp 381 were restricted in their crystal
structure conformation.

4.4

Computational Details

The single-decoupling binding free energy simulations were set up using the Single Decoupling
Method (SDM) workflow (github.com/egallicc/openmm_sdm_workflow). OPLS-AA 2005
force field parameters [42, 69] were assigned using Desmond. SDM alchemical calculations employed the OpenMM [124] MD engine with the AGBNP
(github.com/egallicc/openmm_agbnp_plugin) and SDM integrator plugins
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(github.com/rajatkrpal/openmm_sdm_plugin.git) using the OpenCL platform. The ASyncRE software [49], customized for OpenMM and SDM
(github.com/baofzhang/async_re-openmm.git), was used for the Hamiltonian Replica Exchange in λ space.
A total of 16 replicas were used for T4L complexes and 24 replicas for the Dopamine D3
receptor (D3R), ER-α and Abl1 complexes, set at equally spaced values of λ between 0 and 1. The
λ -dependent parameters, listed in Tables. 4.3, 4.4, and 4.5 of the integrated logistic schedule were
chosen so as to avoid the order/disorder transitions near u = 0, as described in the Results section.
Molecular dynamics runs were conducted for a minimum of 6 ns per replica for T4L, Dopamine
D3 receptor and ER-α complexes with a 1 fs time-step at 300 K, exchanging approximately every
10 to 20 ps. Binding energy samples and trajectory frames were recorded every 5 ps. For the
Abl1 complexes, Molecular Dynamics runs were conducted for 4 ns per replica with 1 fs time-step
at 300 K, however, for these simulations, binding energy samples are collected every 1 ps and
replica-exchange was initiated approximately every 5 ps. A Langevin thermostat at 300 K with
a relaxation time constant of 2 ps was used. The calculations were performed on a farm of GPU
servers at Brooklyn College and on the XSEDE Comet GPU HPC cluster using a mix of GTX 780
Ti, RTX 2080, Titan Xp, K80, and P100 NVIDIA GPUs.

4.5

Results

The adverse effects of order/disorder transitions in alchemical calculations, and the ability of suitably crafted soft-core functions and perturbation potentials to avoid or ameliorate them, are illustrated for four systems: the complex of L99A T4 lysozyme with 3-iodotoluene (Fig. 4.3), the
Dopamine D3 receptor bound to (-)-stepholidine [80] (Fig. 4.4), the Estrogen receptor-α bound to
THC [113] (Fig. 4.5) and the complex between the T315I mutant of the Abl1-kinase with inhibitor
Axitinib [114] (Fig. 4.6). The T4 lysozyme receptor is often used to test alchemical and conformational sampling methods [29, 125, 126]. The other systems are much more challenging and more
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representative of those encountered in medicinal applications. All of these systems display order/disorder transitions along the alchemical path. The T4L/3-iodotoluene complex was simulated
with the hyperbolic tangent (TanhSC), and the rational function soft-core (RatSC) functions with
a linear perturbation schedule as well as with the integrated logistic perturbation potential (ILog)
with the RatSC soft-core function. The D3R/(-)-stepholidine complex was also simulated with the
TanhSC, RatSC as well as with ILog potential and RatSC soft-core functions. The Abl1/Axitinib
complex was simulated with the linear perturbation and RatSC potential as well as with ILog
potential and RatSC soft-core functions. ER-α/THC was simulated with the hyperbolic tangent
(TanhSC) and rational soft core functions (RatSC) and with linear perturbation only. The ERα/THC complex is considered as a model system in this work not only to show that the new soft
core function is efficient in conformational sampling of symmetric ligands but also to test the robustness of the soft-core function in presence of symmetry in ligand molecule. The systems and
simulations considered in this study are summarized in Table. 4.1.
At first, the analytical model for each of the above mentioned systems were parameterized to
study the effects of different soft core functions on analytical predictions. With this information,
customized alchemical schedules with integrated logistic perturbation potential were designed for
each of the systems to avoid order/disorder transitions. Emphasis was given mostly to investigate the effects of different settings on conformational sampling, replica exchange efficiency and
thereby, convergence of the binding free energies.
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Table 4.1: Summary of the alchemical calculations performed in this study
Sim. Id

soft-core function

uamax

ab

biasing potential

No. of replicas

simulation lengthd

T4L99A/3-iodotoluene
1
TanhSC
50
–
Linear
16
6 ns
2
RatSC
50
1/16
Linear
16
6 ns
3
RatSC
50
1/16
ILog
16
6 ns
c
D3R/(-)-stepholidine - Pose 1
4
TanhSC
50
–
Linear
24
6 ns
5
RatSC
50
1/16
Linear
24
6 ns
6
RatSC
50
1/16
ILog
24
6 ns
D3R/(-)-stepholidine - Pose 5c
7
TanhSC
50
–
Linear
24
6 ns
8
RatSC
50
1/16
Linear
24
6 ns
9
RatSC
50
1/16
ILog
24
6 ns
Abl1-Kinase/Axitinib1c
10
RatSC
50
1/16
Linear
24
4 ns
11
RatSC
50
1/16
ILog
24
4 ns
Abl1-Kinase/Axitinib2c
12
RatSC
50
1/16
Linear
24
4 ns
13
RatSC
50
1/16
ILog
24
4 ns
ER-α/THC-leftc
14
TanhSC
50
1/16
Linear
24
6 ns
15
RatSC
50
1/16
Linear
24
12 ns
a In kcal/mol. b soft-core adjustable dimensional exponent. c Starting conformation. d run per replica

4.5.1

Parameterization of the analytical model of alchemical binding

The parameters for the analytical description of p0 (u) in eq. (4.5) [108] for the complexes studied
in this work are listed in Table. 4.2. The good level of agreement between the analytical binding
energy distributions, from eq. (2.17), and the histograms obtained from the alchemical calculations
are illustrated in Fig. 4.7.
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Figure 4.7: The predicted (continuous lines) and observed (points) binding energy probability densities, pλ (u), for
(A) the T4L/3-iodotoluene complex for the linear perturbation function Wλ (u) = λ u and the rational soft-core function
with umax = 50 kcal/mol and a = 1/16 at λ = 0.171 (orange), λ = 0.229 (green), and λ = 0.4 (blue) [37], and for
(B) the D3R/(-)-stepholidine complex with the integrated logistic perturbation function [eq. (4.18)] and the rational
soft-core function with umax = 50 kcal/mol and a = 1/16 at λ = 0.261 (orange), λ = 0.304 (green), and λ = 0.391
(blue). The predicted distributions are obtained using the analytical model for p0 (u), eqs. (4.5) and (4.6), with the
parameters listed in Table 4.2

The model predicts the presence of three modes for each of T4L/3-iodotoluene, D3R/(-)stepholidine and Abl1/Axitinib systems, respectively (Table. 4.2). In the case of T4L/3-iodotoluene,
two of the modes (modes 1 and 2) correspond to alternative binding poses of 3-iodotoluene, one
with strong interactions with the receptor (mode 1, with ūb = −11 kcal/mol) and another (mode
2), more weakly bound, but approximately 13 times more likely to occur than the first in the uncoupled ensemble at λ = 0 . The corresponding values of the statistical weights are provided in
the second column of Table. 4.2. While they formally describe binding poses, the analytical model
predicts that in the absence of receptor-ligand interactions, the probability of occurrence of clashfree configurations is very small for these states (from 10−6 to 10−5 , third column of Table. 4.2).
The third mode of T4L/3-iodotoluene (mode 3, with 89% weight) corresponds to conformations in
which the ligand is nearly freely rotating and translating within the binding site. We refer to modes
such as this as “unbound”, keeping in mind however that in the alchemical approach the ligand
is not allowed to leave the binding site. As reflected by the negligible pb parameter, the highly
unfavorable average binding energy parameter, and the larger nl parameter (Table 4.2, columns 3,
4, and 8, respectively), in this mode clashes with receptor atoms are more severe and occur with
an overwhelmingly large probability.
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Table 4.2: Optimized parameters for the analytical model of binding for the complexes studied in this work

weight
mode 1
mode 2
mode 3

7.5 × 10−3
0.10
0.8925

mode 1
1.5 × 10−9
mode 2
1.2 × 10−4
mode 3
∼ 1b
Abl1/Axitinib1
mode 1 2.5 × 10−10
mode 2
1.0 × 10−4
mode 3
∼ 1b
a In

pb

ūb

σba

εa

ũa

nl

T4L99A/3-iodotoluene
1 × 10−5
−11.0 1.95
1 × 10−6
−4
2.8
0
100
10
D3R/(-)-stepholidine Pose 1
2 × 10−6
−20
3.3
0
30
5.0
0
1000
100

20
20
100

−20
−4
100

5.5
5.5
8

15
30
1000

−8
1 × 105
1 × 105

4
7
60

2.0 × 10−8
0
0

15
250
1000

15
250
1000

4
5
35

−28
250
1000

3.1
12
100

kcal/mol. The description of individual parameters are provided in the text

The analytical model predicts a single binding pose for the D3R/(-)-stepholidine started with
Pose 1 (mode 1 for Pose 1 in Table. 4.2). The bound mode (mode 1) is favored relatively to the
first unbound mode (mode 2) by a more favorable interaction energy (ūb = −20 vs. 30 kcal/mol).
At the same time, as measured by its statistical weight (second column in Table. 4.2), the bound
mode is predicted to be 10−5 less likely than the unbound mode (mode 2) at λ = 0. However,
there appears to a little probability of 2 × 10−6 for the occurrence of configurations free of atomic
clashes of mode 1 at λ = 0 (Table. 4.2, Pose 1 , column 3).
In case of the Abl1/Axitinib complex, the analytical model predicted a single bound pose
(mode 1) for simulations started with Axitinib1 pose with a distribution centered at ub = −28
kcal/mol. Similar to the Dopamine D3 receptor complex, the statistical weight of mode 1 is almost
106 times smaller than that of mode 2 making mode 1 less likely to be observed in the unbound
state. This was also supported by much lower probability pb of around 2.0 × 10−8 in occurrence
of atomic clash-free configurations in mode 1 (Table 4.2, Axitinib1, column 3). The analytical
model for both simulations started with Abl1/Axitinib1 and D3R/(-)-stepholidine Pose 1 were fitted to the histograms of the binding energy distribution from molecular simulations started with
the best bound pose configuration (Pose 1 for D3R/(-)-stepholidine complex and Axitinib1 for
Abl1/Axitinib complex). So, these models only reflect that binding mode for both complexes.
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Inspection of the molecular dynamics trajectories largely confirms the results of statistical analysis above. Indeed, 3-iodotolune is observed to visit predominantly two binding poses related by
a swap of the positions of the methyl and iodo substituents within the binding site. The pose with
weaker interactions (mode 2) is entropically favored and occurs more often at smaller values of λ .
Conversely, the pose with stronger interactions occurs more frequently at values of λ closer to 1.
In all complexes examined and with any of the simulation settings (Table 4.1), we observed
that, while in one of the bound modes, the ligand oscillates around the stable binding pose and that
the range of the oscillations is greater near the uncoupled state at λ = 0. Infrequently, and only if λ
is smaller than a critical value, the ligand transitions to a disordered state where it explores a wide
range of positions and orientations within the binding site. In case of D3R/(-)-stepholidine complexes started with Pose 5, replicas at large λ frequently exchanged with replicas with λ smaller
than the critical value and transitioned to a disordered state where these replicas explored a wide
range of conformations for a substantial amount of time and eventually sampled the conformational
space pertaining to Pose 1. However, the frequency of order/disorder transitions and efficient sampling of conformations depended on the nature of the soft-core function and of the alchemical
perturbation schedule used. For the D3R/(-)-stepholidine complex simulations started with Pose
5, a better rational soft-core function (RatSC) was able to avoid the adverse effect of order/disorder phase transitions with efficient replica diffusion as well as convergence of binding free energy
(Table 4.1, simulation 8). For the Abl1/Axitinib complex, the difference in ligand-receptor interaction energies between the Axitinib1 and Axitinib2 poses is about 10 kcal/mol. In this system, the
RatSC soft-core and the integrated logistic potential generally helped in the diffusion of replicas
in λ space but there were problem with convergence of simulations because of the ligand getting
trapped in incorrect pose (Axitinib2) due to the nature of the binding site. All these observation
are discussed later in detail.
For the ER-α/THC complex, molecular dynamics trajectories showed flipping of the ligand,
thereby keeping the ligand-receptor interactions intact because of the symmetry in the THC molecule
(Fig 4.5). The THC molecule has at least 3 level of symmetry axis that keeps the molecule main-
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taining key hydrogen bonding with the receptor. The ligand can rotate along the long molecular
axis, short molecular and perpendicular axis (Fig. 4.5). Both rotations along the short molecular
axis and the perpendicular axis interchanges the position of two hydroxyl −OH group atoms of
the ligand participating in the hydrogen bonding with His 524 and Glu 353, respectively. Visual
analysis of molecular dynamics trajectories revealed that flipping transitions in these molecules
occurred along the short molecular axis as well as the perpendicular axis during the simulation.
Ligand flipping was observed only with simulation performed with the rational soft-core function
(RatSC) (Table 4.1, simulation 15).

4.5.2

λ - functions

The λ functions obtained from the analytical model described in eqs. (4.13and 4.17) and the parameters in Table 4.2 are shown in Figs. 4.8, 4.9, and 4.10. As mentioned before, the λ -function
depends only on the chemical system and the choice of the soft-core function. Once parameterized, the analytical model yields, using eq. (4.17), the λ function for any choice of binding-energy
based soft core function.
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Figure 4.8: (A) The λ -function for the T4L/3-iodotoluene complex with the rational soft-core function with umax = 50
kcal/mol and a = 1/16 (black) and ∂Wλ (u)/∂ u for a linear perturbation function (green, dashed, λ = 0.229) and
for the integrated logistic function (red, dashed, λ = 0.4, λ1 = 0, λ2 = 0.4, α = 1 (kcal/mol)−1 , u0 = 1 kcal/mol,
w0 = −0.677 kcal/mol. (B) The binding energy probability densities, pλ (u), predicted for the linear (green) and integrated logistic (red) perturbation functions with the parameters as in (A). The maxima and minima of the probability
densities correspond to the intersections of the λ -function with the corresponding ∂Wλ (u)/∂ u curves. The probability
distribution with the linear perturbation is bimodal whereas the one with the integrated logistic potential has a single
maximum.

The non-monotonic behavior of the λ -function corresponds to multi-modal distributions which
may be indicative of order/disorder transitions along the alchemical transformation. The data in
Fig. 4.9 for the T4L/3-iodotoluene system shows that the linear schedule and the TanhSC soft-core
function is expected to yield an order/disorder transition between an ordered state with negative
average binding energy and a disordered state with average binding energy close to umax . These
states correspond, for example, to the intersections in Fig. 4.9 of the horizontal line at λ = 0.217
with the λ -function (as discussed above, the intersection near the upper limit of u corresponds to a
minimum followed by a maximum at u = umax ). In this particular case, we expect that the ordered
state and the disordered state are separated by a large energy gap of more than 50 kcal/mol which
leads to rare transitions and poor replica exchange efficiency (Fig. 4.14A). With the RatSC softcore function (black curve in Fig. 4.9), in contrast, the energy gap between low and high binding
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energy states is significantly reduced (Fig. 4.14B). For instance, at λ = 0.217 the high energy state
of pλ (u) is predicted to peak at u ' 17 kcal/mol rather than at 50 kcal/mol with the TanhSC softcore. As a result, the binding energy gap of the order/disorder transition is predicted to be reduced
by roughly half.
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40
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Figure 4.9: The λ -function for the T4L/3-iodotoluene complex with the hyperbolic tangent soft-core function with
umax = 50 kcal/mol (blue), and with the rational soft-core function with umax = 50 kcal/mol and a = 1/16 (black). The
two functions are equal for u < 0 where the two soft-core functions are the same. A linear λ -state (represented by the
green dashed horizontal line) intersects the λ -functions where the corresponding maxima and minima of the binding
energy distribution occur [37].

As shown in Fig. 4.10, the D3R/(-)-stepholidine system displays order/disorder transitions of
similar nature but of greater strength and complexity than T4L/3-iodotoluene. As indicated by the
presence with the RatSC soft-core function of an additional, strong, peak of the λ -function at high
binding energies, it is expected that the alchemical coupling process for this complex to display
multi-modal behavior. Specifically, starting at λ = 0, sharp transfers of population is expected from
a highly disordered state with binding energies close to umax to a less disordered state with binding
energies in the 10–40 kcal/mol range and then to coupled states at negative binding energies. With
the same RatSC soft-core function as T4L/3-iodotoluene capped at umax = 50 kcal/mol (solid black
curve in Fig. 4.10), entropic bottlenecks against binding occur at binding energies at around 0 and
35 kcal/mol, respectively by this model. These bottlenecks can be identified graphically by locating
the intersections between horizontal lines at λ and the λ -function corresponding to minima of
the binding energy distribution function. The strength of the order/disorder transitions can be
reduced using a less aggressive soft-core function with umax = 100 kcal/mol (dashed black curve
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in Fig. 4.10), at the expense of wider energy gaps between ordered and disordered states. With any
of the soft-core settings, the λ -functions for the D3R/(-)-stepholidine system indicates the RatSC
soft-core function to be significantly superior to the TanhSC soft-core functions in reducing the
binding energy gaps between ordered and disordered states and lead to improved RE efficiency.
A λ -function was also generated for the Abl1/Axitinib1 complex using the analytic model with
rational soft-core function capped at umax = 50 kcal/mol. Based on the feature represented by
the λ -function generated from Abl/Axitinib simulation, an alchemical perturbation scheme was
formulated for the simulating the complex with RatSC soft-core function.
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Figure 4.10: The λ -functions for the D3R/(-)-stepholidine complex with the hyperbolic tangent soft-core function
with umax = 50 kcal/mol (blue, solid) and umax = 50 kcal/mol (blue, dashed), and with the rational soft-core function
with umax = 50 kcal/mol and a = 1/16 (black, solid) and umax = 100 kcal/mol and a = 1/16 (black, dashed). The
λ -functions are equal for u < 0 where the two soft-core functions are the same. A linear λ -state (represented by the
green dashed horizontal line) intersects the λ -functions where the corresponding maxima and minima of the binding
energy distribution occur.

4.5.3

Designing the integrated logistic alchemical schedules

The λ -functions obtained above were used to design alchemical schedules based on the integrated
logistic perturbation function from eq. (4.18) to attempt to avoid order/disorder transitions or at
least reduce their effects. [121] The main design principle (Fig. 4.8) is to vary the λ dependence
of the parameters of the integrated logistic function so as that its derivative with respect to u has
a single intersection with the λ -function yielding a binding energy distribution with a single maximum or, when this is not easily achievable, at least at nearby points, thereby yielding maxima
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and minima separated by small energy gaps. The parameters of the optimized integrated logistic
schedule for the systems studied in this work are listed in Tables. 4.3, 4.4, and 4.5.
Table 4.3: Alchemical schedule of the integrated logistic perturbation function for the T4L/3-iodotoluene complex
λ
λ1
λ2
αa
0.000 0.000 0.000 0.010
0.067 0.000 0.067 0.167
0.133 0.000 0.133 0.333
0.200 0.000 0.200 0.500
0.267 0.000 0.267 0.667
0.333 0.000 0.333 0.833
0.400 0.000 0.400 1.000
0.467 0.111 0.400 1.000
0.533 0.222 0.400 1.000
0.600 0.333 0.400 1.000
0.667 0.444 0.444 1.000
0.733 0.556 0.556 1.000
0.800 0.667 0.667 1.000
0.867 0.778 0.778 1.000
0.933 0.889 0.889 1.000
1.000 1.000 1.000 1.000
a In kcal/mol−1 . b In kcal/mol. [37]

u0 b
4.000
4.000
4.000
4.000
4.000
2.504
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000

w0 b
0.000
-0.544
-0.811
-1.077
-1.344
-1.112
-0.677
-0.289
-0.178
-0.067
0.000
-0.000
0.000
0.000
0.000
0.000

The general design strategy that was followed to parameterize the integrated logistic schedule are illustrated in Fig. 4.11 for the T4L/3-iodotoulene and D3R/(-)-stepholidine systems. The
integrated logistic potential essentially allows using different λ values in different ranges of the
binding energy.
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Table 4.4: Alchemical schedule of the integrated logistic perturbation function for the D3R/(-)-stepholidine complex
with umax = 50 kcal/mol
λ
λ1
λ2
αa
0.000 0.000 0.000 0.200
0.043 0.000 0.077 0.230
0.087 0.000 0.155 0.260
0.130 0.000 0.232 0.290
0.174 0.000 0.310 0.320
0.217 0.000 0.387 0.350
0.261 0.000 0.465 0.380
0.304 0.000 0.542 0.410
0.348 0.000 0.620 0.440
0.391 0.066 0.620 0.470
0.435
0.133 0.620 0.500
0.478
0.200 0.620 0.500
0.522
0.266 0.620 0.500
0.565
0.333 0.620 0.500
0.609
0.400 0.620 0.500
0.652
0.467 0.620 0.500
0.696
0.533 0.620 0.500
0.739
0.600 0.620 0.500
0.783
0.667 0.667 0.500
0.826
0.733 0.733 0.500
0.870
0.800 0.800 0.500
0.913
0.867 0.867 0.500
0.957
0.933 0.933 0.500
1.000
1.000 1.000 0.500
a In kcal/mol−1 . b In kcal/mol

u0 b
5.000
5.000
5.000
5.000
5.000
5.000
5.000
4.000
3.000
2.000
1.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

w0 b
-0.000
-0.617
-1.188
-1.715
-2.221
-2.701
-3.173
-3.084
-2.837
-2.057
-1.295
-0.582
-0.491
-0.398
-0.305
-0.212
-0.121
-0.028
-0.000
-0.000
-0.000
-0.000
-0.000
-0.000

The coupling transformation, with the linear alchemical perturbation involves the progressive
increase of the single coupling parameter λ . The non-linear perturbation scheme is divided into
three phases. In the first phase (Fig. 4.11A and B, top panel), the coupling parameter λ2 , for high
binding energies is increased up to a critical value large enough to clear the maximum of the λ
function while λ1 , the coupling parameter for low binding energies, is left at zero. In the second
phase (Fig. 4.11A and B, bottom panel) λ1 is now increased while λ2 is left unchanged at the
critical value. The second phase ends when λ1 reaches the critical value. Finally, in the third phase
(Fig. 4.11 A and B, bottom panel) λ1 and λ2 are increased in unison thereby acting as a linear
perturbation from critical λ up to λ = 1.
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Table 4.5: Alchemical schedule of the integrated logistic perturbation function for the Abl1/Axitinib complex with
umax = 50 kcal/mol
λ
λ1
λ2
αa
0.000 0.000 0.000 0.250
0.043 0.000 0.037 0.250
0.087 0.000 0.075 0.250
0.130 0.000 0.112 0.250
0.174 0.000 0.149 0.250
0.217 0.000 0.187 0.250
0.261 0.000 0.224 0.250
0.304 0.000 0.261 0.250
0.348 0.063 0.261 0.250
0.391 0.125 0.261 0.250
0.435 0.188 0.261 0.250
0.478 0.250 0.261 0.250
0.522 0.313 0.313 0.250
0.565 0.375 0.375 0.250
0.609 0.438 0.438 0.250
0.652 0.500 0.500 0.250
0.696 0.563 0.563 0.250
0.739 0.625 0.625 0.250
0.783 0.688 0.688 0.250
0.826 0.750 0.750 0.250
0.870 0.813 0.813 0.250
0.913 0.875 0.875 0.250
0.957 0.938 0.938 0.250
1.000 1.000 1.000 0.250
a In kcal/mol−1 . b In kcal/mol
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u0 b
5.000
5.000
5.000
5.000
5.000
5.000
5.000
5.000
4.000
3.000
1.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

w0 b
0.000
-0.288
-0.583
-0.871
-1.158
-1.453
-1.741
-2.029
-1.593
-1.160
-0.463
-0.030
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000

During the whole alchemical process, ∂Wλ (u)/∂ u is designed to intersect the λ -function
mostly at a single point, thereby yielding binding energy distributions with a single mode which
progressively shifts to low binding energies without undergoing strong order/disorder transitions
(Fig. 4.12). Optimized integrated logistic schedules were designed as shown in Fig. 4.11 and Tables. 4.3, 4.4 and 4.5 to avoid phase transition mostly at u ∼ 0. For the D3R/(-)-stepholidine system
and Abl1/Axitinib complexes, no attempts were made to resolve phase transition at larger binding
energies as can be seen in Fig. 4.11B.
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Figure 4.11: The general design strategy of the alchemical coupling schedule using the integrated logistic perturbation
potential to avoid strong order/disorder transitions for the T4L [37] and D3R complexes. Starting at the uncoupled
ensemble with λ1 = 0 and λ2 = 0, λ2 is increased up to a critical value λc = 0.4 in (A, top panel) and up to λc = 0.62
in (B, top panel) sufficiently large to clear the maximum of the λ -function (black, solid line). Then λ1 is increased
leaving λ2 at the critical value λc (A and B, bottom panels). When λ1 exceeds λc , λ2 and λ1 increase in unison,
thereby restoring the linear alchemical schedule (A and B, bottom panels). The α and u0 parameters which control the
steepness and location of the transition from λ1 to λ2 , are adjusted slightly to ensure that the logistic function crosses
the λ -function at only one point or at a set of points near each other.

The binding energy probability distributions obtained from the molecular dynamics replica exchange calculations reported in Figs. 4.12, largely confirm the predictions of the analytical model.
With the TanhSC soft-core potential (Fig. 4.12, panels A and D), the binding energies of disor106

dered states at u ' umax abruptly shifts to negative values as λ is lowered below a critical value
(λ = 0.2 approximately for all systems and settings considered). The distributions of disordered
and ordered states on either side of this critical value are separated by a large binding energy gap
of almost 50 kcal/mol.
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Figure 4.12: The binding energy probability densities, pλ (u), collected from the Hamiltonian replica exchange
simulations of T4L/3-iodotoluene (first row; panels A, B, C) [37], D3R/(-)-stepholidine started with Pose 1 and softcore umax = 50 kcal/mol (second row; panels D, E, and F). The first column contains panels with the TanhSC soft-core
function and the linear alchemical perturbation. The second column corresponds to the the RatSC soft-core function
and the linear alchemical perturbation. The third column is with the RatSC soft-core function and the integrated
logistic perturbation. The binding energy probability distributions are shown in different repeating colors, correspond
to different values of λ . The distributions shift towards lower binding energies, as λ increases.

Consistent with the predicted λ -functions (Figs. 4.9 and 4.10), the binding energy gap is reduced when using the RatSC soft-core potential (Fig. 4.12, panels B and E), mainly by shifting
the distributions at u = umax to lower values. In the case of T4L/3-iodotoluene, the effect is very
substantial to the point that some of the distributions of the disordered states overlap, albeit weakly,
with those of ordered states. As shown in Fig. 4.8, the distributions near the critical λ are bimodal.
The benefit of the RatSC function has a very low effect for the D3R/(-)-stepholidine Pose 1 complex, where slight improvement was observed in reducing the binding energy gap from 50 kcal/mol
to around 20 kcal/mol. showing that this system characterized by a very strong order/disorder tran-
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sition (Fig. 4.12E).
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Figure 4.13: The binding energy probability densities, pλ (u), collected from the Hamiltonian replica exchange simulations of Abl1/Axitinib complex started with Axitinib1 pose and soft-core umax = 50 kcal/mol , (A) with the RatSC
soft-core function and the linear alchemical perturbation. and (B) with the RatSC soft-core function and the integrated
logistic perturbation. The distributions, shown in different repeating colors, correspond to different values of λ . The
distributions shift towards lower binding energies as λ increases.

The Abl1/ Axitinib complexes starting with Axitinib1 (correct) and Axitinib2 (incorrect) poses
were simulated with a combination of rational soft-core RatSC and linear perturbation schedule
as well as RatSC soft-core with the logistic perturbation schedule (ILog) trained on Axitinib1
pose. The TanhSC soft-core function was not considered for this system based on the previous
observations regarding difficulty of converging the free energies in T4L and D3R complexes and
thereby to save computational resources. The corresponding binding energy distributions for simulations started with Axitinib1 are plotted in Fig. 4.13. Similar to what was observed for the
D3R/(-)-stepholidine complex started with Pose 1, the RatSC soft-core function alone was not able
to fill the binding energy gap between the ordered and disordered states in Abl1/Axitinib complex simulation started with Axitinib1 pose (Fig. 4.13A). The binding energy distribution abruptly
shifts from higher energy values to lower energies resulting a gap of greater than 25.0 kcal/mol
(Fig. 4.13A) with no density near u = 0. However, for all the three protein-ligand systems, the integrated logistic alchemical perturbation potential is very effective at canceling the transition near
u = 0 (Fig. 4.12, panels C and F, and Fig. 4.13B), where nearly homogeneous sampling of the
whole binding energy range could be achieved. This result is due to the shifting of the distributions of the ordered state into the “no man’s land” region of binding energies between ordered and
disordered states which are very poorly sampled with the linear potential. The integrated logistic
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alchemical potential still have difficulties in sampling at higher region of binding energies as can
be observed from Fig. 4.13B.

4.5.4

Replica exchange diffusion efficiency

Replica exchange efficiency has been monitored in terms of the extent of diffusion of replicas in
λ -space and binding energy space. The time trajectories of the binding energies sampled by the
replicas from the T4L/3-iodotoulene simulation are shown in Fig. 4.14. These plots show that,
while replicas rapidly equilibrate within the ordered low energy states and disordered high energy
states of the complex, they also interconvert between these states. These interconversions can be
detected by a change from low favorable binding energies to high unfavorable binding energies
and vice versa. In this study, we focused in particular, on these interconversions, to investigate on
the frequency of these transitions. These transitions can be counted as events related to binding
and unbinding. In a replica, a transition from a lower bound of favorable binding energies to
an upper bound of positive and unfavorable binding energies is counted as one unbinding event
and vice versa, counted as one binding event. It was observed that the rate of occurrence of
interconversions heavily depend on the combination of soft-core functions and the perturbation
schemes applied to the simulations. With the TanhSC soft-core potential, replicas never or only
very rarely, underwent these transitions (Fig. 4.14A). The RatSC soft-core reduces the binding
energy gap between ordered and disordered states and allowing the T4L/3-iodotoluene system to
undergo numerous binding/unbinding transitions (Fig. 4.14B).
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Figure 4.14: Binding energy trajectories for selected replicas from the Hamiltonian replica exchange simulations of
T4L/3-iodotoluene with (A) TanhSC soft-core function, (B) with the rational soft-core function and linear perturbation
and (C) with the rational soft-core and integrated logistic perturbation potential. Only the odd-numbered replicas are
shown (8 out of 16) [37].

The RatSC soft-core potential alone was not capable of overcoming strong order/disorder phase
transitions in the simulations of D3R/(-)-stepholidine started with Pose 1 as well as Pose 5 shown
in Fig. 4.15B. More binding/unbinding transitions were observed for the simulation started with
Pose 5 (incorrect pose) and with RatSC soft-core potential (Fig. 4.15E). These transitions were
observed to be two times more frequent by using an integrated logistic potential trained on the
correct pose i.e. Pose 1. However, the logistic potential trained on Pose 1 did not show any better
advantage for the simulations started with Pose 5 (incorrect pose) (Fig. 4.15, compare panels C
and F ).
The simulations of Abl1/Axitinib complexes started with Axitinib1 and Axitinib2 poses also
showed almost no transitions with rational soft-core (RatSC) and linear potential (Fig. 4.16, panels A and C). With the integrated logistic perturbation potential, both simulations started with
Axitinib1 and Axitinib 2 poses were observed to undergo many transitions from lower binding
energies to higher binding energies and vice versa (Fig. 4.16, panels B and D). However, there are
still regions of higher binding energies which are poorly sampled even with the logistic schedule
(ILog) in effect.
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Figure 4.15: Binding energy trajectories for selected replicas from the Hamiltonian replica exchange simulations of
D3R/(-)-stepholidine started with two starting poses. Trajectories in the top row (A, B and C) are from the simulations
where (-)-stepholidine is simulated starting from the crystal structure pose (Pose 1). The bottom row (D, E and F)
shows binding energy trajectories from simulations where (-)-stepholidine is simulated starting with incorrect pose
(Pose 5). One every 3 replicas are shown (8 out of 24). The trajectories in the left column are from simulations carried
with hyperbolic tangent soft-core (TanhSC), trajectories in the middle column were obtained from simulations with
rational soft core applying linear perturbation (RatSC), trajectories on the right column were obtained by applying
logistic alchemical schedule along with the rational soft core potential (ILog).

The ER-α/THC complex is simulated with TanhSC and RatSC soft-core function with a linear
perturbation scheme. This system was chosen to benchmark the ability of the soft-core function to
improve sampling of conformational space for a symmetric ligand (Fig. 4.5) as mentioned previously. Because the ligand molecule is symmetric, conformational sampling is expected to yield a
population of of 50 % for each symmetric pose. Given the geometry of the binding site, transitions
between the two symmetric poses are possible only if when replicas started near λ = 1 unbind and
return to the bound state with an alternate symmetry pose. With the ER-α/THC complexes, none
or very few transitions were observed in the simulations with the TanhSC soft-core (Fig. 4.17A).
More numerous binding and unbinding transitions events were observed with the RatSC soft-core
potential (Fig. 4.17B).
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Figure 4.16: Binding energy trajectories shown for specific replicas from the replica exchange simulations of
Abl1/Axitinib complexes started from two different docked poses. Trajectories in the top row (A and B) were from
the simulations where simulation is started with the crystal structure pose (Axitinib1). The bottom row (C and D)
shows binding energy trajectories from simulations started with incorrect bound pose (Axitinib2). Every 3 alternate
replicas are plotted (8 out of 24). The trajectories in the left column are from simulations carried with rational soft
core (RatSC), trajectories in the right column were obtained from simulations by applying logistic alchemical schedule
along with the rational soft core potential (ILog).
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Table 4.6: Number of binding and unbinding transitions for systems and simulation settings studied in this work
Sim Id Protocol nbind
nunbind
T4L99A/3-iodotoluene counted with range 1a
1
TanhSC
2
2
2
RatSC
52
55
3
ILog
29
29
D3R/(-)-stepholidine Pose 1 counted with range 2b
4
TanhSC
0
0
5
RatSC
10
10
6
ILog
22
22
D3R/(-)-stepholidine Pose 5 counted with range 2b
7
TanhSC
2
2
8
RatSC
26
15
9
ILog
19
11
Abl1/Axitinib1 counted with range 2 b
10
RatSC
0
3
11
ILog
20
20
Abl1/Axitinib1 counted with range 3 c
10
RatSC
0
2
11
ILog
18
17
Abl1/Axitinib2 counted with range 2 b
12
RatSC
8
15
13
ILog
53
50
Abl1/Axitinib2 counted with range 3 c
12
RatSC
0
4
13
ILog
5
2
ER-α/THC counted with range 2 b
14
TanhSC
3
4
15
RatSC
10
13
au
bu
=
−10,
u
=
25
kcal/mol,
=
−30.0,
u
upper
upper = 25 kcal/mol, t > 50
lower
lower
c
ps, ulower = −40.0, uupper = 25 kcal/mol. All systems were simulated with a softcore umax capped at 50 kcal/mol.

The number of binding and unbinding transitions for all complexes for each system are reported
in Table. 4.6. The counts give the information about the number of times a replica goes from a
disordered unbound state to an ordered bound state or vice versa. The ordered and disordered
states were determined based on their binding energy values. Different systems simulated in this
study have different ranges of binding energy sampled during the simulation. These were analyzed
from the binding energy trajectories (Figs. 4.14, 4.15, 4.16 and 4.17). Based on the range of
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the binding energies between unbound and bound state for each complexes, an upper limit uupper
was set halfway between u = 0 and u = umax and a lower limit ulower was set to a value near the
minimum binding energy sampled by the system umin . For the T4l/3-iodotoluene complex, the
range considered is ulower = −10 kcal/mol and uupper = 25 kcal/mol and named as “range 1” in
Table 4.6. For D3R/(-)-stepholidine complex, ulower = −30 kcal/mol and uupper = 25 kcal/mol,
named “range 2” in Table 4.6. The binding and unbinding events for Abl1/Axitinib complex were
counted using two ranges, “range 2” and another range considered where ulower = −40 kcal/mol
and uupper = 25 kcal/mol denoted as “range 3” in Table. 4.6. If u > uupper , the replica was labeled
as disordered (unbound) and if u < ulower , it is labeled as ordered (bound). Based on this criteria,
the TanhSC soft-core potential and the linear alchemical schedule lead to very few binding and
unbinding transitions in all complexes tested. Because of the lack of binding/unbinding events, the
convergence of the calculations with the TanhSC soft-core potential are likely unreliable.
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Figure 4.17: Binding energy trajectories for selected replicas from the Hamiltonian replica exchange simulations of
ER-α/THC complex. One third (8 out of 24) replicas are shown from the simulations (A) with the TanhSC protocol
and (B) with the RatSC protocol.

The RatSC soft-core alone is sufficient to enable many interconversions for the T4L/3-iodotoluene
system, one third more, in fact, than with the integrated logistic potential. For the D3R complexes,
the integrated logistic potential was observed to be effective for simulations started with correct
pose of (-)-stepholidine (Pose 1) but didn’t show a significant effect in improving binding/unbinding transitions for the simulations that are started with incorrect pose (Pose 5). With the
RatSC soft-core itself, many binding/unbinding events were observed in these simulations which
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didn’t improve to any significant measure when combined with an alchemical logistic potential
(Table 4.6).
The integrated logistic alchemical potential (ILog) produces many binding/unbinding events
even for the more challenging Abl1/Axitinib complexes started with Axitinib1 and Axitinib2 poses
where few transitions were observed with the linear potential (Table 4.6, compare simulations 10
and 11 for Axitinib1, 12 and 13 for Axitinib2 with “range 2”). However, in the Abl1 complex
simulations, more complexities were being observed that are unrelated to the binding/unbinding
transitions. The binding energy difference between the two bound pose, Axitinib1 and Axitinib2
is about 10 kcal/mol, favoring the Axitinib1 pose. In the simulations started with incorrect pose
i.e. Axitinib2, binding/unbinding transitions were counted using two different ranges as mentioned
above. In “range 2”, when ulower = −30.0 kcal/mol, more than 50 transition events were counted
throughout the length of the simulation with the ILog protocol , however, when ulower was set to
more negative value, reflecting the binding energy of the correct pose i.e. Axitinib1 which is around
−40.0 kcal/mol, only 1/10th of transitions were observed compared to what was obtained with a
lower limit of −30 kcal/mol, even with the logistic schedule (ILog) (Table 4.6, compare simulation
13 with “range 2” and “range 3”). Thus, no conversions were observed between Axitinib1 and
Axitinib2 pose even with the ILog protocol. This observation is discussed later.
For the ER-α/THC complexes, RatSC soft-core potential with linear perturbation were able to
undergo almost four times more binding/unbinding transitions than that of the TanhSC soft-core
potential, though the number of binding/unbinding events in this system are significantly fewer
than those for T4L, D3R and Abl1 complexes (Table 4.6, compare simulations 14 and 15 ).

4.5.5

Binding free energy calculation and convergence analysis

The estimates of the standard free energy of binding for the systems and settings studied in this
work are listed in Table. 4.7. As the free energy is a thermodynamic state function, binding free
energies should not depend on simulation settings, such as the choice of the starting conformation,
soft-core function and the alchemical schedule. The data in Table. 4.7 shows that all the simu115

lation protocols yield consistent estimates for the T4L/3-iodotoluene complex, thereby validating
the correctness of our implementation. This is particularly so for the simulations with the linear
(RatSC) and integrated logistic (ILog) alchemical schedules (Figs. 4.18B and 4.18C) that achieve
rapid equilibration between coupled and uncoupled states (Figs. 4.14B and 4.14C).
Table 4.7: Standard binding free energy estimates of T4L, D3R and Abl1 complexes

Protocol
∆G◦b a
teq b
T4L/3-iodotoluene
TanhSC
−2.53 ± 0.140 2.0
RatSC
−2.26 ± 0.086 0.9
ILog
−2.32 ± 0.097 1.1
D3R/(-)-stepholidine - Pose 1
TanhSC
−14.2 ± 0.08
–
a
RatSC
−7.11 ± 0.07
1.0
ILog
−7.61 ± 0.07
1.0
D3R/(-)-stepholidine - Pose 5
TanhSC
3.51 ± 0.06
RatSC
−7.25 ± 0.06
3.0
ILog
−6.68 ± 0.07
4.0
Abl1/Axitinib1
RatSC
−17.97 ± 0.03
ILog
−16.74 ± 0.06
Abl1/Axitinib2
RatSC
−4.19 ± 0.03
ILog
−4.93 ± 0.02
a All values are calculated in kcal/mol. b in ns. Simulations where equilibration is not
reached is marked as “-”.

For the D3R/(-)-stepholidine complexes, binding free energies with the TanhSC soft-core greatly
differ from the simulations with RatSC and ILog protocols (Table 4.7). The simulations with the
RatSC and ILog protocols converged to the same or near similar values for both of the Pose 1 and
Pose 5 complexes. However, simulations started with Pose 5 (incorrect pose) with RatSC and ILog
protocols converged to a similar binding free energy as obtained with simulations started with the
Pose 1 (correct pose) (Fig. 4.18, panels E and F, green line). Simulations started in Pose 1 with
the TanhSC protocol never converged within the simulation time, and the binding free energy estimates were very negative (Fig. 4.18D, blue line). On the other hand, simulations started with Pose
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5 ended up predicting a positive binding free energy with the TanhSC protocol (Fig. 4.18D, green
line). This lack of convergence is in accordance with no binding/unbinding transitions observed in
the simulations with TanhSC protocol for these complexes (Fig. 4.15).
Though free energy estimates should not depend on the starting pose of a complex because of
the possibility of interconversions between all possible poses,for the Abl1/Axitinib calculations,
a large difference between binding free energies starting from the correct pose i.e. Axitinib1 and
incorrect pose i.e. Axitinib2 was observed (Table 4.7). It is difficult to say in this complex if
the binding free energies are converged even for Axitinib1 within the time these complexes were
simulated because as shown before, even with the RatSC soft core potential, a gap of almost 30
kcal/mol is observed in the binding energy distribution and with almost no binding/unbinding
transitions, making the predictions unreliable. A much less favorable estimate was obtained from
simulations started with incorrect pose i.e. Axitinib2, clearly, unlike the D3R/(-)-stepholidine
complexes, showing a lack of convergence because of lack of interconversion between Axitinib1
and Axitinib 2 pose even with the logistic perturbation potential.
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Figure 4.18: Reverse cumulative profiles of the binding free energy for the T4L/3-iodotoulene [37] and D3R/(-)stepholidine complexes started with different bound poses. Error bars are drawn at the 2σ level. The horizontal line
represents the best guess estimate of the binding free energy. The vertical dotted line (when present) represent the
equilibration time above which free energy estimates agree within statistical uncertainty.

Equilibration analysis was performed for each simulations in this study. This is done based
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on the reverse cumulative profiles of the binding free energy with respect to the equilibration
time. The data is collected by discarding binding energy values from the beginning of the simulation [104, 127, 128]. For instance, equilibration analysis (Fig. 4.18) indicates that it takes approximately 1 ns of simulation per replica to achieve equilibration for the T4L/3-iodotoluene system
with the RatSC and ILog protocols. Consistent with the smaller number of binding and unbinding
events (Table. 4.6), it takes about twice as long to achieve equilibration with the TanhSC protocol,
although the steady downward drift of the binding free energy is a source of concern in this case
(Fig. 4.18A).
It is not obvious to derive quantitatively converged and minimum variance estimates from reverse cumulative profiles. While the accuracy of the binding free energy improves as more unequilibrated samples are discarded, the precision of the estimate worsens as fewer samples are available.
The trade-off between accuracy and precision is reflected in the steady increase in the size of the
error bars in Fig. 4.18 as the equilibration time increases. Several strategies have been proposed to
extract optimal equilibration times and estimates from reverse cumulative profiles [104, 127, 128].
A simple approach was taken here to calculate the smallest equilibration time that gives a free
energy estimate statistically indistinguishable from those at all subsequent equilibration times.
Equilibration times chosen using this strategy are indicated by vertical lines in Fig. 4.18 and are
reported in the third column of Table. 4.7. The convergence analysis of D3R/ (-)-stepholidine,
Abl/Axitinib and ER-α/THC complexes are discussed in the next section.

4.5.6

Equilibration between different bound poses

In this study, we also investigated the efficacy of the newly developed RatSC rational soft-core
function and alchemical perturbation schemes to equilibrate between different bound poses of the
protein-ligand complexes included in the study. All three systems, D3R/(-)-stepholidine complex,
Abl1/Axitinib complex and ER-α /THC complex exhibit possibility of more than one bound poses,
as revealed by docking experiments, however not all poses are equally favorable. Different poses
of D3R and Abl1 complexes were mentioned previously. In this section, we analyzed whether the
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rational soft-core function and integrated logistic perturbation protocols are able to equilibrate between alternative binding poses and are capable of converging binding free energies of complexes
starting from an incorrect bound pose, by achieving the correct bound pose conformation during
the simulation.
With this motivation, reverse cumulative profiles of the binding free energies were first examined for simulations started with different poses of all three complexes. Equilibration analysis
based on the reverse cumulative plots indicates that both the RatSC and ILog protocol achieves
equilibration of the binding free energy of the correct pose of D3R/(-)-stepholidine complex started
with Pose 1 in about 1 ns of simulation per replica, and the bias of the binding free energy estimate
is less than half a kilo-calorie per mole throughout the run (Figs. 4.18, panels E and F, blue line
Table. 4.7). Both RatSC and ILog protocols were able to yield similar results (−7.11 and −7.61
kcal/mol, within nearly statistical uncertainty). These results, together with the relatively large
number of binding/unbinding transitions (Table. 4.6, Pose 1), confer high confidence in the binding free energy estimates for the D3R/(-)-stepholidine complex started with Pose 1 and simulated
with the ILog protocol. With TanhSC soft-core potential, no equilibration of binding free energy
was observed for the time simulated (6 ns) in the simulations started with (-)-stepholidine Pose
1. The corresponding estimates are significantly more negative as mentioned before than with the
other protocols and display little change as the equilibration time is increased indicating a lack of
convergence (Fig. 4.18D, blue line).
For simulations that were started with incorrect pose i.e. Pose 5, with the TanhSC soft-core
potential, the binding free energy estimates were in the positive range, also indicating a lack of
convergence of this simulation (Fig. 4.18D, green line). This different behavior in the magnitude
of binding free energies is due to a large difference in the binding energies between two starting
poses and and the conformations remained stuck in their starting poses throughout the length of he
simulation because of the lack of binding/unbinding transitions (Figs. 4.18D and Table. 4.6). This
is of particular concern because conventional analysis would erroneously conclude in this case that
the binding free energy estimate is well converged.
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On the other hand, both RatSC and ILog protocols were able to achieve equilibration of the
binding free energies for simulations started with either poses of (-)-stepholidine (Pose 1 and Pose
5). Unlike with the TanhSC soft-core potential, the magnitude of binding free energies at the
beginning of the simulation for Pose 5 with RatSC and ILog protocols were much negative than
that calculated with the TanhSC protocol and that RatSC soft-core alone was able to lower the
binding free energy estimates of Pose 5 within 2 kcal/mol of the binding free energy of Pose 1.
As the simulation progressed, the binding free energy estimate for simulations started with Pose 5
achieved an agreement with the values obtained from simulations started with Pose 1 (Fig. 4.18E
and F, green line). With the RatSC protocol, binding free energy estimates converged after 3.0 ns
of simulation per replica, whereas for the ILog protocol, it took almost 4.0 ns to reach convergence
(Fig. 4.18E and F, green line and Table. 4.7). Binding free energy estimates from the simulations
started from the two poses were in more disagreement at the beginning of the simulation with
the ILog protocol than with the RatSC protocol. It is to be noted, however, that in this case, the
integrated logistic schedule was designed based on the simulation with the correct pose i.e. Pose
1.
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Figure 4.19: Probability of occurrence of correct (Pose 1) and incorrect (Pose 5) poses of (-)-stepholidine bound
to the D3R receptor at λ = 1 for the simulations started with the Pose 1 (blue) and the Pose 5 (green) of bound
(-)-stepholidine with (A) the TanhSC linear protocol and (B) with the RatSC linear protocol.

Simulations started with incorrect bound pose were able achieve convergence by attaining the
correct bound pose conformation during the simulation with both RatSC and ILog protocols. However, with the TanhSC protocol, conformations remain stuck in their incorrect pose and the free
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energy does not converge properly. This is shown by the change in the population of correct and
incorrect poses analyzed at λ = 1 from every 0.5 ns of time window along the length of the simulation (Fig. 4.19). Thus, RatSC rational soft-core potential was able to find the correct bound
conformation for the D3R/(-)-stepholidine complex and after ∼ 6 ns of simulation starting from all
incorrect poses at the start, the population between Pose 5 and Pose 1 reaches a ratio of 3 : 2. If the
simulation started with Pose 5 would have been run until full equilibration, it is expected that at
λ = 1, all incorrect pose conformation will be replaced by the correct pose and only Pose 1 would
remain.
A similar analysis was performed with the trajectories obtained from the simulations of ERα/THC complex with TanhSC and RatSC protocols. Due to the molecular symmetry along three
main symmetry axis of the THC molecule (Fig. 4.5), there is an ability of the molecule to flip and
altering the interaction between the residues of the receptor and hydroxyl groups of the ligand.
To investigate the population of different orientations of the ligand in this complex during the
simulation with different soft-core functions, distances were measured between the interacting
atoms of the ligand and the receptor (Fig. 4.5). The following distances were measured from the
trajectories obtained:
1. between the ring Nitrogen (ND1) of His 524 and hydroxyl hydrogen (HO23) of the ligand,
2. between the carboxylate oxygen of Glu 353 and hydroxyl hydrogen (HO25) of the ligand,
3. between the ring Nitrogen (ND1) of His 524 and hydroxyl hydrogen (HO25) of the ligand
and
4. between the carboxylate oxygen of Glu 353 and hydroxyl hydrogen (HO23) of the ligand.
Three selection criteria were applied to distinguish between alternate poses of the ligand in the
simulations which are as follows:
a) if distances 1 and 2 both are less than 5 Å , the configurations are counted as “left oriented”,
b) if distances 3 and 4 both are less than 5 Å , all configurations are counted as “right oriented”
c) for any distances calculated over 5 Å in above two criteria are counted as “other orientation”
With these criteria in effect, the distances of 1 , 2, 3 and 4 were analyzed from all trajectories.
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Simulations of ER-α complexes with TanhSC protocol were run for 6 ns whereas simulations
with RatSC protocols were run for around 12 ns. The probabilities of occurrences of left and
right oriented conformations in the bound state i.e. at λ = 1 were measured for every 0.5 ns of
simulation window along the total simulation time and are shown in Fig. 4.20.
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Figure 4.20: Probabilities of occurrence of different orientations of the THC ligand in the ER-α/THC complex simulations with (A) TanhSC soft-core and (B) RatSC soft-core potentials. The probabilities as a function of time for left
orientation is shown as blue lines and the probabilities for right orientation is shown as green lines.

All these simulations, regardless of the protocol used, were started initially with in the left
oriented conformation. With the TanhSC protocol, the bound state conformations sampled during
the simulation all stayed in their left orientation up to the time simulated i.e. around 6 ns. Whereas,
with the RatSC protocol, the probabilities of occurrence of right orientation in the bound state
ensemble at λ = 1 increased from 0 to 30 % within the first 3 ns. As the simulation progressed,
very slow changes in the probabilities of left and right orientation were observed, resulting in
around 40 % of the trajectories in “right oriented” conformation at the bound state. Very few
samples were obtained which are neither “left oriented” or “right oriented”. These observations
further confirms the ability of the RatSC soft-core potential to sample conformational space evenly,
reducing the effect of strong order/disorder phase transitions.
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Figure 4.21: Reverse cumulative profiles of the binding free energy for the Abl1/Axitinib complexes. (A) with RatSC
soft-core and (B) with the integrated logistic perturbation potential(ILog). Error bars are drawn at the 2σ level. The
blue line in both plots represents reverse cumulative profile of simulations started with Axitinib1 pose and the green
lines represents simulations started with Axitinib2 pose.

The Abl1/Axitinib complex system demonstrated to be too challenging to be effectively handled by the newly developed rational soft-core potential and the integrated logistic perturbation
protocols. None of the RatSC soft-core as well as a combination of RatSC soft-core with the logistic perturbation schemes were capable of interconversions between Axitinib1 and Axitinib2 poses
in the simulations started with either poses, especially for simulations started with the incorrect
pose (Axitinib2) and thus were unable to achieve equilibration of the binding free energies. This
is reflected from the difference in binding free energy estimates between simulations started with
Axitinib1 and Axitinib2 poses. The magnitude of binding free energies stayed almost the same
throughout the simulation for both protocols starting with Axitinib1 and Axitinib2 respectively
as shown in Fig. 4.21. In the simulation started with Axitinib1 pose, the binding free energy remained very negative while in the simulation started with Axitinib2 pose, the binding free energy
remained less favored throughout the simulation time. Unlike (-)-stepholidine Pose 5 reverse cumulative profile, the binding free energies for simulations started with Axitinib2 did not reach to
an agreement with that of the free energy of the complex started with the Axitinib1 pose. From this
observation, it can be concluded that simulations started with either pose Axitinib1 and Axitinib2,
experienced very poor conformational sampling and thus no interconversions between conformations which remained stuck mostly in their starting pose. This was confirmed by performing a
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similar orientational distribution analysis as done for the ER-α/THC complex.
The correct pose of Axitinib1 is characterized by two hydrogen bonding interactions as mentioned before (Fig. 4.6A). Based on these interactions, the following distances were measured:
1. between the hydroxyl hydrogen of Tyr 253 and pyridine ring nitrogen of the ligand,
2. between the side chain nitrogen of Lys 271 and carbonyl oxygen of the ligand,
3. between the hydroxyl hydrogen of Tyr 253 and carbonyl oxygen of the ligand and
4. between the carboxylate oxygen of Asp 381 and pyridine nitrogen of the ligand.
Three selection criteria were applied to distinguish between two different orientation of the
ligand in the simulations which are as follows:
a) if distances 1 and 2 both are less than 3.5 Å , the configurations are counted as “correct” and
resembles Axitinib1 pose,
b) if distance 3 is less than 3.5 Å and distance 4 both is less than 7 Å , all configurations are
counted as “incorrect” and resembles Axitinib2 pose
c) for any distances calculated which does not obey the above two criteria are counted as
“other”
With these criteria in effect, the distances of 1 , 2, 3 and 4 were analyzed from all trajectories
from simulations started with Axitinib1 and Axitinib2. The population of correct and incorrect
oriented conformations were calculated at λ = 1 for every 0.5 ns of simulation window along the
total length of the simulation (Fig. 4.22).
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Figure 4.22: Probabilities of occurrences different orientations of the Abl1/Axitinib complexes in simulations started
with (A) correct pose, Axitinib1 with linear potential, (B) Axitinib1 with integrated logistic potential, (C) incorrect
pose, Axitinib2 with linear potential, (D) Axitinib2 with integrated logistic potential. Probabilities of occurrence of
different poses are calculated for every 0.5 ns time window throughout the length of the simulation. Probabilities of
occurrences of correct, incorrect and other poses are connected by blue , green and purple lines respectively.

It was observed that with the RatSC protocol, both the simulations started with Axitinib1 and
Axitinib2 remained stuck in their starting pose. For Axitinib1, 90 % of conformations remained
in the starting pose (Fig. 4.22A, blue line). Similarly, for Axitinib2 most conformations stayed
in its starting conformation, which is the incorrect pose (Fig. 4.22B, green line). However, with
the logistic perturbation potential, correct pose configurations were sampled during the simulation
started with incorrect pose, Axitinib2. However, the population of incorrect pose still dominates
at λ = 1 in these simulations started with Axitinib2. Thus, from these and previous observations
from other systems, it is concluded that though the newly developed rational soft-core and alchemical perturbation schemes are capable of reducing the effects of order/disorder phase transitions
encountered in simulations, they still encounter limitations in their efficacy for systems that are
characterized by very severe order/disorder transitions and conformational bottlenecks.
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4.6

Discussion

In this study, we have shown that order/disorder phase transitions are virtually unavoidable and
can occur when using alchemical transformations. The severity of these transitions depends on the
type of molecular systems. When they occur, rare order/disorder transitions impede frequent interchanges between alternative bound conformational states. Order/disorder phase transitions also
lead to very slow equilibration of binding free energy estimates and thus requires longer simulation times. They also require the use of more intermediate states in the alchemical transformation
schedule to keep distributions closer for sufficient overlap and λ -exchanges among replicas during
Hamiltonian Replica Exchange sampling. Nevertheless, introducing more intermediate replicas or
λ states does not always address the bimodal distribution of binding energies encountered during
order/disorder phase transitions attributed to entropic bottlenecks.
A number of methods are available to activate interconversions between energy basins which
are separated by high energy barriers [129–132]. These interconversions are much easier to handle
if the slow collective variable is known [133–135]. Like the process of protein folding, which
is characterized by an entropic bottleneck to transform from a highly disordered random coil to
more ordered secondary and tertiary structure [136, 137], protein-ligand binding involves loss of
rotational and translational motion and the loss of conformational freedom of both the ligand and
the receptor to form a stable complex. In alchemical binding, this is reflected in the slow random
search process of the rare ordered binding pose in the uncoupled ensemble, where the ligand and
receptor are free to explore a wide range of configurations [138, 139].
In this work, to overcome the entropic bottlenecks encountered in alchemical binding, we utilized and extended the formalism and non-Boltzmann conformational sampling simulation techniques developed by Straub at al. for the study of temperature-dependent phase transitions in spin
systems, atomic clusters, and molecular liquids. There is a close analogy between the treatment
of Straub et al. [109, 110, 121, 122] for the canonical ensemble as a function of temperature and
the alchemical ensemble as a function λ considered here. Straub et al. considered non-Boltzmann
sampling with a generalized reduced potential WT (E) where the modes of the energy distribution
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correspond to energies at which the inverse of the microcanonical statistical temperature function
TS (E) equals the inverse of kB ∂WT (E)/∂ E:
∂ S(E)
∂WT (E)
1
≡
= kB
,
TS (E)
∂E
∂E

(4.20)

where S(E) = kB ln Ω(E) is the microcanonical entropy and Ω(E) is the density of states. In
the case of canonical Boltzmann weighting, WT (E) = E/kB T , the condition eq. (4.20) reduces
to 1/TS (E) = 1/T = constant. Near a first order phase transition the function, 1/TS (E) varies
non-monotonically and intersects the constant line 1/T at three energy values corresponding to
the phases in equilibrium and the unstable intermediate phase. In close analogy with Fig. 4.1, the
phase transition can be avoided by using a suitable non-linear sampling potential WT (E) whose
derivative intersects 1/TS (E) at only one value of E. [121]
One of the main results of this work is the finding that the formalism of Straub et al. for
temperature-driven order/disorder transitions extends nearly seamlessly to the alchemical ensemble for binding [1, 29] by applying the following equivalences:

E → u

(4.21)

Ω(E) → p0 (u)

(4.22)

1
→ βλ
kB T
1
→ β λ0 (u)
kB TS (E)
WT (E) → Wλ (u)

(4.23)
(4.24)
(4.25)

These equivalences between canonical and alchemical ensembles were utilized to formulate
alchemical perturbation functions to avoid or reduce order/disorder phase transitions along the alchemical path. This has led to the formulation of the integrated logistic function [eq. (4.18)] which
was successfully implemented to overcome order/disorder transitions in protein-ligand complexes.
All these advancement is achieved based on the availability of an analytical model that predicts the
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probability distribution function p0 (u) [108] and also the λ -function in eq. (4.13), specific for each
system. The analytical model of binding makes it much easier to obtain the probability distribution p0 (u) of binding energies at λ = 0, which is a continuous function and easily differentiable.
Histogram of distributions obtained from molecular simulations are discrete bin values and aren’t
easily differentiable, on the other hand. As p0 (u) for any system can be obtained analytically using
the analytical model [108], the λ -function can be also obtained analytically by differentiating the
logarithm of the probability distribution with respect to the binding energy u.
In this study, the analytical model is used for the first time to model order/disorder transitions
in alchemical calculations. The newly formulated soft-core function along with logistic perturbation schedule has been successful in not only overcoming strong phase transitions between ordered
and disordered states but it also allowed finding the correct bound conformations of the complexes
starting from incorrect poses. This is possible due to even sampling of the conformational space by
applying perturbation schemes that forces the system to visit conformations with higher binding
energies as well by applying perturbation schemes that facilitate more interconversions in the λ
and binding energy space. However, these newly developed rational soft-core and alchemical perturbation potentials are found to be insufficient for systems that exhibit very strong order/disorder
transitions and display multiple bound poses.
The alchemical logistic perturbation scheme allows the system to visit regions of binding energy and λ space which are not reachable when using linear perturbation potentials and facilitate
diffusion of replicas in binding energy and λ space. But systems that exhibit multiple bound poses
i.e. have multiple local minima in the energy landscape separated by large difference in binding
energies did not benefit by a treatment using the logistic perturbation scheme in this work. While
the reason for this behavior is not clearly understood, we suspect that it maybe due to to conformational bottlenecks for the receptor species and will be the subject of future research. Another
broader area of research is the application of the techniques we developed, in alchemical systems
with explicit solvation. Future research in this aspect will focus on calculating hydration free
energies etc. in explicit solvent for systems that experiences strong order/disorder transitions.
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5
Implementation of Customized Force-field
Parameters to Study FXR Complexes
5.1

Farnesoid-X receptors

Farnesoid X receptors are nuclear hormone receptors [140] taking part in many metabolic processes (Fig.5.1). One of the important role of FXR is the regulation of bile acid and cholesterol
synthesis. FXR agonists are also reported to regulate gluconeogenesis and other metabolic pathways. FXR is an important target for treatment of many metabolic diseases [141–143].
This work reported here follows our participation in the D3R Grand Challenge 2. This is a
blinded challenge where we conducted binding free energy calculations for 102 ligands of the Farnesoid X receptor. The dataset was provided by Roche. The ligands belong to four chemical series

Figure 5.1: Crystal Structure of FXR bound to an FXR agonist.
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which include benzimidazoles, sulfonamides, tricyclic and steroid compounds. The main objective
of the challenge was to distinguish between binders and non-binders by performing binding free
energy calculations. Initial binding free energy calculations were performed using the BEDAM
free energy protocol [29] with the OPLS2005 force field and the AGBNP2 implicit solvent model.
The calculations were run using the IMPACT MD platform [69].
The calculations led to very poor predictions with almost no correlation with the experiments
(data not shown). Of the 102 ligands, 36 ligands have crystal structures available. It was observed
that the calculation predicted the affinity of these complexes incorrectly. This was partly because
of starting the calculations with incorrectly docked structures of the complexes as confirmed by
comparing them with the crystal structures. However, ligands which were docked correctly also
suffered poor predictions. Superposition of the predicted bound pose with their corresponding
crystal structures revealed subtle changes in the conformation of the bound pose obtained from
the simulations and about 20% of the ligands were affected by more subtle issues having to do
with the inability of the force field to capture the effects of conformational reorganization upon
binding. Specifically, the bound conformation of these ligands did not match their predominant
solution conformation. Interestingly, all of the ligands that are affected by this subtle defect were
noted to have an amide linker in their structure. One representative case is illustrated in Fig.5.2
for the FXR27 ligand. In FXR27, a specific dihedral angle, CA-CA-NH-CO, is observed to be
different in docked pose and in solution compared to its crystal structure conformation. While the
crystal structure assumes a dihedral angle of approximately 100◦ , both the docked pose and the
predominant conformation in solution present a dihedral angle of around 50◦ . This subtle change
in conformation was also observed in other ligands in this class tested. This observation grew our
interest in studying conformational analysis of FXR27 with different force fields to investigate the
effect of force field parameters on conformational sampling in free energy calculations.
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Figure 5.2: Comparison of the dihedral angle between CA-CA-NH-CO in different bound poses of the FXR27 complex, (a) the CA-CA-NH-CO torsion angle in the crystal structure of FXR27, (b) in the docked structure, (c) and in the
predominant conformation in solution with OPLS2005 force field. The atoms participating in the dihedral angle are
represented in CPK form.

5.2

Effect of force field on the conformational reorganization
of FXR ligands

To investigate the effect of the force field on the conformational reorganization of FXR27, explicit
solvent simulations were performed in collaboration with Dr. Junchao Xia at Temple University,
by using three different force fields, namely OPLS2005 (which was used for the initial set of calculations) [144], OPLS3 [145] and two GAFF AMBER force field parameterizations [146]. The
distribution of the previously mentioned specific dihedral angle (CA-CA-NH-CO) connecting the
phenyl ring and the amide linker was calculated from the trajectories obtained from each individual simulations. The location of maxima and minima of the probability distributions of this angle
with the OPLS2005 approximately match those with of OPLS3 although with very different populations. The results from GAFF and GAFF2 are more consistent with each other but the major
populations are opposite to that of OPLS force fields.
Interestingly, the crystal poses did not correspond to any of the peaks of the probability distribution from any of the force fields tested. Since the major populations in solution are quite
different from the conformations in the bound state, it can be speculated that reorganization free
energies will be large. It was observed that the OPLS2005 and GAFF2 force fields prefer a conformer which differ in their conformation from the bound crystal structure. The receptor bound
conformation has the dihedral angle of around 100◦ (Fig. 5.2). In contrast, the OPLS2005 with
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Figure 5.3: Probability distributions in solution of the dihedral angle between the amide linker and the aromatic ring
of the FXR27 ligand as obtained from 50 ns MD simulations with Desmond and AMBER with SPC explicit solvent
hydration and with OPLS2005, OPLS3, GAFF and GAFF2; dihedral angle of the docking pose and in the crystal
structure are pointed by black arrows,

explicit solvation predicted a lower population at the bound conformation, with preference of conformers at around −180◦ . Interestingly, OPLS3 favors the ~100◦ conformer seen in the bound
crystal structure. So, all these observations suggested that improving the force field parameters
from OPLS2005 to OPLS3 may have the potential to improve the binding free energy prediction,
by predicting conformational reorganization in agreement with the experimental data.

5.3
5.3.1

Incorporation of OPLS3 parameters
Software development and implementation details

The parameters for the OPLS3 force field [145], developed by Schrodinger Inc. are not publicly
available. The OPLS3 force field parameters for all 102 FXR ligands were generously provided
by Schrodinger Inc. These included electrostatic components, partial charges of individual atoms,
as well as Lennard-Jones, bonded and non-bonded interaction parameters, and most importantly
the parameters of the torsional potentials including co-efficients for proper and improper torsions
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[147]. The OPLS3 Force field parameters were provided for all atoms of the ligands and also for
the receptor structure representing the benzimidazole class of ligands.
The parameters for all ligands were provided concatenated in a single file in text format. Each
ligand has its specific atom table, electrostatic, bonds, angles and torsion parameters. At first,
parameters for each ligand were extracted into separate parameter files for all 102 ligands. This
format needed to be converted to the SQLite format of Desmond’s DMS-formatted files that can
be input into the IMPACT and OpenMM MD simulation engines.The conversion of the OPLS3
force field parameters was done using a software utility written in the Python programming language. The most appropriate way we found to implement these new parameters was to update
the force field information in the DMS structure files of the receptor and ligand. The structure
file of the receptor and ligand follows a particular file format known as the Desmond file format
or “DMS”. This is a file format maintained by D. E. Shaw Research (DESRES) and used to run
long time-scale MD simulations on Anton supercomputer and is also easy to maintain, modify and
access in the IMPACT and OpenMM MD programs. The DMS file format is a standalone SQLite
database containing different tables with fields and values. Each table contains different information about the receptor or ligand structure. For example, the “particle” table contains all the atom
indexes, co-ordinates, masses, and charges for each atom of the molecule. Similarly, other tables
contain information about bonds, angles, torsions etc. When a DMS file is prepared using the
Schrodinger utility, these tables get populated by the default OPLS2005 force field server within
the Schrodinger utility. In order to calculate binding free energies using the OPLS3 parameters,
force field information in individual tables of the DMS files of each ligand are updated with the
new parameters which were extracted previously for each of the ligand molecule. The structure
files with updated parameters are then provided to the IMPACT [69] molecular dynamics platform
to compute binding energies using BEDAM.
Tables that contain force field parameters in the DMS file are “particle”, “nonbonded_param”,
“dihedral_trig_param”, “exclusion”, “pair_12_6_es_param”, “stretch_harm_param” and
“angle_harm_param”. Parameters for each ligand are structured in a text table format as used as
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input. At first, values are extracted from each of those text table from a ligand parameter file.
Individual methods are written to extract the values to an internal data structure. For example, the
method extract_atomtable() reads the parameter file and parses the atom number, charge, sigma
and epsilon values to store in a list. Similar methods are written to parse proper and improper torsional force constants, nonbonded scaling factors, bond distances, theta values and force constants
on the angles into separate lists which are later accessed by other methods to update the database
tables.
Once all text tables are parsed from a particular ligand parameter file, using a set of methods
mentioned above, another set of methods are written to update the database tables mentioned previously. For instance, the update_dms() function opens a SQL connection to the DMS structure
file and calls a method add_torsion_to_dms() which reads the DMS file and updates the dihedral_trig_term table with proper and improper torsional force constants already stored in a list.
IMPACT uses similar functional forms as Desmond for calculating the potential energy components attributed to proper and improper torsions. For the proper torsional term,
6

Vt (φi jkl ) = fc0 + ∑ fcn cos(nφi jkl − φ0 )
n=1

where the dihedral force constants fc0 through fc6 are provided in units of energy, φ0 is the dihedral
angle measurement expressed in radians.
The σ and ε values of the non-bonded potential energy component for each atom are read from
the parameter files by the extract_atomtable() method. The expression for the Lennard-Jones 12-6
pair potential between two particles used by the DMS file format is as follows:

VLJ (ri j ) =

ai j bi j
+ 6
ri12j
ri j

where ri j = |ri − r j | is the distance between two particles i and j. ai j and bi j are the coefficients
that depends on the types of particle and are calculated accordingly. These individual values of σ
and ε for each atom particle are combined to produce the form that is accepted by the desmond file
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format as follows:

ai j = 4εi j si j σi12
j
and
bi j = 4εi j si j σi6j
where σi j =

√
√
σi σ j and εi j = εi ε j and s is the custom non-bonded scaling factor provided in

the “NB-14 table” in the parameter file and parsed by the extract_nb14_scaling_factor() method.
The DMS files of the ligand are updated with the new values of ai j and bi j calculated by the
add_nb14_to_dms() method.
An example script is shown here which updates the the torsional force constants in the “dihedral_trig_param” table of the DMS file
def add_torsion_to_dms ( con , paramfile ) :
toratm1 , toratm2 , toratm3 , toratm4 , tor1 , tor2 , tor3 , tor4 =
extract_torsion ( paramfile )
with con :
cur = con . cursor ()
del_dihedral_param =" DELETE FROM dihedral_trig_param "
cur . execute ( del_dihedral_param )
for j in range (0 , len ( toratm1 ) ) :
tatom1 = int ( toratm1 [ j ])
tatom2 = int ( toratm2 [ j ])
tatom3 = int ( toratm3 [ j ])
tatom4 = int ( toratm4 [ j ])
if float ( tor1 [ j ]) == 0.000:
t1 = float ( tor1 [ j ])
else :
t1 = float ( tor1 [ j ]) /2.0
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if float ( tor2 [ j ]) == 0.000 :
t2 = float ( tor2 [ j ])
else :
t2 = - float ( tor2 [ j ]) /2.0
if float ( tor3 [ j ]) == 0.000:
t3 = float ( tor3 [ j ])
else :
t3 = float ( tor3 [ j ]) /2.0
if float ( tor4 [ j ]) == 0.000:
t4 = float ( tor4 [ j ])
else :
t4 = - float ( tor4 [ j ]) /2.0
t0 = float ( t1 - t2 + t3 - t4 )

dihedral_param_cmd = """ INSERT INTO dihedral_trig_param ( fc0 ,
fc1 , fc2 , fc3 , fc4 ) SELECT {0} , {1} , {2} , {3} , {4}
EXCEPT
SELECT fc0 , fc1 , fc2 , fc3 , fc4 FROM dihedral_trig_param WHERE
fc0 = {0} AND fc1 = {1} AND fc2 = {2} AND fc3 = {3} AND fc4
= {4} """ . format ( t0 , t1 , t2 , t3 , t4 )

paramid_select = " SELECT id FROM dihedral_trig_param WHERE fc0
= {0} AND fc1 = {1} AND fc2 = {2} AND fc3 = {3} AND fc4 =
{4}" . format ( t0 , t1 , t2 , t3 , t4 )
cur . execute ( dihedral_param_cmd )
cur . execute ( paramid_select )
param = cur . fetchone () [0]
update_dihedral_param = " UPDATE dihedral_trig_param SET phi0 =
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{0} , fc5 = {0} , fc6 = {0} " . format (0.0)
cur . execute ( update_dihedral_param )
update_parent_term = """ INSERT INTO dihedral_trig_term ( p0 , p1 ,
p2 , p3 ) SELECT {0} , {1} , {2} , {3}
EXCEPT
SELECT p0 , p1 , p2 , p3 FROM dihedral_trig_term WHERE p0 = {0}
AND p1 = {1} AND p2 = {2} AND p3 = {3} """. format (( tatom1
-1) , ( tatom2 -1) , ( tatom3 -1) , ( tatom4 -1) )
cur . execute ( update_parent_term )
update_dihedral_term_param = " UPDATE dihedral_trig_term SET
param = {0} WHERE p0 = {1} AND p1 = {2} AND p2 = {3} AND p3
= {4} ". format ( param , ( tatom1 -1) , ( tatom2 -1) , ( tatom3 -1) ,
( tatom4 -1) )
cur . execute ( update_dihedral_term_param )
if tatom1 > tatom4 :
tatom_tmp = tatom4
tatom4 = tatom1
tatom1 = tatom_tmp
insert_torsionatm_to_exclusion = """ INSERT INTO exclusion ( p0 ,
p1 ) SELECT {0} , {1}
EXCEPT
SELECT p0 , p1 FROM exclusion WHERE p0 = {0} AND p1 = {1}""" .
format ( tatom1 -1 , tatom4 -1)
cur . execute ( insert_torsionatm_to_exclusion )
return [ toratm1 , toratm4 ]

A general workflow of creating structures with OPLS3 parameters is shown in Fig.5.4.
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Figure 5.4: An automated workflow generated to incorporate the new OPLS3 force field parameters to the MD
simulation package.

5.4

Validation of the OPLS3 parameterization

Single point total potential energies were calculated for each ligand in the dataset after force-field
parameterization. The total energies for individual ligands were successfully reproduced within
0.01 kcal/mol with very few exceptions as compared to the OPLS3 force field server, provided by
Schrodinger Inc. (Table.5.1).
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Table 5.1: Comparison of the total potential energies of the benzimidazole group of ligands using the old and new
force field parameters along with the energy values obtained from the OPLS3-Forcefield server. All quantities are
measured in kcal/mol.
Ligand

Potential Energy
-OPLS3-IMPACT

OPLS3-Force field server

OPLS2005-Force field
server

FXR2
FXR6
FXR7
FXR8
FXR9
FXR13
FXR14
FXR19
FXR20
FXR21
FXR22
FXR24
FXR25
FXR26
FXR27
FXR28
FXR29
FXR30
FXR31
FXR32
FXR35
FXR36

63.61
−3.29
18.93
24.14
32.33
49.17
17.96
−26.29
21.49
20.30
46.53
30.31
33.43
29.48
37.39
58.39
38.50
−59.06
−67.11
30.90
−24.26
61.81

63.61
−3.31
18.93
24.13
32.33
49.16
17.96
−26.30
21.49
20.30
46.51
30.30
33.42
29.47
37.38
58.41
38.51
−59.06
−67.11
30.91
−24.26
61.82

64.10
29.90
16.70
14.96
22.73
42.15
34.99
1.86
16.79
12.94
31.63
7.35
31.92
−14.68
−2.30
13.80
17.98
−23.74
−28.69
19.46
−3.50
25.92

Potential energies calculated with a non-bonded cutoff of 140 Å and includes customized torsional parameters used in
OPLS3 force field server. All values are calculated in kcal/mol.

5.5

Binding affinity predictions with OPLS2005 and OPLS3
force fields

To calculate the binding free energies of the FXR complexes in two different force fields, separate
conformational reservoirs of all benzimidazole group of ligands and as well as the receptor were
prepared for the two force fields. For the ligands, individual temperature replica exchange simulations without the receptor were run with eight intermediate replicas equispaced between 300K and
600K. Each replica was run for about 20 ns and conformational ensembles at 300K were collected
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Figure 5.5: A) Comparison of binding free energies obtained with OPLS2005 and OPLS3 force field parameters, B)
Comparison of binding energies for the benzimidazole class of ligands with the OPLS2005 and OPLS3 force fields

from all the trajectories. For the receptor, eighteen intermediate replicas were added during the
temperature replica exchange simulations for smooth transition between 300K and 400K. During
the simulation, conformations from the reservoirs were randomly selected to add to the replicas at
λ = 0.
Using the reservoir conformations, Hamiltonian replica-exchange simulations were carried out
for each receptor-ligand complexes prepared with the two force fields. A comparison of the binding
affinities obtained with the OPLS2005 and OPLS3 force fields is shown in Fig. 5.5 and Table 5.2.
About 40 % of the benzimidazole ligands tested have binding free energies which are within
1.5 kcal/mol difference between OPLS3 and OPLS2005 simulations. Another 40%, i.e. 9 out
of 22 ligands tested, have more favorable binding affinities with the OPLS3 force field than with
OPLS2005. Only four out of 22 ligands are observed to have slightly more favorable binding
affinities in OPLS2005 force field. Binding energies are observed to be similar for the two force
fields with few exceptions where binding energies are more favorable in presence of OPLS2005
force field. Thermodynamic decomposition of the binding free energies to obtain reorganization
free energy (see Chapter 3, eq. 3.1) shows that the complexes suffered more conformational reorganization with OPLS2005 than in OPLS3 (Fig. 5.6).
In order to understand the effect of conformational reorganization in binding affinity prediction
with the two force fields, we examined the differences in binding affinities and reorganization free
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141

∆G◦b b

OPLS2005
∆Eb c
∆G◦reorg d

∆G◦b b

OPLS3
∆Eb c
∆G◦reorg d

FXR2
−7.32
1.14 ± 0.08
−26.58 ± 0.19 −27.73 ± 0.27
−2.52 ± 0.08
−31.05 ± 0.2 28.53 ± 0.28
FXR6
−9.91
−7.8 ± 0.15
−44.82 ± 0.2 −37.03 ± 0.34
−11.9 ± 0.09
−44.05 ± 0.2 32.15 ± 0.29
FXR7
−9.08
−10.28 ± 0.14 −50.78 ± 0.17
40.50 ± 0.31
−14.00 ± 0.1 −49.14 ± 0.18 35.14 ± 0.28
FXR8
−7.24
−7.97 ± 0.09 −39.96 ± 0.18
31.99 ± 0.26
−8.9 ± 0.09
−41.43 ± 0.22 32.53 ± 0.30
FXR9
−7.14
8.62 ± 0.1
−26.8 ± 0.17
35.42 ± 0.28
0.48 ± 0.09
−32.59 ± 0.19 33.07 ± 0.28
FXR13 −10.44
−9.62 ± 0.11 −50.51 ± 0.18
40.89 ± 0.29
−12.25 ± 0.09 −50.34 ± 0.22 38.09 ± 0.31
FXR14
−11
−10.33 ± 0.15 −47.26 ± 0.21
36.93 ± 0.35
−12.97 ± 0.09 −47.40 ± 0.2 34.43 ± 0.29
FXR19 −9.66
−9.72 ± 0.09
39.88 ± 0.18
30.16 ± 0.27
−10.63 ± 0.09 −41.74 ± 0.17 31.11 ± 0.26
FXR20 −10.8
−8.79 ± 0.11 −45.00 ± 0.22
36.21 ± 0.32
−7.79 ± 0.14 −45.98 ± 0.22 38.19 ± 0.36
FXR21 −8.39
−9.69 ± 0.08 −39.86 ± 0.20
30.17 ± 0.29
−12.71 ± 0.09 −43.72 ± 0.18 31.01 ± 0.26
FXR22 −11.04
−9.49 ± 0.7
−43.81 ± 1.22
34.32 ± 1.92
−5.64 ± 0.1
−41.04 ± 0.27 35.40 ± 0.32
FXR24 −10.55
−8.16 ± 0.09 −40.31 ± 0.17
32.15 ± 0.27
−9.16 ± 0.15 −42.82 ± 0.20 33.66 ± 0.35
FXR25 −9.89
−8.91 ± 0.09 −40.42 ± 0.18
31.51 ± 0.27
−8.47 ± 0.14 −43.87 ± 0.18 35.40 ± 0.32
FXR26 −7.86
−6.54 ± 0.15 −43.97 ± 0.21
37.43 ± 0.36
−12.00 ± 0.09 −45.02 ± 0.20 33.02 ± 0.29
FXR27 −11.06
−14.6 ± 0.11 −59.40 ± 0.26
44.80 ± 0.36
−13.98 ± 0.1 −59.81 ± 0.25 45.83 ± 0.35
FXR28 −10.53
−15.8 ± 0.1
−63.40 ± 0.30
47.60 ± 0.4
−13.10 ± 0.1 −56.82 ± 0.19 43.72 ± 0.29
FXR29 −10.16
−17.13 ± 0.11 −60.91 ± 0.26
43.78 ± 0.37
−13.79 ± 0.11 −58.58 ± 0.23 44.79 ± 0.34
FXR30 −9.79
−11.73 ± 0.15 −66.27 ± 0.28
54.54 ± 0.43
−11.40 ± 0.1 −55.65 ± 0.27 44.25 ± 0.38
FXR31 −11.08
−6.54 ± 0.09 −40.66 ± 0.19
34.12 ± 0.29
−5.17 ± 0.15 −39.48 ± 0.19 34.31 ± 0.34
FXR32 −9.84
−0.12 ± 0.13 −37.91 ± 0.19
37.79 ± 0.32
−1.43 ± 0.14 −39.63 ± 0.19 38.20 ± 0.33
FXR35 −9.27
−21.17 ± 0.12 −70.3 ± 0.28
49.13 ± 0.4
−18.70 ± 0.16 −63.55 ± 0.28 44.85 ± 0.43
FXR36 −10.03
−13.37 ± 0.15
64.92 ± 0.23
51.55 ± 0.38
−17.49 ± 0.11 −65.98 ± 0.23 48.49 ± 0.34
a
b
All values in kcal/mol. Experimental binding free energy. Predicted binding free energy. c Average interaction energy of the bound complex at
λ = 1. The uncertainty is estimated as the standard error of the mean. d Reorganization free energy as calculated using eq. 3.1. The uncertainty is
computed by error propagation.
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Table 5.2: Binding affinities of FXR complexes and the thermodynamic decompositions in energy and reorganization components with the OPLS2005 and the
OPLS3 force field parameters.
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Figure 5.6: Comparison of the binding reorganization free energies ∆G◦reorg calculated by thermodynamic decomposition for all benzimidazole ligands obtained with the OPLS2005 and OPLS3 force fields .

energies between the two force fields:

∆∆G◦bind = ∆G◦OPLS2005 − ∆G◦OPLS3

(5.1)

∆∆G◦reorg = ∆G◦reorg(OPLS2005) − ∆G◦reorg(OPLS3)

(5.2)

and

The analysis shows that FXR20, 22, 25, 27 and 29, are more penalized by reorganization in OPLS3
than with OPLS2005 (Fig. 5.7 bottom left quadrant).
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Figure 5.7: Correlation of the changes of reorganization binding free energies in going from the OPLS3 to the
OPLS2005 force field to the corresponding changes in binding free energies..

The complexes in the top left quadrant of Fig. 5.7 and the bottom right quadrant are those that
display small changes in reorganization free energy when changing the force field. The changes in
binding affinities for these ligands is evidently due to other factors including the average interaction
energies of the complexes governed by the force field. Conversely, the complexes in the top right
quadrant are the ones most positively affected by the new OPLS3 force field because of smaller
reorganization free energy penalties.
FXR 6, 7, 9, 13, 14, 26, 36 have more favorable binding affinity and experienced less reorganization effects with OPLS3 force field compared to OPLS2005 (Table 5.2). Further investigation
of these ligands revealed that most of the ligands in this group have a cyclohexyl side group connected by an amide linker to the benzimidazole moiety. Dihedral angle distribution between the
cyclohexyl group and the amide linker for FXR6 was obtained similarly as analyzed for FXR27
reported above. The analysis revealed that FXR6 assumes two main conformational states in solution. Based on the position of the hydrogens in the cyclohexyl ring, these two conformations were
named as “axial” and “equatorial (Fig. 5.8).
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Equatorial (bound state)

Axial

Figure 5.8: Two different conformations of the cyclohexyl amide side group for FXR6

Population analysis of these two conformations in solution for two different force fields was
performed. The corresponding percent occupancies are given in Table. 5.3.
Table 5.3: Distribution of populations of the equatorial and axial conformational states of FXR6 in solution for the
OPLS2005 and OPLS3 force fields

Equatorial (%)
OPLS2005
46
OPLS3
98

Axial (%)
54
2

In the crystal structure of the bound complex, FXR6 is found in the equatorial conformation
(Fig. 5.8) The equatorial conformation is also the most probable conformation of the ligand in
solution according to the OPLS3 force field (98% population, see Table 5.3). With OPLS2005,
however, FXR6 visits the bound equatorial conformation with less than 50% probability and would
therefore be predicted to incur a larger reorganization free energy penalty for binding than with
OPLS3. These observations point to the fact that the quality of the force field plays a critical role
in representing these systems. A presumably more accurate force field is able to reduce penalties
due to conformation reorganization and lead to stronger binding affinities.
Treatment of enclosed hydration effects in these systems resulted in a 50 % correlation with
experiments when simulated with OPLS2005 force field (Fig. 5.9). Binding free energy calculations with a better OPLS3 force field along with enclosed hydration effects is yet to be studied. To
investigate further, a more elaborate way to look at these systems, especially the ligands with cyclohexyl amide groups, will have to be considered to survey the intra-molecular strain experienced
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Figure 5.9: Calculated binding free energies of FXR ligands with available crystal structures compared with their
experimental binding affinities obtained from measured IC50 values.

by the ligands in two different force fields. From the previous observations, it can be suggested that
a force field with a more accurate parameterization will have the ability to reduce intra-molecular
strain, relieving these systems from large reorganization penalties.
Calculation of binding affinities with OPLS3 parameters and further analysis were done in
collaboration with Dr. Lauren Wickstrom at Borough of Manhattan Community College, CUNY.
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6
Chapter Six: Modeling of
α-Hydroxytropolones
6.1

α-hydroxytropolones and 3,7-dihydroxytropolones

7-hydroxytropolones, also commonly called α-hydroxytropolones (αHT), are seven member ring
troponoids which have three adjacent oxygen-containing substituents (Fig. 6.1). These molecules
have proven to be very useful as scaffold to target metalloenzymes containing divalent cations
in the active site. 3,7-dihydroxytropolones (3,7dHT), on the other hand, have four contiguous
oxygen-containing substituents (eg. compound 6a in Fig. 6.1) which, as discussed below, may offer
additional opportunities to bind to metal centers. α-hydroxytropolones have been very promising
in medicinal chemistry platforms with a broad range of biological activity which has been validated both experimentally [148–150] as well as computationally characterized [106]. The hydroxytropolone considered here have substitutions at R1 , R2 and R3 positions of the seven membered
tropolone ring. The R1 position has always a methyl substitution and the R4 position has always
a hydrogen atom(Fig. 6.1). The nature of substitutions at R2 and R3 is found to greatly affect
the potency of inhibition against HIV RNase H [106, 151]. In 3,7-dihydroxytropolones, the R3
position is substituted by another hydroxyl group while keeping the R2 position open for specific
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Figure 6.1: Structure of α-hydroxytropolone and the compounds tested in this study. All these compounds are
described in the text.

substitutions. In a study conducted by the research group of Dr. Ryan Murelli at Brooklyn College,
CUNY, it was observed that either a change from αHT to 3,7dHT (10 to 6a) or a change in R2 from
a methyl ester to a biphenyl ketone (10 to 12) (Fig. 6.1) resulted in lower inhibitory potency against
the pUL15 enzyme of the Herpes Simplex Virus. However, changing from αHT to 3,7dHT along
with substitution of R2 position with a biphenyl ketone (10 to 6e) resulted an increase in potency
at pUL15 receptor [152]. It was hypothesized that the added hydroxyl group at R3 position in
3,7dHTs may allow the phenyl side chain to accommodate to a different configuration as opposed
to in αHT and may result in favorable contacts thus rendering it more active. This hypothesis
was tested using molecular docking calculations of the 3,7dHT compound 12 against a pUL15C
receptor model [152].

6.2

Modeling of the interaction of pUL15C with
3,7-dihydroxytropolones

6.2.1

Generation of pUL15C homology model

The metal cations bound structural model of pUL15C employed in the molecular docking calculations were obtained by structural alignment of the metal-binding DEDD motif residues D509,
E581, D706, and D707 of apo pUL15C crystal structure (PDB ID - 4IOX) [153] with the DEDD
motif of the crystal structure of HIV RT RNase H bound to divalent manganese cations and β 147

thujaplicinol (PDB id 3K2P) [154]. The resulting structure of holo pUL15C was refined by energy
minimization and simulated annealing using the Impact molecular modeling program [69].

6.2.2

Molecular docking of αHT compound 12 and 3,7 dHT compound 6e

The receptor grid for docking was generated using the default parameters available in the Schrodinger
Suite 2016-3 with one special adjustment in that metal constraints were applied to allow metalligand interaction at the binding site. Glide docking [3] was performed with the ligands αHT
compound 12 and 3,7 dHT compound 6e using Glide Standard Precision (SP). Several binding
poses were obtained for the molecule 6e, out of which the best binding pose is shown in Fig. 6.2.

Figure 6.2: The structure of the complex between UL15 (PDB ID - 4IOX) and 3,7-dHT 6e (green) predicted by
molecular docking. In this orientation, the biphenyl group of the ligand is nested into a hydrophobic groove formed
by Lys 640, Asn 583 and Leu 636. The manganese cations are shown in purple. Possible pi-cation contacts between
the biphenyl group of the ligand and Lys 640 of UL15 and close proximity to Asn 583 which could take part in NH-π
interactions are shown using dashed lines [152].

This predicted binding pose reveals favorable π-cation interactions between the quaternary
ammonium cation of Lys 640 and the phenyl ring π system of the biphenyl group of the ligand.
The biphenyl group is thought to be further stabilized by accommodating within a hydrophobic
groove formed between Lys 640 and Asn 583 with possible hydrophobic interaction with the Leu
636 present inside the groove. Further stabilization could also be achieved through interactions of
the biaryl side chain of 3,7 dHT 6e with Asn 583 through NH-π interactions. These interactions are
never observed during the extensive molecular docking and molecular dynamics calculations of the
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compound 12, lacking an additional metal-coordinating oxygen, which cannot adopt an orientation
compatible with the formation of these favorable contacts. This docking analysis was helpful to
understand and predict the nature of binding this 3,7-dihydrxytropolone at the pUL15C receptor.
The results of this study have been reported in a peer-reviewed publication [152].

6.3

Prediction of pKas of α-hydroxytropolones

Aqueous pKa values of compounds are important to understand their applicability and efficacy in
pharmacological applications [155]. The pKa values can provide many useful information about
potential drug molecules, such as their solubility, absorption rate, bio-availability and the strength
of binding to the target [155]. In this study, we focused on a set of α-hydroxytropolones (αHT)
with different substitutions and we investigated the effect of substitutions on the pKa values. These
compounds have at least three intrinsic pKa values corresponding to each of the three hydroxyl
groups on the seven membered ring. One of the possible orders of deprotonation in αHTs is
illustrated in Fig. 6.3.

Figure 6.3: Order of deprotonation in α-hydroxytropolones [156]

We attempted to predict pKa2 and pKa3 as shown in the Fig. 6.3 as these two oxygens are
thought to coordinate with the metal ions at the active site.

6.4

pKapredictions with the Jaguar quantum chemistry software

We predicted the pKa s of eight different substitutions of αHTs listed in Fig. 6.4. Different pKa prediction tools were considered for this study, including Gaussian and NwChem. The most reliable
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Figure 6.4: Compounds tested for pKa predictions [156]

predictions were obtained using the Jaguar pKa prediction tool [157] of the Schrodinger’s molecular modeling Suite. pKa2 values were calculated by starting from a neutral molecule whereas pKa3
was calculated starting from a singly deprotonated molecule holding a overall charge of −1.

Figure 6.5: Thermodynamic cycle used for calculation of pKa s. The subscript (g) denotes the entity on gas phase
while the subscript (aq) indicates the entity in aqueous phase

The deprotonation of a compound in aqueous solution can be represented as part of a thermodynamic cycle in Fig. 6.5 [158]. One part of this cycle occurs in vacuum where the gas phase
deprotonation energy, ∆Gg of the molecule is calculated. The three other legs are calculated in a
model of the water solvent. These are the free energy of solvation of the protonated form, ∆GAH
sol ,
−

+

H
of the deprotonated form, ∆GA
sol , and of the proton, ∆Gsol . The last leg is the free energy of depro-

tonation of the molecule in solution , represented by ∆Ga . The latter is calculated from all other
terms using the relation
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−

+

A
H
∆Ga = ∆Gg − ∆GAH
sol + ∆Gsol + ∆Gsol

(6.1)

The acidity constant of a compound and ∆Ga are linked by a thermodynamic relation:

pKa =

∆Ga
2.303RT

(6.2)

where R is the gas constant and T is the temperature. Jaguar uses this fundamental thermodynamic
cycle to calculate raw pKa values of a given compound and then uses empirical linear correction
parameters a and b optimized for each functional group to obtain the corrected pKa :

pKfinal
= a pKa + b
a

(6.3)

The predictions and experimental pKa for both pKa2 and pKa3 for all molecules tested are
provided in Table 6.1. It can be seen from the predictions that pKa2 for most of the compounds
were either over predicted or under predicted by around 2 pH units.
Predictions were made by altering the order of deprotonation between the two oxygen atoms
and for all compounds, it was observed that oxygen atom nearest to the R3 position (shown in
Fig. 6.1 αHT) gets protonated first in the predictions, in accordance to the experimental pKa s
obtained. Most interesting of all predictions is compound 8 in which the Jaguar pKa predictions
exactly matches with the experimental value.
Table 6.1: Predicted and calculated pKa values of αHTs studied in this work
Predicted
Experimentala
pKa2 pka3
pKa2
pKa3
1
7.9
12.6
6.4
11.6
2
8.1
12.1
6.0
11.8
3
8.8
10.0
6.0
11.7
4
7.4
11.2
5.9
11.9
5
7.9
11.0
6.5
> 12
6
6
10.2
4.3
10.9
7
6.1
10.1
4.8
10.9
8
5.0
10.6
5.0
10.6
a Experimental pK values are recently published in [156].
a
αHT
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This compound has two methyl esters at R2 and R3 positions of the tropolone ring. In this compound the C=O group of the methyl esters are observed to be oriented opposite to each other in
the final output structure after pKa calculations, resulting in a twist of the tropolone ring. These
pKa s predictions were obtained before experimentally determinations using UV-Vis spectrophotometric methods [156]. Thus, even though the prediction were off by some orders of magnitude,
computational pKa predictions are able to show consistent trends in the order of deprotonation of
the tropolone group.
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